Journal Article
. 2013 Jun; 369(2):122-33.
doi: 10.1056/NEJMoa1302369.

Nivolumab plus ipilimumab in advanced melanoma

Jedd D Wolchok 1 Harriet Kluger  Margaret K Callahan  Michael A Postow  Naiyer A Rizvi  Alexander M Lesokhin  Neil H Segal  Charlotte E Ariyan  Ruth-Ann Gordon  Kathleen Reed  Matthew M Burke  Anne Caldwell  Stephanie A Kronenberg  Blessing U Agunwamba  Xiaoling Zhang  Israel Lowy  Hector David Inzunza  William Feely  Christine E Horak  Quan Hong  Alan J Korman  Jon M Wigginton  Ashok Gupta  Mario Sznol  
  • PMID: 23724867
  •     20 References
  •     1753 citations


Background: In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase 1 trial. On the basis of their distinct immunologic mechanisms of action and supportive preclinical data, we conducted a phase 1 trial of nivolumab combined with ipilimumab in patients with advanced melanoma.

Methods: We administered intravenous doses of nivolumab and ipilimumab in patients every 3 weeks for 4 doses, followed by nivolumab alone every 3 weeks for 4 doses (concurrent regimen). The combined treatment was subsequently administered every 12 weeks for up to 8 doses. In a sequenced regimen, patients previously treated with ipilimumab received nivolumab every 2 weeks for up to 48 doses.

Results: A total of 53 patients received concurrent therapy with nivolumab and ipilimumab, and 33 received sequenced treatment. The objective-response rate (according to modified World Health Organization criteria) for all patients in the concurrent-regimen group was 40%. Evidence of clinical activity (conventional, unconfirmed, or immune-related response or stable disease for ≥24 weeks) was observed in 65% of patients. At the maximum doses that were associated with an acceptable level of adverse events (nivolumab at a dose of 1 mg per kilogram of body weight and ipilimumab at a dose of 3 mg per kilogram), 53% of patients had an objective response, all with tumor reduction of 80% or more. Grade 3 or 4 adverse events related to therapy occurred in 53% of patients in the concurrent-regimen group but were qualitatively similar to previous experience with monotherapy and were generally reversible. Among patients in the sequenced-regimen group, 18% had grade 3 or 4 adverse events related to therapy and the objective-response rate was 20%.

Conclusions: Concurrent therapy with nivolumab and ipilimumab had a manageable safety profile and provided clinical activity that appears to be distinct from that in published data on monotherapy, with rapid and deep tumor regression in a substantial proportion of patients. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; number, NCT01024231.).

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
Robert D Schreiber, Lloyd J Old, Mark J Smyth.
Science, 2011 Mar 26; 331(6024). PMID: 21436444
Highly Cited. Review.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, +23 authors, Jon M Wigginton.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658128    Free PMC article.
Highly Cited.
Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg.
Cell, 2011 Mar 08; 144(5). PMID: 21376230
Highly Cited. Review.
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.
Janis M Taube, Robert A Anders, +8 authors, Lieping Chen.
Sci Transl Med, 2012 Mar 31; 4(127). PMID: 22461641    Free PMC article.
Highly Cited.
Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
Lawrence Fong, Eric J Small.
J Clin Oncol, 2008 Oct 08; 26(32). PMID: 18838703
Systematic Review.
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
Jedd D Wolchok, Axel Hoos, +9 authors, F Stephen Hodi.
Clin Cancer Res, 2009 Nov 26; 15(23). PMID: 19934295
Highly Cited.
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.
Richard V Parry, Jens M Chemnitz, +6 authors, James L Riley.
Mol Cell Biol, 2005 Oct 18; 25(21). PMID: 16227604    Free PMC article.
Highly Cited.
What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?
Caroline Robert, Francois Ghiringhelli.
Oncologist, 2009 Aug 04; 14(8). PMID: 19648604
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
Julie R Brahmer, Charles G Drake, +17 authors, Suzanne L Topalian.
J Clin Oncol, 2010 Jun 03; 28(19). PMID: 20516446    Free PMC article.
Highly Cited.
Toxicity and response criteria of the Eastern Cooperative Oncology Group.
M M Oken, R H Creech, +4 authors, P P Carbone.
Am J Clin Oncol, 1982 Dec 01; 5(6). PMID: 7165009
Highly Cited.
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival.
J Delyon, C Mateus, +7 authors, C Robert.
Ann Oncol, 2013 Feb 27; 24(6). PMID: 23439861
Highly Cited.
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody.
Evan J Lipson, William H Sharfman, +10 authors, Suzanne L Topalian.
Clin Cancer Res, 2012 Nov 22; 19(2). PMID: 23169436    Free PMC article.
Highly Cited.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Michael A Curran, Welby Montalvo, Hideo Yagita, James P Allison.
Proc Natl Acad Sci U S A, 2010 Feb 18; 107(9). PMID: 20160101    Free PMC article.
Highly Cited.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, +26 authors, BRIM-3 Study Group.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639808    Free PMC article.
Highly Cited.
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.
Geoffrey Y Ku, Jianda Yuan, +7 authors, Jedd D Wolchok.
Cancer, 2010 Feb 10; 116(7). PMID: 20143434    Free PMC article.
Highly Cited.
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
Steven J O'Day, Omid Hamid, Walter J Urba.
Cancer, 2007 Nov 16; 110(12). PMID: 18000991
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, +21 authors, Jedd D Wolchok.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639810
Highly Cited.
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.
J D Wolchok, J S Weber, +7 authors, C Lebbé.
Ann Oncol, 2013 May 15; 24(8). PMID: 23666915    Free PMC article.
Highly Cited.
From ASCO-targeted therapies: Anti-PD-1 approaches--important steps forward in metastatic melanoma.
Mina Razzak.
Nat Rev Clin Oncol, 2013 Jun 12; 10(7). PMID: 23752732
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
Christopher J Nirschl, Charles G Drake.
Clin Cancer Res, 2013 Jul 23; 19(18). PMID: 23868869    Free PMC article.
Highly Cited. Review.
Melanoma combination therapies ward off tumor resistance.
Ken Garber.
Nat Biotechnol, 2013 Aug 10; 31(8). PMID: 23929325
Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells.
E Passante, M L Würstle, +2 authors, M Rehm.
Cell Death Differ, 2013 Aug 13; 20(11). PMID: 23933815    Free PMC article.
Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity.
Aurélien Marabelle, Holbrook Kohrt, Ronald Levy.
Clin Cancer Res, 2013 Aug 24; 19(19). PMID: 23965900    Free PMC article.
Zebrafish cancer: the state of the art and the path forward.
Richard White, Kristin Rose, Leonard Zon.
Nat Rev Cancer, 2013 Aug 24; 13(9). PMID: 23969693    Free PMC article.
Highly Cited. Review.
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
Howard L Kaufman, John M Kirkwood, +27 authors, Michael B Atkins.
Nat Rev Clin Oncol, 2013 Aug 29; 10(10). PMID: 23982524
Highly Cited.
Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients.
D Reyes, L Salazar, +8 authors, F Salazar-Onfray.
Br J Cancer, 2013 Aug 31; 109(6). PMID: 23989944    Free PMC article.
Melanoma-associated leukoderma - immunology in black and white?
Hadas Prag Naveh, Uma N M Rao, Lisa H Butterfield.
Pigment Cell Melanoma Res, 2013 Sep 10; 26(6). PMID: 24010963    Free PMC article.
Changing T-cell enigma: cancer killing or cancer control?
Thomas Wieder, Heidi Braumüller, +2 authors, Martin Röcken.
Cell Cycle, 2013 Sep 10; 12(19). PMID: 24013429    Free PMC article.
Immunotherapy at large: Balancing tumor immunity and inflammatory pathology.
Glenn Dranoff.
Nat Med, 2013 Sep 10; 19(9). PMID: 24013749    Free PMC article.
How to detour Treg cells in T cell-based antitumor immune therapy.
Shu Zheng, Yanwei Shen, Yongmao Song, Ying Yuan.
Onco Targets Ther, 2013 Sep 18; 6. PMID: 24043948    Free PMC article.
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response.
Mario Sznol, Lieping Chen.
Clin Cancer Res, 2013 Sep 21; 19(19). PMID: 24048329    Free PMC article.
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Esra A Akbay, Shohei Koyama, +24 authors, Kwok-Kin Wong.
Cancer Discov, 2013 Oct 01; 3(12). PMID: 24078774    Free PMC article.
Highly Cited.
Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses.
Denarda Dangaj, Nathalie Scholler.
Oncoimmunology, 2013 Oct 02; 2(8). PMID: 24083083    Free PMC article.
Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy.
Christel Devaud, Liza B John, +2 authors, Michael H Kershaw.
Oncoimmunology, 2013 Oct 02; 2(8). PMID: 24083084    Free PMC article.
Highly Cited. Review.
The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.
Ryan J Sullivan, Patricia M Lorusso, Keith T Flaherty.
Clin Cancer Res, 2013 Oct 04; 19(19). PMID: 24089441    Free PMC article.
HLA ligandome tumor antigen discovery for personalized vaccine approach.
Hans-Georg Rammensee, Harpreet Singh-Jasuja.
Expert Rev Vaccines, 2013 Oct 05; 12(10). PMID: 24090147    Free PMC article.
Resistance to RAF inhibitors revisited.
Edward Hartsough, Yongping Shao, Andrew E Aplin.
J Invest Dermatol, 2013 Oct 11; 134(2). PMID: 24108405    Free PMC article.
Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
Sarah E Church, Shawn M Jensen, +2 authors, Bernard A Fox.
Eur J Immunol, 2013 Oct 12; 44(1). PMID: 24114780    Free PMC article.
Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?
Nayoung Lee, Steven R Barthel, Tobias Schatton.
Lab Invest, 2013 Oct 16; 94(1). PMID: 24126889    Free PMC article.
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.
Jeffrey S Weber, Ragini Reiney Kudchadkar, +11 authors, Y Ann Chen.
J Clin Oncol, 2013 Oct 23; 31(34). PMID: 24145345    Free PMC article.
Highly Cited.
Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.
D Atanackovic, T Luetkens, N Kröger.
Leukemia, 2013 Oct 25; 28(5). PMID: 24153012
Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function.
Patrick A Ott, Nina Bhardwaj.
Front Immunol, 2013 Nov 07; 4. PMID: 24194739    Free PMC article.
Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells.
Kyle K Payne, Christine K Zoon, +6 authors, Masoud H Manjili.
Breast Cancer Res Treat, 2013 Nov 08; 142(1). PMID: 24197563    Free PMC article.
Microenvironmental regulation of tumor progression and metastasis.
Daniela F Quail, Johanna A Joyce.
Nat Med, 2013 Nov 10; 19(11). PMID: 24202395    Free PMC article.
Highly Cited. Review.
Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma.
Giulio Tosti, Emilia Cocorocchio, Elisabetta Pennacchioli.
Clin Cosmet Investig Dermatol, 2013 Nov 10; 6. PMID: 24204168    Free PMC article.
PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads.
Edward Seung, Timothy E Dudek, +3 authors, Andrew M Tager.
PLoS One, 2013 Nov 10; 8(10). PMID: 24204962    Free PMC article.
Tolerance and exhaustion: defining mechanisms of T cell dysfunction.
Andrea Schietinger, Philip D Greenberg.
Trends Immunol, 2013 Nov 12; 35(2). PMID: 24210163    Free PMC article.
Highly Cited. Review.
Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.
Simon Turcotte, Alena Gros, +4 authors, Steven A Rosenberg.
Clin Cancer Res, 2013 Nov 13; 20(2). PMID: 24218514    Free PMC article.
Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions.
Shigeo Koido, Sadamu Homma, +14 authors, Hisao Tajiri.
Oncoimmunology, 2013 Nov 15; 2(9). PMID: 24228229    Free PMC article.
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application.
Taku Okazaki, Shunsuke Chikuma, +2 authors, Tasuku Honjo.
Nat Immunol, 2013 Nov 19; 14(12). PMID: 24240160
Highly Cited. Review.
Inhibiting the inhibitors: Checkpoints blockade in solid tumors.
Domenico Mavilio, Enrico Lugli.
Oncoimmunology, 2013 Nov 19; 2(9). PMID: 24244910    Free PMC article.
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer.
Charles G Drake, Evan J Lipson, Julie R Brahmer.
Nat Rev Clin Oncol, 2013 Nov 20; 11(1). PMID: 24247168    Free PMC article.
Highly Cited. Review.
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu.
Andre Kunert, Trudy Straetemans, +4 authors, Reno Debets.
Front Immunol, 2013 Nov 23; 4. PMID: 24265631    Free PMC article.
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
Christine Feig, James O Jones, +12 authors, Douglas T Fearon.
Proc Natl Acad Sci U S A, 2013 Nov 28; 110(50). PMID: 24277834    Free PMC article.
Highly Cited.
Palliative treatment of metastatic colorectal cancer: what is the optimal approach?
John H Strickler, Herbert I Hurwitz.
Curr Oncol Rep, 2013 Dec 03; 16(1). PMID: 24293074
Recent developments in the treatment of renal cell carcinoma.
Janice P Dutcher.
Ther Adv Urol, 2013 Dec 03; 5(6). PMID: 24294292    Free PMC article.
Cancer immunotherapy: are we there yet?
Zihai Li, Lieping Chen, Mark P Rubinstein.
Exp Hematol Oncol, 2013 Dec 12; 2(1). PMID: 24326015    Free PMC article.
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.
Jason R Westin, Fuliang Chu, +19 authors, Sattva S Neelapu.
Lancet Oncol, 2013 Dec 18; 15(1). PMID: 24332512    Free PMC article.
Highly Cited.
Advances in chimeric antigen receptor immunotherapy for neuroblastoma.
Andras Heczey, Chrystal U Louis.
Discov Med, 2013 Dec 18; 16(90). PMID: 24333408    Free PMC article.
Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.
Angela Vasaturo, Stefania Di Blasio, +4 authors, Stanleyson V Hato.
Front Immunol, 2013 Dec 19; 4. PMID: 24348481    Free PMC article.
Drug development: Releasing the brakes.
Karen Weintraub.
Nature, 2013 Dec 20; 504(7480). PMID: 24352363
Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions.
Filippos Porichis, Meghan G Hart, +8 authors, Daniel E Kaufmann.
J Virol, 2013 Dec 20; 88(5). PMID: 24352453    Free PMC article.
Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity.
Arthur E Frankel.
Clin Pharmacol, 2013 Dec 20; 5(Suppl 1). PMID: 24353448    Free PMC article.
Is there a future for adoptive cell transfer in melanoma patients?
Michal J Besser.
Oncoimmunology, 2013 Dec 20; 2(10). PMID: 24353909    Free PMC article.
Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion.
Pavan Bachireddy, Ursula Hainz, +15 authors, Catherine J Wu.
Blood, 2013 Dec 21; 123(9). PMID: 24357730    Free PMC article.
Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients.
Franz Buchegger, Steven M Larson, +6 authors, Daniel E Speiser.
Clin Dev Immunol, 2013 Dec 29; 2013. PMID: 24371449    Free PMC article.
DC-based immunotherapy for hematological malignancies.
Toshio Kitawaki.
Int J Hematol, 2014 Jan 01; 99(2). PMID: 24379028
Immunotherapy for colorectal cancer.
Shigeo Koido, Toshifumi Ohkusa, +12 authors, Hisao Tajiri.
World J Gastroenterol, 2014 Jan 01; 19(46). PMID: 24379570    Free PMC article.
Immunology and immunotherapy of chronic myeloid leukemia.
Mette Ilander, Can Hekim, Satu Mustjoki.
Curr Hematol Malig Rep, 2014 Jan 07; 9(1). PMID: 24390549
Guest editorial: Immunotherapy for hematological malignancies: the quest to overcome tolerogenic drive.
Norimitsu Kadowaki.
Int J Hematol, 2014 Jan 08; 99(2). PMID: 24395282
Beyond sipuleucel-T: immune approaches to treating prostate cancer.
Michael L Cheng, Lawrence Fong.
Curr Treat Options Oncol, 2014 Jan 10; 15(1). PMID: 24402184    Free PMC article.
Replenish the source within: Rescuing tumor-infiltrating lymphocytes by double checkpoint blockade.
Jaikumar Duraiswamy, Gordon Freeman, George Coukos.
Oncoimmunology, 2014 Jan 10; 2(10). PMID: 24404420    Free PMC article.
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter.
David C Binder, Hans Schreiber.
Cancer Res, 2014 Jan 11; 74(2). PMID: 24408925    Free PMC article.
Melanoma: from melanocyte to genetic alterations and clinical options.
Corine Bertolotto.
Scientifica (Cairo), 2014 Jan 15; 2013. PMID: 24416617    Free PMC article.
GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.
David A Schaer, Sadna Budhu, +8 authors, Jedd D Wolchok.
Cancer Immunol Res, 2014 Jan 15; 1(5). PMID: 24416730    Free PMC article.
Highly Cited.
Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma.
Koichi Shimizu, Yoshihito Kotera, +7 authors, Masakazu Yamamoto.
Hum Vaccin Immunother, 2014 Jan 15; 10(4). PMID: 24419174    Free PMC article.
Melanoma in 2013: Melanoma--the run of success continues.
Dirk Schadendorf, Axel Hauschild.
Nat Rev Clin Oncol, 2014 Jan 15; 11(2). PMID: 24419300
Adoptive immunotherapy for cancer or viruses.
Marcela V Maus, Joseph A Fraietta, +3 authors, Carl H June.
Annu Rev Immunol, 2014 Jan 16; 32. PMID: 24423116    Free PMC article.
Highly Cited. Review.
On the TRAIL to overcome BRAF-inhibitor resistance.
Peter Geserick, Meenhard Herlyn, Martin Leverkus.
J Invest Dermatol, 2014 Jan 16; 134(2). PMID: 24424456
Dendritic cell-based immunotherapy for myeloid leukemias.
Christian M Schürch, Carsten Riether, Adrian F Ochsenbein.
Front Immunol, 2014 Jan 16; 4. PMID: 24427158    Free PMC article.
Mitigating the toxic effects of anticancer immunotherapy.
Tara C Gangadhar, Robert H Vonderheide.
Nat Rev Clin Oncol, 2014 Jan 22; 11(2). PMID: 24445516
Highly Cited. Review.
Targeting brain metastases in patients with melanoma.
Dionysis Papadatos-Pastos, Aspasia Soultati, Mark Harries.
Biomed Res Int, 2014 Jan 24; 2013. PMID: 24455677    Free PMC article.
Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression.
Shannon K Oda, Pamela Strauch, +5 authors, Raul M Torres.
Cancer Immunol Res, 2014 Jan 24; 1(4). PMID: 24455753    Free PMC article.
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.
Pierre G Coulie, Benoît J Van den Eynde, Pierre van der Bruggen, Thierry Boon.
Nat Rev Cancer, 2014 Jan 25; 14(2). PMID: 24457417
Highly Cited. Review.
Melanoma brain metastasis globally reconfigures chemokine and cytokine profiles in patient cerebrospinal fluid.
Edwin Lok, Amy S Chung, Kenneth D Swanson, Eric T Wong.
Melanoma Res, 2014 Jan 28; 24(2). PMID: 24463459    Free PMC article.
Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy.
Alexander Dömling, Tad A Holak.
Angew Chem Int Ed Engl, 2014 Jan 30; 53(9). PMID: 24474145    Free PMC article.
In vivo discovery of immunotherapy targets in the tumour microenvironment.
Penghui Zhou, Donald R Shaffer, +17 authors, Kai W Wucherpfennig.
Nature, 2014 Jan 31; 506(7486). PMID: 24476824    Free PMC article.
Highly Cited.
Immunotherapy for prostate cancer: recent developments and future challenges.
Michael T Schweizer, Charles G Drake.
Cancer Metastasis Rev, 2014 Jan 31; 33(2-3). PMID: 24477411    Free PMC article.
Immunotherapy for solid tumors--a review for surgeons.
Abdul Saied, Venu G Pillarisetty, Steven C Katz.
J Surg Res, 2014 Feb 04; 187(2). PMID: 24485876    Free PMC article.
Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.
Douglas B Johnson, Erika K Wallender, +7 authors, Jeffrey A Sosman.
Cancer Immunol Res, 2014 Feb 04; 1(6). PMID: 24490176    Free PMC article.
Neoadjuvant treatment of melanoma: case reports and review.
Shachar Laks, Kevin A Brueske, Eddy C Hsueh.
Exp Hematol Oncol, 2014 Feb 07; 2(1). PMID: 24499550    Free PMC article.
Potential of new therapies like anti-PD1 in kidney cancer.
Anasuya Gunturi, David F McDermott.
Curr Treat Options Oncol, 2014 Feb 08; 15(1). PMID: 24504486
Dabrafenib for treatment of BRAF-mutant melanoma.
Radhika Kainthla, Kevin B Kim, Gerald S Falchook.
Pharmgenomics Pers Med, 2014 Feb 12; 7. PMID: 24516336    Free PMC article.
New modalities of cancer treatment for NSCLC: focus on immunotherapy.
Marianne Davies.
Cancer Manag Res, 2014 Feb 13; 6. PMID: 24520205    Free PMC article.
New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.
Deepak Mittal, Matthew M Gubin, Robert D Schreiber, Mark J Smyth.
Curr Opin Immunol, 2014 Feb 18; 27. PMID: 24531241    Free PMC article.
Highly Cited. Review.
The GIST of targeted therapy for malignant melanoma.
Danielle M Bello, Ronald P Dematteo, Charlotte E Ariyan.
Ann Surg Oncol, 2014 Feb 18; 21(6). PMID: 24531699    Free PMC article.
New treatments for metastatic melanoma.
Craig Gedye, David Hogg, Marcus Butler, Anthony M Joshua.
CMAJ, 2014 Feb 20; 186(10). PMID: 24549129    Free PMC article.
Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice.
Judith T Murphy, Andre P Burey, +4 authors, Jedd D Wolchok.
Blood, 2014 Feb 22; 123(14). PMID: 24558202    Free PMC article.
High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies.
David C Binder, Hans Schreiber.
Oncoimmunology, 2014 Feb 25; 2(12). PMID: 24563823    Free PMC article.
Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer?
Julie R Brahmer.
Semin Oncol, 2014 Feb 26; 41(1). PMID: 24565586    Free PMC article.
Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.
Camilla Jandus, Kayluz Frias Boligan, +11 authors, Stephan von Gunten.
J Clin Invest, 2014 Feb 27; 124(4). PMID: 24569453    Free PMC article.
Highly Cited.
Cancer: Inflammation lights the way to metastasis.
Seth B Coffelt, Karin E de Visser.
Nature, 2014 Feb 28; 507(7490). PMID: 24572360
A2A blockade enhances anti-metastatic immune responses.
Paul A Beavis, Nicole Milenkovski, +2 authors, Phillip K Darcy.
Oncoimmunology, 2014 Feb 28; 2(12). PMID: 24575377    Free PMC article.
Melanoma: smart therapeutic strategies in immuno-oncology.
Alexander M M Eggermont, Caroline Robert.
Nat Rev Clin Oncol, 2014 Mar 05; 11(4). PMID: 24590131
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Suzanne L Topalian, Mario Sznol, +18 authors, F Stephen Hodi.
J Clin Oncol, 2014 Mar 05; 32(10). PMID: 24590637    Free PMC article.
Highly Cited.
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".
Lucia Gelao, Carmen Criscitiello, +2 authors, Giuseppe Curigliano.
Toxins (Basel), 2014 Mar 07; 6(3). PMID: 24594636    Free PMC article.
Involvement of a non-human sialic Acid in human cancer.
Annie N Samraj, Heinz Läubli, Nissi Varki, Ajit Varki.
Front Oncol, 2014 Mar 07; 4. PMID: 24600589    Free PMC article.
Microenvironmental clues for glioma immunotherapy.
Michael Platten, Katharina Ochs, +2 authors, Wolfgang Wick.
Curr Neurol Neurosci Rep, 2014 Mar 08; 14(4). PMID: 24604058
Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.
Maxine Bauzon, Terry Hermiston.
Front Immunol, 2014 Mar 08; 5. PMID: 24605114    Free PMC article.
Targeting the PD-1 pathway: a promising future for the treatment of melanoma.
Andrew Mamalis, Manveer Garcha, Jared Jagdeo.
Arch Dermatol Res, 2014 Mar 13; 306(6). PMID: 24615548    Free PMC article.
Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies.
Mark Linch, Aisha B Miah, +2 authors, Charlotte Benson.
Nat Rev Clin Oncol, 2014 Mar 20; 11(4). PMID: 24642677
Highly Cited. Review.
Melanoma immunotherapy.
Martina Sanlorenzo, Igor Vujic, +10 authors, Susanna Ortiz-Urda.
Cancer Biol Ther, 2014 Mar 22; 15(6). PMID: 24651672    Free PMC article.
The importance of animal models in tumor immunity and immunotherapy.
Sadna Budhu, Jedd Wolchok, Taha Merghoub.
Curr Opin Genet Dev, 2014 Mar 25; 24. PMID: 24657536    Free PMC article.
Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model.
Raffaella Iannone, Lucio Miele, +2 authors, Silvana Morello.
Am J Cancer Res, 2014 Mar 25; 4(2). PMID: 24660106    Free PMC article.
Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes.
Christopher A Barker, Michael A Postow.
Int J Radiat Oncol Biol Phys, 2014 Mar 26; 88(5). PMID: 24661650    Free PMC article.
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.
Alena Gros, Paul F Robbins, +13 authors, Steven A Rosenberg.
J Clin Invest, 2014 Mar 29; 124(5). PMID: 24667641    Free PMC article.
Highly Cited.
Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.
Darshil J Shah, Roxana S Dronca.
Mayo Clin Proc, 2014 Apr 02; 89(4). PMID: 24684873    Free PMC article.
Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma.
Elizabeth Ann L Enninga, Shernan G Holtan, +4 authors, Svetomir N Markovic.
Mayo Clin Proc, 2014 Apr 02; 89(4). PMID: 24684874    Free PMC article.
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.
Xiaozhou Fan, Sergio A Quezada, +2 authors, James P Allison.
J Exp Med, 2014 Apr 02; 211(4). PMID: 24687957    Free PMC article.
Highly Cited.
Immunologic and clinical effects of targeting PD-1 in lung cancer.
R D Harvey.
Clin Pharmacol Ther, 2014 Apr 03; 96(2). PMID: 24690569    Free PMC article.
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Derek A Wainwright, Alan L Chang, +9 authors, Maciej S Lesniak.
Clin Cancer Res, 2014 Apr 03; 20(20). PMID: 24691018    Free PMC article.
Highly Cited.
VISTA Regulates the Development of Protective Antitumor Immunity.
Isabelle Le Mercier, Wenna Chen, +5 authors, Li Wang.
Cancer Res, 2014 Apr 03; 74(7). PMID: 24691994    Free PMC article.
Highly Cited.
Combination therapies for the treatment of advanced melanoma: a review of current evidence.
Mark Voskoboynik, Hendrik-Tobias Arkenau.
Biochem Res Int, 2014 Apr 03; 2014. PMID: 24693430    Free PMC article.
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.
Fernando Aranda, Erika Vacchelli, +5 authors, Lorenzo Galluzzi.
Oncoimmunology, 2014 Apr 05; 3(1). PMID: 24701370    Free PMC article.
Highly Cited.
Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma.
Ian-James Malm, Tullia C Bruno, +6 authors, Young J Kim.
Head Neck, 2014 Apr 09; 37(8). PMID: 24710745    Free PMC article.
Immune-checkpoint inhibitors march on, now in combinations.
Cormac Sheridan.
Nat Biotechnol, 2014 Apr 10; 32(4). PMID: 24714455
Tumor antigen discovery through translation of the cancer genome.
Michael S Khodadoust, Ash A Alizadeh.
Immunol Res, 2014 Apr 11; 58(2-3). PMID: 24718952
Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors.
Alexander Eggermont, Caroline Robert, Jean Charles Soria, Laurence Zitvogel.
Oncoimmunology, 2014 Apr 11; 3(1). PMID: 24719793    Free PMC article.
Molecular pathways and therapeutic targets in lung cancer.
Emma Shtivelman, Thomas Hensing, +4 authors, Ravi Salgia.
Oncotarget, 2014 Apr 12; 5(6). PMID: 24722523    Free PMC article.
Highly Cited. Review.
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.
D Rossille, M Gressier, +11 authors, Groupe Ouest-Est des Leucémies et Autres Maladies du Sang.
Leukemia, 2014 Apr 16; 28(12). PMID: 24732592
Highly Cited.
Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ.
Ping-Chih Ho, Katrina M Meeth, +3 authors, Susan M Kaech.
Cancer Res, 2014 Apr 17; 74(12). PMID: 24736544    Free PMC article.
Molecular pathways: interleukin-15 signaling in health and in cancer.
Anjali Mishra, Laura Sullivan, Michael A Caligiuri.
Clin Cancer Res, 2014 Apr 17; 20(8). PMID: 24737791    Free PMC article.
BRAF and beyond: Tailoring strategies for the individual melanoma patient.
Anthony Jarkowski, Nikhil I Khushalani.
J Carcinog, 2014 Apr 17; 13. PMID: 24737949    Free PMC article.
Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.
Patrick M Glassman, Joseph P Balthasar.
Cancer Biol Med, 2014 Apr 17; 11(1). PMID: 24738036    Free PMC article.
Pathways and therapeutic targets in melanoma.
Emma Shtivelman, Michael Q A Davies, +5 authors, David E Fisher.
Oncotarget, 2014 Apr 20; 5(7). PMID: 24743024    Free PMC article.
Highly Cited. Review.
Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy.
Thomas E Stinchcombe.
Med Oncol, 2014 Apr 22; 31(5). PMID: 24748366    Free PMC article.
Immunotherapy for brain cancer: recent progress and future promise.
Christopher M Jackson, Michael Lim, Charles G Drake.
Clin Cancer Res, 2014 Apr 29; 20(14). PMID: 24771646    Free PMC article.
Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer.
Julie R Brahmer, Drew M Pardoll.
Cancer Immunol Res, 2014 Apr 30; 1(2). PMID: 24777499    Free PMC article.
Highly Cited. Review.
Sarcoma immunotherapy: past approaches and future directions.
S P D'Angelo, W D Tap, G K Schwartz, R D Carvajal.
Sarcoma, 2014 Apr 30; 2014. PMID: 24778572    Free PMC article.
Evolving strategies for cancer and autoimmunity: back to the future.
Peter J L Lane, Fiona M McConnell, +3 authors, David R Withers.
Front Immunol, 2014 May 02; 5. PMID: 24782861    Free PMC article.
Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.
Kendall C Shibuya, Vikas K Goel, +8 authors, Venu G Pillarisetty.
PLoS One, 2014 May 06; 9(5). PMID: 24794217    Free PMC article.
T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy.
Ignacio Melero, Ana Rouzaut, Greg T Motz, George Coukos.
Cancer Discov, 2014 May 06; 4(5). PMID: 24795012    Free PMC article.
Highly Cited.
Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.
Francesca Avogadri, Roberta Zappasodi, +8 authors, Taha Merghoub.
Cancer Immunol Res, 2014 May 06; 2(5). PMID: 24795357    Free PMC article.
Restoring the balance: immunotherapeutic combinations for autoimmune disease.
Dawn E Smilek, Mario R Ehlers, Gerald T Nepom.
Dis Model Mech, 2014 May 06; 7(5). PMID: 24795433    Free PMC article.
Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning.
Dominik Wolf, Annkristin Heine, Peter Brossart.
Oncoimmunology, 2014 May 07; 3(1). PMID: 24800168    Free PMC article.
BRAFV600E-mutant melanoma presenting with cardiac involvement.
Douglas B Johnson, Jeffrey A Sosman.
J Natl Compr Canc Netw, 2014 May 09; 12(5). PMID: 24812130    Free PMC article.
Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.
Mohammad Atefi, Earl Avramis, +9 authors, Antoni Ribas.
Clin Cancer Res, 2014 May 09; 20(13). PMID: 24812408    Free PMC article.
Highly Cited.
Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.
Kim A Reiss, Patrick M Forde, Julie R Brahmer.
Immunotherapy, 2014 May 13; 6(4). PMID: 24815784    Free PMC article.
Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1.
Markus Moehler, Katrin Goepfert, +4 authors, Jean Rommelaere.
Front Oncol, 2014 May 14; 4. PMID: 24822170    Free PMC article.
Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors.
Willem W Overwijk, Ena Wang, +2 authors, Nicholas P Restifo.
J Immunother Cancer, 2013 Jan 01; 1. PMID: 24829748    Free PMC article.
Rational combinations of immunotherapeutics that target discrete pathways.
Stefani Spranger, Thomas Gajewski.
J Immunother Cancer, 2013 Jan 01; 1. PMID: 24829752    Free PMC article.
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.
Stefani Spranger, Holly K Koblish, +3 authors, Thomas F Gajewski.
J Immunother Cancer, 2014 May 16; 2. PMID: 24829760    Free PMC article.
Highly Cited.
Colorectal cancer and immunity: what we know and perspectives.
Simon Pernot, Magali Terme, +4 authors, Julien Taieb.
World J Gastroenterol, 2014 May 17; 20(14). PMID: 24833840    Free PMC article.
Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.
Harm Westdorp, Annette E Sköld, +6 authors, I Jolanda M de Vries.
Front Immunol, 2014 May 17; 5. PMID: 24834066    Free PMC article.
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy.
David A Schaer, Daniel Hirschhorn-Cymerman, Jedd D Wolchok.
J Immunother Cancer, 2014 May 24; 2. PMID: 24855562    Free PMC article.
Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program.
Roxanne Payne, Lyn Glenn, +6 authors, Brendan D Curti.
J Immunother Cancer, 2014 May 24; 2. PMID: 24855563    Free PMC article.
Does the immune system naturally protect against cancer?
Alexandre Corthay.
Front Immunol, 2014 May 27; 5. PMID: 24860567    Free PMC article.
Highly Cited. Review.
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer.
Raju R Raval, Andrew B Sharabi, +2 authors, Padmanee Sharma.
J Immunother Cancer, 2014 Jun 03; 2. PMID: 24883190    Free PMC article.
A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study).
Shoichi Hazama, Yusuke Nakamura, +25 authors, Masaaki Oka.
J Transl Med, 2014 Jun 03; 12. PMID: 24884643    Free PMC article.
What have we learned from cancer immunotherapy in the last 3 years?
Paolo A Ascierto, Francesco M Marincola.
J Transl Med, 2014 Jun 03; 12. PMID: 24886164    Free PMC article.
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.
J Louise Lines, Lorenzo F Sempere, +2 authors, Randolph Noelle.
Cancer Immunol Res, 2014 Jun 05; 2(6). PMID: 24894088    Free PMC article.
Highly Cited.
Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1.
Yi-Chi M Kong, Jeffrey C Flynn.
Front Immunol, 2014 Jun 07; 5. PMID: 24904570    Free PMC article.
Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via a proteasome-mediated degradation mechanism.
Laïla-Aïcha Hanafi, Dominique Gauchat, +5 authors, Réjean Lapointe.
PLoS One, 2014 Jun 10; 9(6). PMID: 24911872    Free PMC article.
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.
Tai Hato, Lipika Goyal, +2 authors, Andrew X Zhu.
Hepatology, 2014 Jun 11; 60(5). PMID: 24912948    Free PMC article.
Highly Cited. Review.
Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex.
Eyal Greenberg, Steven Hajdu, +6 authors, Gal Markel.
Open Biol, 2014 Jun 13; 4(6). PMID: 24920276    Free PMC article.
B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.
Aaron Scott Mansfield, Anja C Roden, +5 authors, Eugene D Kwon.
J Thorac Oncol, 2014 Jun 14; 9(7). PMID: 24926549    Free PMC article.
Induced regulatory T cells in inhibitory microenvironments created by cancer.
Theresa L Whiteside.
Expert Opin Biol Ther, 2014 Jun 18; 14(10). PMID: 24934899    Free PMC article.
Statin use and its effect on all-cause mortality of melanoma patients: a population-based Dutch cohort study.
Elisabeth Livingstone, Loes M Hollestein, +6 authors, Esther de Vries.
Cancer Med, 2014 Jun 18; 3(5). PMID: 24935402    Free PMC article.
The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation.
Sandra Demaria, Karsten A Pilones, +2 authors, Silvia C Formenti.
Radiat Res, 2014 Jun 18; 182(2). PMID: 24937779    Free PMC article.
[Advances of immunotherapy in small cell lung cancer].
Jingjing Liu, Shuang Zhang, Hui Li, Ying Cheng.
Zhongguo Fei Ai Za Zhi, 2014 Jun 21; 17(6). PMID: 24949688    Free PMC article.
A 20-year experience of hepatic resection for melanoma: is there an expanding role?
Mark B Faries, Anna Leung, +4 authors, Anton J Bilchik.
J Am Coll Surg, 2014 Jun 24; 219(1). PMID: 24952441    Free PMC article.
The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.
Delia Nelson, Scott Fisher, Bruce Robinson.
J Immunol Res, 2014 Jun 24; 2014. PMID: 24955376    Free PMC article.
Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.
Siwen Hu-Lieskovan, Lidia Robert, Blanca Homet Moreno, Antoni Ribas.
J Clin Oncol, 2014 Jun 25; 32(21). PMID: 24958825    Free PMC article.
Highly Cited. Review.
Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).
Sadek Malas, Micaela Harrasser, Katie E Lacy, Sophia N Karagiannis.
Oncol Rep, 2014 Jun 28; 32(3). PMID: 24969320    Free PMC article.
The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade.
Antoni Ribas, Paul C Tumeh.
Clin Cancer Res, 2014 Jun 28; 20(19). PMID: 24970841    Free PMC article.
p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.
Nicola R Hardwick, Mary Carroll, +12 authors, Vincent Chung.
Clin Cancer Res, 2014 Jul 06; 20(17). PMID: 24987057    Free PMC article.
Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists.
Michail V Sitkovsky, Stephen Hatfield, +3 authors, Akio Ohta.
Cancer Immunol Res, 2014 Jul 06; 2(7). PMID: 24990240    Free PMC article.
Therapeutic vaccines for cancer: an overview of clinical trials.
Ignacio Melero, Gustav Gaudernack, +8 authors, Håkan Mellstedt.
Nat Rev Clin Oncol, 2014 Jul 09; 11(9). PMID: 25001465
Highly Cited. Review.
Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model.
Zineb Belcaid, Jillian A Phallen, +17 authors, Michael Lim.
PLoS One, 2014 Jul 12; 9(7). PMID: 25013914    Free PMC article.
Highly Cited.
New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy.
Jason J Luke, Patrick A Ott.
Drug Healthc Patient Saf, 2014 Jul 16; 6. PMID: 25018652    Free PMC article.
Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.
Megan N Breit, William C Kisseberth, +6 authors, Cheryl A London.
BMC Vet Res, 2014 Jul 16; 10. PMID: 25022346    Free PMC article.
Nivolumab: a review of its use in patients with malignant melanoma.
Emma D Deeks.
Drugs, 2014 Jul 16; 74(11). PMID: 25022950
Distinctive features of CD4+ T cell dysfunction in chronic viral infections.
Antigoni Morou, Brent E Palmer, Daniel E Kaufmann.
Curr Opin HIV AIDS, 2014 Jul 16; 9(5). PMID: 25023623    Free PMC article.
Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts.
Stefanie N Linch, William L Redmond.
Oncoimmunology, 2014 Jul 23; 3. PMID: 25050194    Free PMC article.
Castration-resistant prostate cancer: latest evidence and therapeutic implications.
Daniel L Suzman, Emmanuel S Antonarakis.
Ther Adv Med Oncol, 2014 Jul 25; 6(4). PMID: 25057303    Free PMC article.
Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma.
Derek A Wainwright, Maciej S Lesniak.
Oncoimmunology, 2014 Jul 25; 3. PMID: 25057450    Free PMC article.
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.
KiBem Kim, Andrew D Skora, +8 authors, Shibin Zhou.
Proc Natl Acad Sci U S A, 2014 Jul 30; 111(32). PMID: 25071169    Free PMC article.
Highly Cited.
Current status of cancer immunotherapy.
K Kono.
J Stem Cells Regen Med, 2014 Jul 31; 10(1). PMID: 25075156    Free PMC article.
Adaptive immunity in cancer immunology and therapeutics.
Emma L Spurrell, Michelle Lockley.
Ecancermedicalscience, 2014 Jul 31; 8. PMID: 25075215    Free PMC article.
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Yu Zhu, Brett L Knolhoff, +7 authors, David G DeNardo.
Cancer Res, 2014 Aug 02; 74(18). PMID: 25082815    Free PMC article.
Highly Cited.
Current and future systemic treatment options in metastatic pancreatic cancer.
Cagatay Arslan, Suayib Yalcin.
J Gastrointest Oncol, 2014 Aug 02; 5(4). PMID: 25083302    Free PMC article.
High sensitivity of cancer exome-based CD8 T cell neo-antigen identification.
Marit M van Buuren, Jorg Ja Calis, Ton Nm Schumacher.
Oncoimmunology, 2014 Aug 02; 3. PMID: 25083320    Free PMC article.
Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression.
Mark J Smyth, Michele W L Teng.
Oncoimmunology, 2014 Aug 02; 3. PMID: 25083324    Free PMC article.
Trial Watch: Toll-like receptor agonists in oncological indications.
Fernando Aranda, Erika Vacchelli, +8 authors, Lorenzo Galluzzi.
Oncoimmunology, 2014 Aug 02; 3. PMID: 25083332    Free PMC article.
Comparison of gene expression patterns across 12 tumor types identifies a cancer supercluster characterized by TP53 mutations and cell cycle defects.
E Martínez, K Yoshihara, +3 authors, R G W Verhaak.
Oncogene, 2014 Aug 05; 34(21). PMID: 25088195    Free PMC article.
Immune checkpoint inhibitors in NSCLC.
Douglas B Johnson, Matthew J Rioth, Leora Horn.
Curr Treat Options Oncol, 2014 Aug 07; 15(4). PMID: 25096781    Free PMC article.
Sugars boost exhausted tumor-infiltrating lymphocytes by counteracting immunosuppressive activities of galectins.
Monica Gordon-Alonso, Nathalie Demotte, Pierre van der Bruggen.
Oncoimmunology, 2014 Aug 07; 3. PMID: 25097806    Free PMC article.
Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation.
Miguel F Sanmamed, Lieping Chen.
Cancer J, 2014 Aug 08; 20(4). PMID: 25098285    Free PMC article.
Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.
Lauren C Harshman, Toni K Choueiri, Charles Drake, F Stephen Hodi.
Cancer J, 2014 Aug 08; 20(4). PMID: 25098288    Free PMC article.
Oncolytic viruses as anticancer vaccines.
Norman Woller, Engin Gürlevik, +2 authors, Florian Kühnel.
Front Oncol, 2014 Aug 08; 4. PMID: 25101244    Free PMC article.
Acquired and intrinsic resistance in cancer immunotherapy.
Sander Kelderman, Ton N M Schumacher, John B A G Haanen.
Mol Oncol, 2014 Aug 12; 8(6). PMID: 25106088    Free PMC article.
Biology of advanced uveal melanoma and next steps for clinical therapeutics.
Jason J Luke, Pierre L Triozzi, +15 authors, Richard D Carvajal.
Pigment Cell Melanoma Res, 2014 Aug 13; 28(2). PMID: 25113308    Free PMC article.
Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection.
Pablo Penaloza-MacMaster, Alice O Kamphorst, +10 authors, Rafi Ahmed.
J Exp Med, 2014 Aug 13; 211(9). PMID: 25113973    Free PMC article.
Highly Cited.
PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence.
Scott S Tykodi.
Onco Targets Ther, 2014 Aug 13; 7. PMID: 25114573    Free PMC article.
Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape?
Valentin S Bruttel, Jörg Wischhusen.
Front Immunol, 2014 Aug 15; 5. PMID: 25120546    Free PMC article.
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
Channing J Paller, Penelope A Bradbury, +13 authors, Mark J Ratain.
Clin Cancer Res, 2014 Aug 16; 20(16). PMID: 25125258    Free PMC article.
Vaccines, new opportunities for a new society.
Rino Rappuoli, Mariagrazia Pizza, Giuseppe Del Giudice, Ennio De Gregorio.
Proc Natl Acad Sci U S A, 2014 Aug 20; 111(34). PMID: 25136130    Free PMC article.
Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.
Zineb Belcaid, Martine L M Lamfers, Victor W van Beusechem, Rob C Hoeben.
Hum Gene Ther, 2014 Aug 22; 25(10). PMID: 25141764    Free PMC article.
Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.
Min Dai, Yuen Yee Yip, Ingegerd Hellstrom, Karl Erik Hellstrom.
Clin Cancer Res, 2014 Aug 22; 21(5). PMID: 25142145    Free PMC article.
Immunotherapy in pediatric malignancies: current status and future perspectives.
Christian M Capitini, Mario Otto, Kenneth B DeSantes, Paul M Sondel.
Future Oncol, 2014 Aug 26; 10(9). PMID: 25145434    Free PMC article.
Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients.
Vincenzo Formica, Jessica Luccchetti, +7 authors, Mario Roselli.
Med Oncol, 2014 Aug 26; 31(9). PMID: 25148896
Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment.
Kousaku Mimura, Ley-Fang Kua, +8 authors, Koji Kono.
Cancer Sci, 2014 Aug 27; 105(10). PMID: 25154680    Free PMC article.
Vaccine therapies for patients with glioblastoma.
Eli T Sayegh, Taemin Oh, +2 authors, Andrew T Parsa.
J Neurooncol, 2014 Aug 29; 119(3). PMID: 25163836
Antibody-based immunotherapy for malignant glioma.
Patrick C Gedeon, Katherine A Riccione, Peter E Fecci, John H Sampson.
Semin Oncol, 2014 Sep 01; 41(4). PMID: 25173142    Free PMC article.
No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.
Maria Romina Girotti, Grazia Saturno, Paul Lorigan, Richard Marais.
Mol Oncol, 2014 Sep 03; 8(6). PMID: 25178978    Free PMC article.
Combining radiation and immunotherapy: a new systemic therapy for solid tumors?
Chad Tang, Xiaohong Wang, +14 authors, James W Welsh.
Cancer Immunol Res, 2014 Sep 05; 2(9). PMID: 25187273    Free PMC article.
Highly Cited. Review.
Immune checkpoint inhibitors in clinical trials.
Elad Sharon, Howard Streicher, Priscila Goncalves, Helen X Chen.
Chin J Cancer, 2014 Sep 06; 33(9). PMID: 25189716    Free PMC article.
Cancer immunotherapy in clinical practice -- the past, present, and future.
Gaurav Goel, Weijing Sun.
Chin J Cancer, 2014 Sep 06; 33(9). PMID: 25189717    Free PMC article.
Novel anti-melanoma treatment: focus on immunotherapy.
Meng-Ze Hao, Wen-Ya Zhou, +4 authors, Ji-Long Yang.
Chin J Cancer, 2014 Sep 06; 33(9). PMID: 25189718    Free PMC article.
Immunotherapy advances for glioblastoma.
David A Reardon, Gordon Freeman, +7 authors, Glenn Dranoff.
Neuro Oncol, 2014 Sep 06; 16(11). PMID: 25190673    Free PMC article.
Highly Cited. Review.
The relationship between blood IL-12p40 level and melanoma progression.
Shenying Fang, Yuling Wang, +14 authors, Jeffrey E Lee.
Int J Cancer, 2014 Sep 10; 136(8). PMID: 25196740    Free PMC article.
Immune modulation for cancer therapy.
J Naidoo, D B Page, J D Wolchok.
Br J Cancer, 2014 Sep 12; 111(12). PMID: 25211661    Free PMC article.
Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor.
Kyriakos Neofytou, Elizabeth C Smyth, +3 authors, Satvinder Mudan.
Med Oncol, 2014 Sep 15; 31(10). PMID: 25218270
Clinical cancer research: the past, present and the future.
Vincent T DeVita, Alexander M M Eggermont, Samuel Hellman, David J Kerr.
Nat Rev Clin Oncol, 2014 Sep 24; 11(11). PMID: 25245981
Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.
David L Bajor, Xiaowei Xu, +8 authors, Robert H Vonderheide.
Cancer Immunol Res, 2014 Sep 26; 2(11). PMID: 25252722    Free PMC article.
T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?
Daniel E Speiser, Daniel T Utzschneider, +3 authors, Dietmar Zehn.
Nat Rev Immunol, 2014 Sep 27; 14(11). PMID: 25257362
Highly Cited.
The future of glioblastoma therapy: synergism of standard of care and immunotherapy.
Mira A Patel, Jennifer E Kim, +2 authors, Michael Lim.
Cancers (Basel), 2014 Oct 01; 6(4). PMID: 25268164    Free PMC article.
Strategies for modern biomarker and drug development in oncology.
Alan D Smith, Desam Roda, Timothy A Yap.
J Hematol Oncol, 2014 Oct 04; 7. PMID: 25277503    Free PMC article.
Highly Cited. Review.
The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity.
Suzanne Ostrand-Rosenberg, Lucas A Horn, Samuel T Haile.
J Immunol, 2014 Oct 05; 193(8). PMID: 25281753    Free PMC article.
Highly Cited. Review.
Translational research in oncology--10 years of progress and future prospects.
James H Doroshow, Shivaani Kummar.
Nat Rev Clin Oncol, 2014 Oct 08; 11(11). PMID: 25286976
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
Stephanie R Jackson, Jinyun Yuan, Ryan M Teague.
Immunotherapy, 2014 Oct 08; 6(7). PMID: 25290416    Free PMC article.
The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014.
Paolo A Ascierto, Raffaele Addeo, +9 authors, Vincenzo Montesarchio.
J Transl Med, 2014 Oct 22; 12. PMID: 25331657    Free PMC article.
[Advances of PD-1/PD-L1 signaling pathway in immune escape and treatment for 
non-small cell lung cancer].
Cheng Lin, Xiong Chen, +2 authors, Xuenong Ou-Yang.
Zhongguo Fei Ai Za Zhi, 2014 Oct 25; 17(10). PMID: 25342040    Free PMC article.
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.
Paolo A Ascierto, Antonio M Grimaldi, +32 authors, Magdalena Thurin.
J Transl Med, 2014 Oct 29; 12. PMID: 25348889    Free PMC article.
Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.
Yu Sawada, Toshiaki Yoshikawa, +3 authors, Tetsuya Nakatsura.
Int J Oncol, 2014 Oct 31; 46(1). PMID: 25354479    Free PMC article.
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.
Anna Sophie Berghoff, Barbara Kiesel, +14 authors, Wolfgang Wick.
Neuro Oncol, 2014 Oct 31; 17(8). PMID: 25355681    Free PMC article.
Highly Cited.
Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.
Michael R Olin, G Elizabeth Pluhar, +3 authors, Christopher L Moertel.
Crit Rev Immunol, 2014 Nov 19; 34(5). PMID: 25404047    Free PMC article.
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, +18 authors, Timothy A Chan.
N Engl J Med, 2014 Nov 20; 371(23). PMID: 25409260    Free PMC article.
Highly Cited.
Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome.
Mizuki Nishino, Anita Giobbie-Hurder, Nikhil H Ramaiya, F Stephen Hodi.
J Immunother Cancer, 2014 Nov 21; 2(1). PMID: 25411640    Free PMC article.
The melanoma revolution: from UV carcinogenesis to a new era in therapeutics.
Jennifer A Lo, David E Fisher.
Science, 2014 Nov 22; 346(6212). PMID: 25414302    Free PMC article.
Highly Cited. Review.
Awareness and understanding of cancer immunotherapy in Europe.
Håkan Mellstedt, Gustav Gaudernack, +7 authors, Christoph Zielinski.
Hum Vaccin Immunother, 2014 Nov 27; 10(7). PMID: 25424789    Free PMC article.
PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, +23 authors, Antoni Ribas.
Nature, 2014 Nov 28; 515(7528). PMID: 25428505    Free PMC article.
Highly Cited.
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Matthew M Gubin, Xiuli Zhang, +24 authors, Robert D Schreiber.
Nature, 2014 Nov 28; 515(7528). PMID: 25428507    Free PMC article.
Highly Cited.
Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies?
Lei Zheng.
Immunotherapy, 2014 Nov 28; 6(10). PMID: 25428641    Free PMC article.
Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.
Xin Gao, Xuefeng Wang, +14 authors, Binfeng Lu.
J Immunol, 2014 Nov 28; 194(1). PMID: 25429071    Free PMC article.
Highly Cited.
Partial hepatectomy for primary hepatic melanoma: a report of two cases and review of the literature.
Yuhua Zhang, Zhiming Hu, +3 authors, Chengwu Zhang.
World J Surg Oncol, 2014 Nov 29; 12. PMID: 25430016    Free PMC article.
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
Kim C Ohaegbulam, Amer Assal, +2 authors, Xingxing Zang.
Trends Mol Med, 2014 Dec 03; 21(1). PMID: 25440090    Free PMC article.
Highly Cited. Review.
Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions.
Abhishek Tripathi, Charles G Drake, Lauren C Harshman.
BioDrugs, 2014 Dec 03; 28(6). PMID: 25445176    Free PMC article.
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
Robert J Motzer, Brian I Rini, +12 authors, Hans J Hammers.
J Clin Oncol, 2014 Dec 03; 33(13). PMID: 25452452    Free PMC article.
Highly Cited.
PD-1 blockade in renal cell carcinoma: to equilibrium and beyond.
Lauren C Harshman, Charles G Drake, Toni K Choueiri.
Cancer Immunol Res, 2014 Dec 07; 2(12). PMID: 25480555    Free PMC article.
Adding fuel to the fire: immunogenic intensification.
Geraldine O'Sullivan Coyne, James L Gulley.
Hum Vaccin Immunother, 2014 Dec 09; 10(11). PMID: 25483630    Free PMC article.
Novel dendritic cell-based vaccination in late stage melanoma.
Erika J Schneble, Xianzhong Yu, T E Wagner, George E Peoples.
Hum Vaccin Immunother, 2014 Dec 09; 10(11). PMID: 25483650    Free PMC article.
Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review.
Daniel M Geynisman, Chun-Ru Chien, +2 authors, Ya-Chen Tina Shih.
Hum Vaccin Immunother, 2014 Dec 09; 10(11). PMID: 25483656    Free PMC article.
Systematic Review.
CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.
Mustafa Diken, Sebastian Boegel, +6 authors, Sebastian Kreiter.
Hum Vaccin Immunother, 2014 Dec 09; 10(10). PMID: 25483671    Free PMC article.
Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway.
Parisa Momtaz, Michael A Postow.
Pharmgenomics Pers Med, 2014 Dec 09; 7. PMID: 25484597    Free PMC article.
[Molecular diagnostics of melanomas].
K G Griewank.
Pathologe, 2014 Dec 11; 36(1). PMID: 25491471
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.
Maria Romina Girotti, Filipa Lopes, +25 authors, Caroline Springer.
Cancer Cell, 2014 Dec 17; 27(1). PMID: 25500121    Free PMC article.
Highly Cited.
Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.
Ann L White, H T Claude Chan, +15 authors, Martin J Glennie.
Cancer Cell, 2014 Dec 17; 27(1). PMID: 25500122    Free PMC article.
Immune escape mechanisms as a guide for cancer immunotherapy.
Gregory L Beatty, Whitney L Gladney.
Clin Cancer Res, 2014 Dec 17; 21(4). PMID: 25501578    Free PMC article.
Highly Cited. Review.
Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity.
C Göbel, F Breitenbuecher, +7 authors, M Schuler.
Cell Death Dis, 2014 Dec 17; 5. PMID: 25501829    Free PMC article.
Current and emerging therapies for bone metastatic castration-resistant prostate cancer.
Jeremy S Frieling, David Basanta, Conor C Lynch.
Cancer Control, 2014 Dec 17; 22(1). PMID: 25504285    Free PMC article.
The delicate balance of melanoma immunotherapy.
David E Gyorki, Margaret Callahan, Jedd D Wolchok, Charlotte E Ariyan.
Clin Transl Immunology, 2013 Aug 01; 2(8). PMID: 25505953    Free PMC article.
Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies.
Jing Liu, Stephen J Blake, Mark J Smyth, Michele Wl Teng.
Clin Transl Immunology, 2014 Dec 17; 3(8). PMID: 25505970    Free PMC article.
Novel immunotherapies for hematologic malignancies.
Michelle H Nelson, Chrystal M Paulos.
Immunol Rev, 2014 Dec 17; 263(1). PMID: 25510273    Free PMC article.
The TLR2 agonist in polysaccharide-K is a structurally distinct lipid which acts synergistically with the protein-bound β-glucan.
Kenneth Quayle, Catherine Coy, Leanna Standish, Hailing Lu.
J Nat Med, 2014 Dec 17; 69(2). PMID: 25510899
Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cells.
Melissa M Berrien-Elliott, Jinyun Yuan, +4 authors, Ryan M Teague.
Cancer Immunol Res, 2014 Dec 18; 3(2). PMID: 25516478    Free PMC article.
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.
Rakesh K Jain.
Cancer Cell, 2014 Dec 18; 26(5). PMID: 25517747    Free PMC article.
Highly Cited. Review.
Are macrophages in tumors good targets for novel therapeutic approaches?
Samthosh V Alahari, Shengli Dong, Suresh K Alahari.
Mol Cells, 2014 Dec 19; 38(2). PMID: 25518927    Free PMC article.
Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.
Geoffrey T Gibney, Ragini R Kudchadkar, +13 authors, Jeffrey S Weber.
Clin Cancer Res, 2014 Dec 20; 21(4). PMID: 25524312    Free PMC article.
Highly Cited.
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
Andrew B Sharabi, Christopher J Nirschl, +5 authors, Charles G Drake.
Cancer Immunol Res, 2014 Dec 21; 3(4). PMID: 25527358    Free PMC article.
Highly Cited.
A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma.
Ragini Kudchadkar, Scott Ernst, +7 authors, Jeffrey Weber.
Cancer Med, 2014 Dec 24; 4(5). PMID: 25533314    Free PMC article.
Clinical blockade of PD1 and LAG3--potential mechanisms of action.
Linh T Nguyen, Pamela S Ohashi.
Nat Rev Immunol, 2014 Dec 24; 15(1). PMID: 25534622
Highly Cited. Review.
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
Daniel Morgensztern, Meghan J Campo, +21 authors, Ramaswamy Govindan.
J Thorac Oncol, 2014 Dec 24; 10(1 Suppl 1). PMID: 25535693    Free PMC article.
Classification of current anticancer immunotherapies.
Lorenzo Galluzzi, Erika Vacchelli, +85 authors, Guido Kroemer.
Oncotarget, 2014 Dec 30; 5(24). PMID: 25537519    Free PMC article.
Highly Cited. Review.
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
Rituparna Das, Rakesh Verma, +8 authors, Kavita M Dhodapkar.
J Immunol, 2014 Dec 30; 194(3). PMID: 25539810    Free PMC article.
Highly Cited.
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.
Sandra P D'Angelo, Alexander N Shoushtari, +8 authors, William D Tap.
Hum Pathol, 2014 Dec 30; 46(3). PMID: 25540867    Free PMC article.
Highly Cited.
Microenvironmental regulation of therapeutic response in cancer.
Florian Klemm, Johanna A Joyce.
Trends Cell Biol, 2014 Dec 30; 25(4). PMID: 25540894    Free PMC article.
Highly Cited. Review.
HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).
Daniel J Kowalewski, Heiko Schuster, +7 authors, Juliane Sarah Stickel.
Proc Natl Acad Sci U S A, 2014 Dec 31; 112(2). PMID: 25548167    Free PMC article.
Highly Cited.
The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy.
Joanne Leung, Woong-Kyung Suh.
Immune Netw, 2015 Jan 01; 14(6). PMID: 25550693    Free PMC article.
Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential.
Morganna Freeman-Keller, Jeffrey S Weber.
Ther Adv Med Oncol, 2015 Jan 02; 7(1). PMID: 25553080    Free PMC article.
Therapeutic targeting of tumor suppressor genes.
Luc G T Morris, Timothy A Chan.
Cancer, 2015 Jan 06; 121(9). PMID: 25557041    Free PMC article.
T-cell exhaustion in allograft rejection and tolerance.
Edward B Thorp, Christian Stehlik, M Javeed Ansari.
Curr Opin Organ Transplant, 2015 Jan 08; 20(1). PMID: 25563990    Free PMC article.
Interleukin-7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression.
Yuichiro Shindo, Jacqueline Unsinger, +2 authors, Richard S Hotchkiss.
Shock, 2015 Jan 08; 43(4). PMID: 25565644    Free PMC article.
Understanding the complexity and malleability of T-cell recognition.
John J Miles, James McCluskey, Jamie Rossjohn, Stephanie Gras.
Immunol Cell Biol, 2015 Jan 15; 93(5). PMID: 25582337
Overcoming tumor immune evasion with an unique arbovirus.
Bruce Lyday, Tony Chen, Santosh Kesari, Boris Minev.
J Transl Med, 2015 Jan 17; 13. PMID: 25592450    Free PMC article.
Predictive biomarkers for dasatinib treatment in melanoma.
Alex J Eustace, Susan Kennedy, +6 authors, Norma O'Donovan.
Oncoscience, 2015 Jan 17; 1(2). PMID: 25594008    Free PMC article.
Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy.
Marina Moskalenko, Michael Pan, +11 authors, Yvonne Saenger.
Cancer Immunol Res, 2015 Jan 21; 3(3). PMID: 25600438    Free PMC article.
Immune Checkpoint Blockade in Cancer Therapy.
Michael A Postow, Margaret K Callahan, Jedd D Wolchok.
J Clin Oncol, 2015 Jan 22; 33(17). PMID: 25605845    Free PMC article.
Highly Cited. Review.
[Systemic treatment of distant metastatic malignant melanoma].
E Dabrowski, E Dippel.
Radiologe, 2015 Jan 23; 55(2). PMID: 25609506
Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.
Teresa Kim, Rodabe N Amaria, +3 authors, Jennifer A Wargo.
Cancer Biol Med, 2015 Jan 23; 11(4). PMID: 25610709    Free PMC article.
Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma.
Weiqing Jing, Jill A Gershan, +4 authors, Bryon D Johnson.
J Immunother Cancer, 2015 Jan 24; 3(1). PMID: 25614821    Free PMC article.
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
Luis H Camacho.
Cancer Med, 2015 Jan 27; 4(5). PMID: 25619164    Free PMC article.
Primary malignant melanoma of the trachea: A case report.
Hisao Imai, Yoshio Kiyohara, +12 authors, Toshiaki Takahashi.
Oncol Lett, 2015 Jan 28; 9(2). PMID: 25624894    Free PMC article.
PD-1 and PD-L1 antibodies for melanoma.
Katy K Tsai, Inés Zarzoso, Adil I Daud.
Hum Vaccin Immunother, 2015 Jan 28; 10(11). PMID: 25625924    Free PMC article.
Potential for immunotherapy in soft tissue sarcoma.
William W Tseng, Neeta Somaiah, Edgar G Engleman.
Hum Vaccin Immunother, 2015 Jan 28; 10(11). PMID: 25625925    Free PMC article.
Radiation meets immunotherapy - a perfect match in the era of combination therapy?
Klara Soukup, Xinhui Wang.
Int J Radiat Biol, 2015 Jan 30; 91(4). PMID: 25630486    Free PMC article.
CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic.
Margaret K Callahan, Michael A Postow, Jedd D Wolchok.
Front Oncol, 2015 Feb 03; 4. PMID: 25642417    Free PMC article.
Highly Cited. Review.
Immunomodulation of Selective Naive T Cell Functions by p110δ Inactivation Improves the Outcome of Mismatched Cell Transplantation.
Jean-Marc Doisne, Christian M Hüber, Klaus Okkenhaug, Francesco Colucci.
Cell Rep, 2015 Feb 11; 10(5). PMID: 25660021    Free PMC article.
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Dirk Schadendorf, F Stephen Hodi, +7 authors, Jedd D Wolchok.
J Clin Oncol, 2015 Feb 11; 33(17). PMID: 25667295    Free PMC article.
Highly Cited.
Evaluating biomarkers in melanoma.
Panagiotis Karagiannis, Matthew Fittall, Sophia N Karagiannis.
Front Oncol, 2015 Feb 11; 4. PMID: 25667918    Free PMC article.
Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein.
Ryan S Cross, Jordane Malaterre, +4 authors, Robert G Ramsay.
Clin Transl Immunology, 2015 Feb 12; 4(1). PMID: 25671128    Free PMC article.
Immunotherapy for the treatment of breast cancer.
Brenda Ernst, Karen S Anderson.
Curr Oncol Rep, 2015 Feb 14; 17(2). PMID: 25677118
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.
Rafael Winograd, Katelyn T Byrne, +8 authors, Robert H Vonderheide.
Cancer Immunol Res, 2015 Feb 14; 3(4). PMID: 25678581    Free PMC article.
Highly Cited.
PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma.
Jason J Luke, Patrick A Ott.
Oncotarget, 2015 Feb 17; 6(6). PMID: 25682878    Free PMC article.
Highly Cited. Review.
γδ T Cell Immunotherapy-A Review.
Hirohito Kobayashi, Yoshimasa Tanaka.
Pharmaceuticals (Basel), 2015 Feb 17; 8(1). PMID: 25686210    Free PMC article.
Immunotherapeutic advancements for glioblastoma.
Leonel Ampie, Eric C Woolf, Christopher Dardis.
Front Oncol, 2015 Feb 18; 5. PMID: 25688335    Free PMC article.
Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies.
Joanna Y Wang, Chetan Bettegowda.
J Neurooncol, 2015 Feb 24; 123(3). PMID: 25697584
Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma.
William W Tseng, Shruti Malu, +10 authors, Patrick Hwu.
Sarcoma, 2015 Feb 24; 2015. PMID: 25705114    Free PMC article.
The role of mast cells in cancers.
Thiago T Maciel, Ivan C Moura, Olivier Hermine.
F1000Prime Rep, 2015 Feb 24; 7. PMID: 25705392    Free PMC article.
Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials.
David A Reardon, Hideho Okada.
J Neurooncol, 2015 Feb 25; 123(3). PMID: 25707876
Chitosan hydrogel vaccine generates protective CD8 T cell memory against mouse melanoma.
Andrew J Highton, Thunjiradasiree Kojarunchitt, +2 authors, Roslyn A Kemp.
Immunol Cell Biol, 2015 Feb 25; 93(7). PMID: 25708538
Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.
Mariana Aris, María Marcela Barrio.
Front Immunol, 2015 Feb 25; 6. PMID: 25709607    Free PMC article.
Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.
Yasuharu Nishimura, Yusuke Tomita, +2 authors, Masanori Shinohara.
Cancer Sci, 2015 Mar 03; 106(5). PMID: 25726868    Free PMC article.
Targeting cancer-specific mutations by T cell receptor gene therapy.
Thomas Blankenstein, Matthias Leisegang, Wolfgang Uckert, Hans Schreiber.
Curr Opin Immunol, 2015 Mar 03; 33. PMID: 25728991    Free PMC article.
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.
Idit Sagiv-Barfi, Holbrook E K Kohrt, +3 authors, Ronald Levy.
Proc Natl Acad Sci U S A, 2015 Mar 03; 112(9). PMID: 25730880    Free PMC article.
Highly Cited.
Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.
Douglas B Johnson, Christine M Lovly, +12 authors, Jeffrey A Sosman.
Cancer Immunol Res, 2015 Mar 05; 3(3). PMID: 25736262    Free PMC article.
Highly Cited.
The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma.
Pengyuan Yang, Geoffrey J Markowitz, Xiao-Fan Wang.
Natl Sci Rev, 2015 Mar 06; 1(3). PMID: 25741453    Free PMC article.
The role of checkpoints in the treatment of GBM.
Jennifer E Kim, Michael Lim.
J Neurooncol, 2015 Mar 10; 123(3). PMID: 25749875    Free PMC article.
Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.
N Lendvai, A D Cohen, H J Cho.
Bone Marrow Transplant, 2015 Mar 10; 50(6). PMID: 25751647
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
Christina Twyman-Saint Victor, Andrew J Rech, +22 authors, Andy J Minn.
Nature, 2015 Mar 11; 520(7547). PMID: 25754329    Free PMC article.
Highly Cited.
Nivolumab in NSCLC: latest evidence and clinical potential.
Raghav Sundar, Byoung-Chul Cho, Julie R Brahmer, Ross A Soo.
Ther Adv Med Oncol, 2015 Mar 11; 7(2). PMID: 25755681    Free PMC article.
Highly Cited. Review.
Nivolumab in melanoma: latest evidence and clinical potential.
Douglas B Johnson, Chengwei Peng, Jeffrey A Sosman.
Ther Adv Med Oncol, 2015 Mar 11; 7(2). PMID: 25755682    Free PMC article.
Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer.
Colin R Lindsay, Pavlina Spiliopoulou, Ashita Waterston.
Ther Adv Med Oncol, 2015 Mar 11; 7(2). PMID: 25755683    Free PMC article.
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.
Stefanie N Linch, Michael J McNamara, William L Redmond.
Front Oncol, 2015 Mar 13; 5. PMID: 25763356    Free PMC article.
Highly Cited. Review.
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, +21 authors, Timothy A Chan.
Science, 2015 Mar 15; 348(6230). PMID: 25765070    Free PMC article.
Highly Cited.
TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10.
Ileana S Mauldin, Ena Wang, +3 authors, Craig L Slingluff.
Int J Cancer, 2015 Mar 15; 137(6). PMID: 25765738    Free PMC article.
Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study.
André P Fay, Sabina Signoretti, +12 authors, Toni K Choueiri.
J Immunother Cancer, 2015 Mar 15; 3. PMID: 25767716    Free PMC article.
Oncolytic virus immunotherapy for melanoma.
Neal Dharmadhikari, Janice M Mehnert, Howard L Kaufman.
Curr Treat Options Oncol, 2015 Mar 18; 16(3). PMID: 25777572
C-reactive protein as a marker of melanoma progression.
Shenying Fang, Yuling Wang, +14 authors, Jeffrey E Lee.
J Clin Oncol, 2015 Mar 18; 33(12). PMID: 25779565    Free PMC article.
Immunotherapy: The development of immunotherapy in urothelial bladder cancer.
Tom Powles.
Nat Rev Clin Oncol, 2015 Mar 18; 12(4). PMID: 25781573
Haematological malignancies: at the forefront of immunotherapeutic innovation.
Pavan Bachireddy, Ute E Burkhardt, Mohini Rajasagi, Catherine J Wu.
Nat Rev Cancer, 2015 Mar 20; 15(4). PMID: 25786696    Free PMC article.
Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.
Suzanne Ostrand-Rosenberg, Lucas A Horn, Juan A Alvarez.
Cancer Immunol Immunother, 2015 Mar 21; 64(10). PMID: 25792524    Free PMC article.
Overcoming T cell exhaustion in infection and cancer.
Kristen E Pauken, E John Wherry.
Trends Immunol, 2015 Mar 24; 36(4). PMID: 25797516    Free PMC article.
Highly Cited. Review.
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.
David F McDermott, Charles G Drake, +18 authors, Michael B Atkins.
J Clin Oncol, 2015 Mar 25; 33(18). PMID: 25800770    Free PMC article.
Highly Cited.
The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date.
Katy K Tsai, Adil I Daud.
Drugs, 2015 Mar 25; 75(6). PMID: 25802230
A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors.
Christoph C Zielinski.
Transl Lung Cancer Res, 2015 Mar 26; 3(6). PMID: 25806335    Free PMC article.
Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
Edward J Wyluda, Jihua Cheng, +8 authors, Joseph J Drabick.
Cancer Biol Ther, 2015 Mar 26; 16(5). PMID: 25806780    Free PMC article.
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Kathleen M Mahoney, Gordon J Freeman, David F McDermott.
Clin Ther, 2015 Apr 01; 37(4). PMID: 25823918    Free PMC article.
Highly Cited. Review.
New clinical advances in immunotherapy for the treatment of solid tumours.
Valentina A Zavala, Alexis M Kalergis.
Immunology, 2015 Apr 01; 145(2). PMID: 25826229    Free PMC article.
Impact of the immune system and immunotherapy in colorectal cancer.
Janet L Markman, Stephen L Shiao.
J Gastrointest Oncol, 2015 Apr 02; 6(2). PMID: 25830040    Free PMC article.
Epidemiology of melanoma in the South of Brazil: study of a city in the Vale do Itajaí from 1999 to 2013.
Adma Silva de Lima, Carlos Efrain Stein, Karla Patricia Casemiro, Rodrigo Kraft Rovere.
An Bras Dermatol, 2015 Apr 02; 90(2). PMID: 25830987    Free PMC article.
Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.
Kavitha Gowrishankar, Dilini Gunatilake, +3 authors, Peter Hersey.
PLoS One, 2015 Apr 07; 10(4). PMID: 25844720    Free PMC article.
Highly Cited.
Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes.
Shenying Fang, Yuling Wang, +15 authors, Jeffrey E Lee.
J Invest Dermatol, 2015 Apr 08; 135(9). PMID: 25848976    Free PMC article.
Broadening the repertoire of melanoma-associated T-cell epitopes.
Thomas Mørch Frøsig, Rikke Lyngaa, +5 authors, Sine Reker Hadrup.
Cancer Immunol Immunother, 2015 Apr 10; 64(5). PMID: 25854582    Free PMC article.
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers.
B Homet Moreno, A Ribas.
Br J Cancer, 2015 Apr 10; 112(9). PMID: 25856776    Free PMC article.
Highly Cited. Review.
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll.
Cancer Cell, 2015 Apr 11; 27(4). PMID: 25858804    Free PMC article.
Highly Cited. Review.
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.
Florencia Paula Madorsky Rowdo, Antonela Baron, Mariela Urrutia, José Mordoh.
Front Immunol, 2015 Apr 11; 6. PMID: 25859247    Free PMC article.
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.
Padmanee Sharma, James P Allison.
Cell, 2015 Apr 11; 161(2). PMID: 25860605    Free PMC article.
Highly Cited. Review.
Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy.
Hiromi Kumon, Katsumi Sasaki, +7 authors, Yasutomo Nasu.
Clin Med Insights Oncol, 2015 Apr 11; 9. PMID: 25861236    Free PMC article.
Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma.
Metin Kurtoglu, Nicole N Davarpanah, +3 authors, Andrea B Apolo.
Clin Genitourin Cancer, 2015 Apr 12; 13(5). PMID: 25862322    Free PMC article.
TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Joe-Marc Chauvin, Ornella Pagliano, +8 authors, Hassane M Zarour.
J Clin Invest, 2015 Apr 14; 125(5). PMID: 25866972    Free PMC article.
Highly Cited.
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
K Abiko, N Matsumura, +7 authors, M Mandai.
Br J Cancer, 2015 Apr 14; 112(9). PMID: 25867264    Free PMC article.
Highly Cited.
An exhaustion-like phenotype constrains the activity of CD4+ T cells specific for a self and melanoma antigen.
Matthew P Rausch, Karen Taraszka Hastings.
PLoS One, 2015 Apr 16; 10(4). PMID: 25875653    Free PMC article.
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.
Juan Fu, David B Kanne, +16 authors, Young Kim.
Sci Transl Med, 2015 Apr 17; 7(283). PMID: 25877890    Free PMC article.
Highly Cited.
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A Postow, Jason Chesney, +18 authors, F Stephen Hodi.
N Engl J Med, 2015 Apr 22; 372(21). PMID: 25891304    Free PMC article.
Highly Cited.
The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies.
Gaetano Bertino, Shirin Demma, +9 authors, Michele Malaguarnera.
Biomed Res Int, 2015 Apr 22; 2015. PMID: 25893197    Free PMC article.
Tumor infiltrating lymphocytes in ovarian cancer.
Phillip P Santoiemma, Daniel J Powell.
Cancer Biol Ther, 2015 Apr 22; 16(6). PMID: 25894333    Free PMC article.
Highly Cited. Review.
The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry.
Carole Fakhry, Klaus K Andersen, +2 authors, David W Eisele.
Cancer Prev Res (Phila), 2015 Apr 22; 8(7). PMID: 25896236    Free PMC article.
Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infection.
Wiebke Sondermann, Klaus G Griewank, +8 authors, Uwe Hillen.
PLoS One, 2015 Apr 22; 10(4). PMID: 25897843    Free PMC article.
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.
Heinz Läubli, Cathrin Balmelli, +3 authors, Alfred Zippelius.
J Immunother Cancer, 2015 Apr 23; 3. PMID: 25901283    Free PMC article.
Highly Cited.
The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors.
Emanuela Romano, Pedro Romero.
J Immunother Cancer, 2015 Apr 23; 3. PMID: 25901287    Free PMC article.
Immune Mechanisms Are Major Players in Cancer.
Karl Erik Hellstrom, Ingegerd Hellstrom.
Clin Cancer Res, 2015 Apr 24; 21(16). PMID: 25904750    Free PMC article.
Mechanisms of action of therapeutic antibodies for cancer.
J M Redman, E M Hill, D AlDeghaither, L M Weiner.
Mol Immunol, 2015 Apr 29; 67(2 Pt A). PMID: 25911943    Free PMC article.
Toxicities of Immunotherapy for the Practitioner.
Jeffrey S Weber, James C Yang, Michael B Atkins, Mary L Disis.
J Clin Oncol, 2015 Apr 29; 33(18). PMID: 25918278    Free PMC article.
Highly Cited. Review.
IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma.
Craig C Carson, Stergios J Moschos, +23 authors, Nancy E Thomas.
Clin Cancer Res, 2015 May 03; 21(9). PMID: 25934889    Free PMC article.
Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment.
Mizuki Nishino, Sree H Tirumani, Nikhil H Ramaiya, F Stephen Hodi.
Eur J Radiol, 2015 May 06; 84(7). PMID: 25937524    Free PMC article.
In vivo RNAi screens: concepts and applications.
Shane Crotty, Matthew E Pipkin.
Trends Immunol, 2015 May 06; 36(5). PMID: 25937561    Free PMC article.
Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.
Franz J Gassner, Nadja Zaborsky, +6 authors, Roland Geisberger.
Br J Haematol, 2015 May 06; 170(4). PMID: 25940792    Free PMC article.
Co-blockade of immune checkpoints and adenosine A2A receptor suppresses metastasis.
Arabella Young, Deepak Mittal, +5 authors, Mark J Smyth.
Oncoimmunology, 2015 May 06; 3(10). PMID: 25941583    Free PMC article.
Novel immune checkpoint blocker approved for the treatment of advanced melanoma.
Lorenzo Galluzzi, Guido Kroemer, Alexander Eggermont.
Oncoimmunology, 2015 May 06; 3(11). PMID: 25941597    Free PMC article.
Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity.
Henri-Alexandre Michaud, Jean-François Eliaou, +2 authors, Laurent Gros.
Oncoimmunology, 2015 May 06; 3(9). PMID: 25941618    Free PMC article.
Lymphoma: immune evasion strategies.
Ranjan Upadhyay, Linda Hammerich, +3 authors, Joshua D Brody.
Cancers (Basel), 2015 May 06; 7(2). PMID: 25941795    Free PMC article.
Regulation of viability, differentiation and death of human melanoma cells carrying neural stem cell biomarkers: a possibility for neural trans-differentiation.
Vladimir N Ivanov, Tom K Hei.
Apoptosis, 2015 May 09; 20(7). PMID: 25953317    Free PMC article.
SOCS1 Mimetics and Antagonists: A Complementary Approach to Positive and Negative Regulation of Immune Function.
Chulbul M I Ahmed, Joseph Larkin, Howard M Johnson.
Front Immunol, 2015 May 09; 6. PMID: 25954276    Free PMC article.
From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy.
Amelia E Firor, Alexander Jares, Yupo Ma.
Exp Biol Med (Maywood), 2015 May 10; 240(8). PMID: 25956686    Free PMC article.
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.
Leticia Corrales, Laura Hix Glickman, +10 authors, Thomas F Gajewski.
Cell Rep, 2015 May 12; 11(7). PMID: 25959818    Free PMC article.
Highly Cited.
Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types.
Tara C Gangadhar, April Ks Salama.
Onco Targets Ther, 2015 May 12; 8. PMID: 25960664    Free PMC article.
Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab.
Serena S Kwek, Jera Lewis, +7 authors, Lawrence Fong.
Cancer Immunol Res, 2015 May 15; 3(9). PMID: 25968455    Free PMC article.
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.
Stefani Spranger, Riyue Bao, Thomas F Gajewski.
Nature, 2015 May 15; 523(7559). PMID: 25970248
Highly Cited.
Therapeutic potential and challenges of natural killer cells in treatment of solid tumors.
Andrea Gras Navarro, Andreas T Björklund, Martha Chekenya.
Front Immunol, 2015 May 15; 6. PMID: 25972872    Free PMC article.
Highly Cited. Review.
Immunotherapeutic approaches to sarcoma.
Melissa Burgess, Hussein Tawbi.
Curr Treat Options Oncol, 2015 May 16; 16(6). PMID: 25975445
Classifying Cancers Based on T-cell Infiltration and PD-L1.
Michele W L Teng, Shin Foong Ngiow, Antoni Ribas, Mark J Smyth.
Cancer Res, 2015 May 16; 75(11). PMID: 25977340    Free PMC article.
Highly Cited. Review.
Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment.
Andrew B Sharabi, Phuoc T Tran, +2 authors, Theodore L Deweese.
Oncology (Williston Park), 2015 May 17; 29(5). PMID: 25979541    Free PMC article.
Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.
Hanna A Knaus, Christopher G Kanakry, Leo Luznik, Ivana Gojo.
Curr Drug Targets, 2015 May 20; 18(3). PMID: 25981611    Free PMC article.
Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system.
Loretta J Nastoupil, Sattva S Neelapu.
Curr Oncol Rep, 2015 May 20; 17(7). PMID: 25986722
NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade.
Frederick J Kohlhapp, Joseph R Broucek, +16 authors, Howard L Kaufman.
J Immunother Cancer, 2015 May 21; 3. PMID: 25992289    Free PMC article.
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma.
Danielle M Lussier, John L Johnson, Pooja Hingorani, Joseph N Blattman.
J Immunother Cancer, 2015 May 21; 3. PMID: 25992292    Free PMC article.
Highly Cited.
Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds?
Brendon J Coventry, Dominique Baume, Carrie Lilly.
Cancer Manag Res, 2015 May 23; 7. PMID: 25995649    Free PMC article.
Building better monoclonal antibody-based therapeutics.
George J Weiner.
Nat Rev Cancer, 2015 May 23; 15(6). PMID: 25998715    Free PMC article.
Highly Cited. Review.
Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model.
Jyothi Thyagabhavan Mony, Lixin Zhang, +8 authors, Anda M Vlad.
Cancer Immunol Immunother, 2015 May 23; 64(9). PMID: 25998800    Free PMC article.
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
Benjamin Boyerinas, Caroline Jochems, +4 authors, Jeffrey Schlom.
Cancer Immunol Res, 2015 May 28; 3(10). PMID: 26014098    Free PMC article.
Highly Cited.
Multiplying therapies and reducing toxicity in metastatic melanoma.
Paul R Massey, Vinay Prasad, William D Figg, Tito Fojo.
Cancer Biol Ther, 2015 May 29; 16(7). PMID: 26016850    Free PMC article.
Inhibitory receptors as targets for cancer immunotherapy.
Meghan E Turnis, Lawrence P Andrews, Dario A A Vignali.
Eur J Immunol, 2015 May 29; 45(7). PMID: 26018646    Free PMC article.
Beyond adjuvants: immunomodulation strategies to enhance T cell immunity.
Alice O Kamphorst, Koichi Araki, Rafi Ahmed.
Vaccine, 2015 May 30; 33 Suppl 2. PMID: 26022562    Free PMC article.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2015 Jun 02; 373(1). PMID: 26027431    Free PMC article.
Highly Cited.
Programmed death-1 checkpoint blockade in acute myeloid leukemia.
Alison Sehgal, Theresa L Whiteside, Michael Boyiadzis.
Expert Opin Biol Ther, 2015 Jun 04; 15(8). PMID: 26036819    Free PMC article.
PD-1/PD-L1 inhibitors.
Joel Sunshine, Janis M Taube.
Curr Opin Pharmacol, 2015 Jun 07; 23. PMID: 26047524    Free PMC article.
Highly Cited. Review.
Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate γδ-Low T Cells.
Yasutomo Imai, Natarajan Ayithan, +3 authors, Sam T Hwang.
J Immunol, 2015 Jun 07; 195(2). PMID: 26048148    Free PMC article.
Evolving Concepts: Immunity in Oncology from Targets to Treatments.
Hina Khan, Rasim Gucalp, Iuliana Shapira.
J Oncol, 2015 Jun 11; 2015. PMID: 26060497    Free PMC article.
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Gregory K Pennock, Laura Q M Chow.
Oncologist, 2015 Jun 13; 20(7). PMID: 26069281    Free PMC article.
Concepts of immunotherapy for glioma.
Mira A Patel, Drew M Pardoll.
J Neurooncol, 2015 Jun 14; 123(3). PMID: 26070552    Free PMC article.
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
Luisa Carbognin, Sara Pilotto, +11 authors, Giampaolo Tortora.
PLoS One, 2015 Jun 19; 10(6). PMID: 26086854    Free PMC article.
Highly Cited.
Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.
Sree Harsha Tirumani, Nikhil H Ramaiya, +4 authors, Mizuki Nishino.
Cancer Immunol Res, 2015 Jun 24; 3(10). PMID: 26100356    Free PMC article.
Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809).
Douglas G McNeel, Yu-Hui Chen, +4 authors, Robert S DiPaola.
Hum Vaccin Immunother, 2015 Jun 26; 11(10). PMID: 26111351    Free PMC article.
Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia.
Peter Hokland, Hans B Ommen, Matthew P Mulé, Christopher S Hourigan.
Semin Hematol, 2015 Jun 27; 52(3). PMID: 26111465    Free PMC article.
Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors.
Tai-Tsang Chen.
J Natl Cancer Inst, 2015 Jun 27; 107(9). PMID: 26113579    Free PMC article.
CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells.
Pablo Penaloza-MacMaster, Nicholas M Provine, Eryn Blass, Dan H Barouch.
J Immunol, 2015 Jun 28; 195(3). PMID: 26116499    Free PMC article.
Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.
Shannon K Quirk, Anna K Shure, Devendra K Agrawal.
Transl Res, 2015 Jun 30; 166(5). PMID: 26118951    Free PMC article.
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.
Michele W L Teng, Edward P Bowman, +4 authors, Daniel J Cua.
Nat Med, 2015 Jun 30; 21(7). PMID: 26121196
Highly Cited. Review.
Inflammation and cancer: advances and new agents.
Shanthini M Crusz, Frances R Balkwill.
Nat Rev Clin Oncol, 2015 Jul 01; 12(10). PMID: 26122183
Highly Cited. Review.
Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy.
David P Carbone, David R Gandara, +2 authors, Luis Paz-Ares.
J Thorac Oncol, 2015 Jul 03; 10(7). PMID: 26134219    Free PMC article.
The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer.
Nicole Antonio, Marie Louise Bønnelykke-Behrndtz, +6 authors, Paul Martin.
EMBO J, 2015 Jul 03; 34(17). PMID: 26136213    Free PMC article.
Highly Cited.
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.
Aitziber Buqué, Norma Bloy, +12 authors, Lorenzo Galluzzi.
Oncoimmunology, 2015 Jul 03; 4(4). PMID: 26137403    Free PMC article.
GITR agonist enhances vaccination responses in lung cancer.
Li X Zhu, Michael Davoodi, +8 authors, Sherven Sharma.
Oncoimmunology, 2015 Jul 03; 4(4). PMID: 26137407    Free PMC article.
The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy.
Simon Walz, Juliane S Stickel, +12 authors, Stefan Stevanović.
Blood, 2015 Jul 04; 126(10). PMID: 26138685    Free PMC article.
Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion.
Marilyn Giordano, Coralie Henin, +10 authors, Grégory Verdeil.
EMBO J, 2015 Jul 04; 34(15). PMID: 26139534    Free PMC article.
Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.
Guido Kroemer, Lorenzo Galluzzi.
Oncoimmunology, 2015 Jul 04; 4(7). PMID: 26140249    Free PMC article.
What's new in melanoma? Combination!
Paolo A Ascierto, Francesco M Marincola, Michael B Atkins.
J Transl Med, 2015 Jul 05; 13. PMID: 26141621    Free PMC article.
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment.
Claire Vanpouille-Box, Karsten A Pilones, +2 authors, Sandra Demaria.
Vaccine, 2015 Jul 08; 33(51). PMID: 26148880    Free PMC article.
Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.
Pierre Combe, Eleonore de Guillebon, +3 authors, Stéphane Oudard.
Oncoimmunology, 2015 Jul 15; 4(5). PMID: 26155388    Free PMC article.
Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy.
Nicola Mozzillo, Ester Simeone, +15 authors, Paolo A Ascierto.
Oncoimmunology, 2015 Jul 15; 4(6). PMID: 26155423    Free PMC article.
Clinical Development of Immune Checkpoint Inhibitors.
Ayumu Ito, Shunsuke Kondo, Kohei Tada, Shigehisa Kitano.
Biomed Res Int, 2015 Jul 15; 2015. PMID: 26161407    Free PMC article.
Inhibitory Receptors Beyond T Cell Exhaustion.
Silvia A Fuertes Marraco, Natalie J Neubert, Grégory Verdeil, Daniel E Speiser.
Front Immunol, 2015 Jul 15; 6. PMID: 26167163    Free PMC article.
Highly Cited. Review.
Immunotherapy for Bone and Soft Tissue Sarcomas.
Takenori Uehara, Tomohiro Fujiwara, +3 authors, Heiichiro Udono.
Biomed Res Int, 2015 Jul 15; 2015. PMID: 26167500    Free PMC article.
Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy.
Anna Niezgoda, Piotr Niezgoda, Rafał Czajkowski.
Biomed Res Int, 2015 Jul 15; 2015. PMID: 26171394    Free PMC article.
Highly Cited. Review.
Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy.
Tauqeer Ahmed, Ritwik Pandey, Bhavini Shah, Jason Black.
BMJ Case Rep, 2015 Jul 16; 2015. PMID: 26174726    Free PMC article.
RAC1 P29S regulates PD-L1 expression in melanoma.
Ha Linh Vu, Sheera Rosenbaum, +2 authors, Andrew E Aplin.
Pigment Cell Melanoma Res, 2015 Jul 16; 28(5). PMID: 26176707    Free PMC article.
Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes.
Tania Køllgaard, Selma Ugurel-Becker, +3 authors, Per Thor Straten.
PLoS One, 2015 Jul 16; 10(7). PMID: 26176858    Free PMC article.
CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy.
Lena M Kranz, Matthias Birtel, +8 authors, Mustafa Diken.
Hum Vaccin Immunother, 2015 Jul 18; 12(1). PMID: 26186022    Free PMC article.
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.
Alexander Faje.
Pituitary, 2015 Jul 19; 19(1). PMID: 26186958
Highly Cited. Review.
Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations.
W Joost Lesterhuis, Catherine Rinaldi, +8 authors, Richard A Lake.
Sci Rep, 2015 Jul 22; 5. PMID: 26193793    Free PMC article.
Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Ignacio Melero, David M Berman, +3 authors, John Haanen.
Nat Rev Cancer, 2015 Jul 25; 15(8). PMID: 26205340
Highly Cited. Review.
Molecular and cellular insights into T cell exhaustion.
E John Wherry, Makoto Kurachi.
Nat Rev Immunol, 2015 Jul 25; 15(8). PMID: 26205583    Free PMC article.
Highly Cited. Review.
Therapeutic cancer vaccines.
Cornelis J M Melief, Thorbald van Hall, +2 authors, Sjoerd H van der Burg.
J Clin Invest, 2015 Jul 28; 125(9). PMID: 26214521    Free PMC article.
Highly Cited. Review.
Metastatic melanoma: New paradigms of treatment and new toxicities.
Caroline Robert, Christina Mateus, +3 authors, Alexander M Eggermont.
EJC Suppl, 2013 Sep 01; 11(2). PMID: 26217144    Free PMC article.
Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy.
Maria Libera Ascierto, Ignacio Melero, Paolo Antonio Ascierto.
Front Oncol, 2015 Jul 29; 5. PMID: 26217587    Free PMC article.
Nivolumab: A Review in Advanced Melanoma.
Lesley J Scott.
Drugs, 2015 Jul 30; 75(12). PMID: 26220912
Myeloid Cells as Targets for Therapy in Solid Tumors.
Tiziana Cotechini, Terry R Medler, Lisa M Coussens.
Cancer J, 2015 Jul 30; 21(4). PMID: 26222088    Free PMC article.
Combination cancer immunotherapy and new immunomodulatory targets.
Kathleen M Mahoney, Paul D Rennert, Gordon J Freeman.
Nat Rev Drug Discov, 2015 Aug 01; 14(8). PMID: 26228759
Highly Cited. Review.
PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation.
Y Kong, J Zhang, +6 authors, H Zheng.
Blood Cancer J, 2015 Aug 01; 5. PMID: 26230954    Free PMC article.
Prospects of immune checkpoint modulators in the treatment of glioblastoma.
Matthias Preusser, Michael Lim, +2 authors, John H Sampson.
Nat Rev Neurol, 2015 Aug 12; 11(9). PMID: 26260659    Free PMC article.
Highly Cited. Review.
Pseudoprogression and Immune-Related Response in Solid Tumors.
Victoria L Chiou, Mauricio Burotto.
J Clin Oncol, 2015 Aug 12; 33(31). PMID: 26261262    Free PMC article.
Highly Cited.
The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities.
Daniel J Silver, Maksim Sinyuk, +2 authors, Justin D Lathia.
Neuro Oncol, 2015 Aug 13; 18(2). PMID: 26264894    Free PMC article.
Melanoma Risk and Survival among Organ Transplant Recipients.
Hilary A Robbins, Christina A Clarke, +9 authors, Eric A Engels.
J Invest Dermatol, 2015 Aug 14; 135(11). PMID: 26270022    Free PMC article.
Nivolumab in the treatment of malignant melanoma: review of the literature.
Emi Mashima, Akiha Inoue, +10 authors, Motonobu Nakamura.
Onco Targets Ther, 2015 Aug 15; 8. PMID: 26273207    Free PMC article.
Current position of TNF-α in melanomagenesis.
Iuliana Nenu, Diana Tudor, Adriana Gabriela Filip, Ioana Baldea.
Tumour Biol, 2015 Aug 19; 36(9). PMID: 26279161
The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy.
Lijie Zhai, Mahua Dey, +11 authors, Derek A Wainwright.
J Clin Neurosci, 2015 Aug 19; 22(12). PMID: 26279502    Free PMC article.
Immunotherapy of Childhood Sarcomas.
Stephen S Roberts, Alexander J Chou, Nai-Kong V Cheung.
Front Oncol, 2015 Aug 25; 5. PMID: 26301204    Free PMC article.
Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer.
Naoyuki Sakamoto, Takeshi Ishikawa, +11 authors, Toshikazu Yoshikawa.
J Transl Med, 2015 Aug 26; 13. PMID: 26303618    Free PMC article.
Strategies for combining immunotherapy with radiation for anticancer therapy.
Steven N Seyedin, Jonathan E Schoenhals, +14 authors, James W Welsh.
Immunotherapy, 2015 Aug 28; 7(9). PMID: 26310908    Free PMC article.
Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.
Michael T Barrett, Karen S Anderson, +9 authors, Barbara A Pockaj.
Oncotarget, 2015 Sep 01; 6(28). PMID: 26317899    Free PMC article.
Highly Cited.
[Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015].
S Laban, J Doescher, +4 authors, T K Hoffmann.
HNO, 2015 Sep 01; 63(9). PMID: 26319429
Enhancing Cancer Immunotherapy Via Activation of Innate Immunity.
Jacob L Goldberg, Paul M Sondel.
Semin Oncol, 2015 Sep 01; 42(4). PMID: 26320061    Free PMC article.
Antagonists of PD-1 and PD-L1 in Cancer Treatment.
Evan J Lipson, Patrick M Forde, +3 authors, Suzanne L Topalian.
Semin Oncol, 2015 Sep 01; 42(4). PMID: 26320063    Free PMC article.
Highly Cited. Review.
Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy.
Jennifer A Wargo, Alexandre Reuben, +2 authors, Ryan J Sullivan.
Semin Oncol, 2015 Sep 01; 42(4). PMID: 26320064    Free PMC article.
Immune Modulation in Hematologic Malignancies.
Madhav V Dhodapkar, Kavita M Dhodapkar.
Semin Oncol, 2015 Sep 01; 42(4). PMID: 26320065    Free PMC article.
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
Thomas F Gajewski.
Semin Oncol, 2015 Sep 01; 42(4). PMID: 26320069    Free PMC article.
Highly Cited. Review.
IL-36γ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses.
Xuefeng Wang, Xin Zhao, +19 authors, Binfeng Lu.
Cancer Cell, 2015 Sep 01; 28(3). PMID: 26321222    Free PMC article.
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.
Chih-Hao Chang, Jing Qiu, +11 authors, Erika L Pearce.
Cell, 2015 Sep 01; 162(6). PMID: 26321679    Free PMC article.
Highly Cited.
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses.
Ping-Chih Ho, Jessica Dauz Bihuniak, +15 authors, Susan M Kaech.
Cell, 2015 Sep 01; 162(6). PMID: 26321681    Free PMC article.
Highly Cited.
Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.
Edmund K Moon, Raghuveer Ranganathan, +7 authors, Steven M Albelda.
Clin Cancer Res, 2015 Sep 02; 22(2). PMID: 26324743    Free PMC article.
Cancer immunotherapy: harnessing the immune system to battle cancer.
Yiping Yang.
J Clin Invest, 2015 Sep 02; 125(9). PMID: 26325031    Free PMC article.
Highly Cited. Review.
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
Elizabeth Buchbinder, F Stephen Hodi.
J Clin Invest, 2015 Sep 02; 125(9). PMID: 26325034    Free PMC article.
Analysis of SDHD promoter mutations in various types of melanoma.
Simone L Scholz, Susanne Horn, +15 authors, Klaus G Griewank.
Oncotarget, 2015 Sep 04; 6(28). PMID: 26327518    Free PMC article.
Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer.
Kristen M Kreamer.
J Adv Pract Oncol, 2015 Sep 04; 5(6). PMID: 26328216    Free PMC article.
An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
A E Rice, Y E Latchman, +3 authors, F R Jones.
Cancer Gene Ther, 2015 Sep 05; 22(9). PMID: 26337747
Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site.
Maxime Thoreau, HweiXian Leong Penny, +10 authors, Nadège Bercovici.
Oncotarget, 2015 Sep 05; 6(29). PMID: 26337837    Free PMC article.
Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.
Rebecca Karp Leaf, Hearn Jay Cho, David Avigan.
Curr Hematol Malig Rep, 2015 Sep 05; 10(4). PMID: 26338470
Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages.
Martin J Cannon, Debopam Ghosh, Swetha Gujja.
Vaccines (Basel), 2015 Sep 08; 3(2). PMID: 26343197    Free PMC article.
The Promise of Preventive Cancer Vaccines.
Pier-Luigi Lollini, Federica Cavallo, Patrizia Nanni, Elena Quaglino.
Vaccines (Basel), 2015 Sep 08; 3(2). PMID: 26343198    Free PMC article.
Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators.
Isabelle Le Mercier, J Louise Lines, Randolph J Noelle.
Front Immunol, 2015 Sep 09; 6. PMID: 26347741    Free PMC article.
Highly Cited. Review.
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine.
Todd Bartkowiak, Shailbala Singh, +6 authors, Michael A Curran.
Proc Natl Acad Sci U S A, 2015 Sep 10; 112(38). PMID: 26351680    Free PMC article.
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth.
Sonja Kleffel, Christian Posch, +19 authors, Tobias Schatton.
Cell, 2015 Sep 12; 162(6). PMID: 26359984    Free PMC article.
Highly Cited.
PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro.
Lina Quan, Xue Chen, +4 authors, Yue Liu.
PLoS One, 2015 Sep 12; 10(9). PMID: 26361042    Free PMC article.
Gene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma.
Matthew A Care, David R Westhead, Reuben M Tooze.
Genome Med, 2015 Sep 13; 7. PMID: 26362649    Free PMC article.
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
J Naidoo, D B Page, +5 authors, J D Wolchok.
Ann Oncol, 2015 Sep 16; 26(12). PMID: 26371282    Free PMC article.
Highly Cited. Review.
Immunotherapies for bladder cancer: a new hope.
Farhad Fakhrejahani, Yusuke Tomita, +3 authors, Andrea B Apolo.
Curr Opin Urol, 2015 Sep 16; 25(6). PMID: 26372038    Free PMC article.
PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.
Francesco Sabbatino, Vincenzo Villani, +17 authors, Cristina R Ferrone.
Clin Cancer Res, 2015 Sep 17; 22(2). PMID: 26373575    Free PMC article.
Primary pulmonary melanoma: a report of two cases.
Mototsugu Watanabe, Hiromasa Yamamoto, +4 authors, Shinichiro Miyoshi.
World J Surg Oncol, 2015 Sep 18; 13. PMID: 26376781    Free PMC article.
Adaptive Immunity to Leukemia Is Inhibited by Cross-Reactive Induced Regulatory T Cells.
Luke S Manlove, Katherine E Berquam-Vrieze, +3 authors, Michael A Farrar.
J Immunol, 2015 Sep 18; 195(8). PMID: 26378075    Free PMC article.
Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics.
Elizabeth Ann L Enninga, Wendy K Nevala, Shernan G Holtan, Svetomir N Markovic.
Front Immunol, 2015 Sep 18; 6. PMID: 26379664    Free PMC article.
The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma.
Lijo John, C Lance Cowey.
Dermatol Ther (Heidelb), 2015 Sep 21; 5(3). PMID: 26387031    Free PMC article.
Anti-HBV Drugs: Progress, Unmet Needs, and New Hope.
Lei Kang, Jiaqian Pan, +3 authors, Jing Tang.
Viruses, 2015 Sep 22; 7(9). PMID: 26389937    Free PMC article.
Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity.
Katherine A Waugh, Sonia M Leach, Jill E Slansky.
Vaccines (Basel), 2015 Sep 24; 3(3). PMID: 26393659    Free PMC article.
Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer.
Seiji Oguro, Yoshinori Ino, +7 authors, Nobuyoshi Hiraoka.
Cancer Sci, 2015 Sep 24; 106(12). PMID: 26395180    Free PMC article.
New developments in the management of advanced melanoma - role of pembrolizumab.
Giuseppina Improta, Isabella Leone, +3 authors, Filippo Fraggetta.
Onco Targets Ther, 2015 Sep 24; 8. PMID: 26396529    Free PMC article.
Nivolumab in combination with ipilimumab for the treatment of melanoma.
Rajasekharan Somasundaram, Meenhard Herlyn.
Expert Rev Anticancer Ther, 2015 Sep 25; 15(10). PMID: 26402246    Free PMC article.
Nivolumab and Olaparib.
Dominic A Solimando, J Aubrey Waddell.
Hosp Pharm, 2015 Sep 26; 50(5). PMID: 26405320    Free PMC article.
Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy.
Jian Qiao, Mahua Dey, +7 authors, Maciej S Lesniak.
Oncoimmunology, 2015 Sep 26; 4(8). PMID: 26405578    Free PMC article.
Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.
Alan Serrels, Tom Lund, +15 authors, Margaret C Frame.
Cell, 2015 Sep 26; 163(1). PMID: 26406376    Free PMC article.
Highly Cited.
Potentiality of immunotherapy against hepatocellular carcinoma.
Nobuhiro Tsuchiya, Yu Sawada, +2 authors, Tetsuya Nakatsura.
World J Gastroenterol, 2015 Oct 01; 21(36). PMID: 26420958    Free PMC article.
The continuing evolution of targeted therapy for inflammatory skin disease.
C Schlapbach, A A Navarini.
Semin Immunopathol, 2015 Oct 02; 38(1). PMID: 26423993
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy.
Stuart J Gallagher, Jessamy C Tiffen, Peter Hersey.
Cancers (Basel), 2015 Oct 02; 7(4). PMID: 26426052    Free PMC article.
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis.
Roberto Iacovelli, Franco Nolè, +9 authors, Camillo Porta.
Target Oncol, 2015 Oct 03; 11(2). PMID: 26429561
Systematic Review.
Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice.
Luís Felipe Campesato, Romualdo Barroso-Sousa, +6 authors, Anamaria A Camargo.
Oncotarget, 2015 Oct 07; 6(33). PMID: 26439694    Free PMC article.
Highly Cited.
Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway.
Rajmohan Murali, Raghu Chandramohan, +22 authors, Klaus G Griewank.
Oncotarget, 2015 Oct 07; 6(34). PMID: 26440310    Free PMC article.
Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.
Gregory A Chang, Jyothirmayee S Tadepalli, +10 authors, David Polsky.
Mol Oncol, 2015 Oct 07; 10(1). PMID: 26440707    Free PMC article.
Establishing the pig as a large animal model for vaccine development against human cancer.
Nana H Overgaard, Thomas M Frøsig, +6 authors, Gregers Jungersen.
Front Genet, 2015 Oct 07; 6. PMID: 26442104    Free PMC article.
Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data.
Patrick A Ott, F Stephen Hodi, Elizabeth I Buchbinder.
Front Oncol, 2015 Oct 07; 5. PMID: 26442214    Free PMC article.
Highly Cited. Review.
PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy.
Anne-Marit Sponaas, Neda Nejati Moharrami, +4 authors, Anders Sundan.
PLoS One, 2015 Oct 09; 10(10). PMID: 26444869    Free PMC article.
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.
Morganna Freeman-Keller, Youngchul Kim, +3 authors, Jeffrey S Weber.
Clin Cancer Res, 2015 Oct 09; 22(4). PMID: 26446948    Free PMC article.
Highly Cited.
Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages.
Aya Kakizaki, Taku Fujimura, +4 authors, Setsuya Aiba.
Oncoimmunology, 2015 Oct 10; 4(11). PMID: 26451326    Free PMC article.
Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue.
M Stroh, D J Carlile, +10 authors, A Phipps.
CPT Pharmacometrics Syst Pharmacol, 2015 Oct 10; 4(9). PMID: 26451328    Free PMC article.
An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
Martha R Neagu, David A Reardon.
Curr Treat Options Oncol, 2015 Oct 12; 16(11). PMID: 26454859
Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance.
Terry R Medler, Tiziana Cotechini, Lisa M Coussens.
Trends Cancer, 2015 Oct 13; 1(1). PMID: 26457331    Free PMC article.
Immunotherapy and tumor microenvironment.
Haidong Tang, Jian Qiao, Yang-Xin Fu.
Cancer Lett, 2015 Oct 20; 370(1). PMID: 26477683    Free PMC article.
Highly Cited. Review.
Immunological landscape and immunotherapy of hepatocellular carcinoma.
Jesús Prieto, Ignacio Melero, Bruno Sangro.
Nat Rev Gastroenterol Hepatol, 2015 Oct 21; 12(12). PMID: 26484443
Highly Cited. Review.
Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors.
Jennifer Kleponis, Richard Skelton, Lei Zheng.
Cancer Biol Med, 2015 Oct 22; 12(3). PMID: 26487965    Free PMC article.
Predictive factors for immunotherapy in melanoma.
Cristina Teixidó, Maria González-Cao, Niki Karachaliou, Rafael Rosell.
Ann Transl Med, 2015 Oct 22; 3(15). PMID: 26488004    Free PMC article.
Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy.
Kelly Kersten, Camilla Salvagno, Karin E de Visser.
Front Immunol, 2015 Oct 27; 6. PMID: 26500653    Free PMC article.
Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.
David A Reardon, Mark R Gilbert, Wolfgang Wick, Linda Liau.
Neuro Oncol, 2015 Oct 31; 17 Suppl 7. PMID: 26516225    Free PMC article.
Nivolumab plus ipilimumab in the treatment of advanced melanoma.
Katy K Tsai, Adil I Daud.
J Hematol Oncol, 2015 Nov 01; 8. PMID: 26518223    Free PMC article.
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
Lijie Zhai, Stefani Spranger, +4 authors, Derek A Wainwright.
Clin Cancer Res, 2015 Nov 01; 21(24). PMID: 26519060    Free PMC article.
Highly Cited. Review.
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.
Hideho Okada, Michael Weller, +16 authors, David A Reardon.
Lancet Oncol, 2015 Nov 08; 16(15). PMID: 26545842    Free PMC article.
Highly Cited. Review.
DNA methylation subgroups in melanoma are associated with proliferative and immunological processes.
Martin Lauss, Markus Ringnér, +6 authors, Göran Jönsson.
BMC Med Genomics, 2015 Nov 08; 8. PMID: 26545983    Free PMC article.
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells.
Kathleen M Mahoney, Heather Sun, +8 authors, Gordon J Freeman.
Cancer Immunol Res, 2015 Nov 08; 3(12). PMID: 26546452    Free PMC article.
Highly Cited.
Cancer immunotherapy: Strategies for personalization and combinatorial approaches.
Vishwanath Sathyanarayanan, Sattva S Neelapu.
Mol Oncol, 2015 Nov 10; 9(10). PMID: 26548534    Free PMC article.
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.
Elizabeth I Buchbinder, Anupam Desai.
Am J Clin Oncol, 2015 Nov 13; 39(1). PMID: 26558876    Free PMC article.
Highly Cited. Review.
Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.
Amer Assal, Justin Kaner, Gopichand Pendurti, Xingxing Zang.
Immunotherapy, 2015 Nov 17; 7(11). PMID: 26567614    Free PMC article.
A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers.
George R Nahas, Nykia D Walker, Margarette Bryan, Pranela Rameshwar.
Breast Cancer (Auckl), 2015 Nov 17; 9(Suppl 2). PMID: 26568682    Free PMC article.
Residual inflammation and viral reservoirs: alliance against an HIV cure.
Marta Massanella, Rémi Fromentin, Nicolas Chomont.
Curr Opin HIV AIDS, 2015 Nov 18; 11(2). PMID: 26575148    Free PMC article.
Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
Karishma R Rajani, Richard G Vile.
Viruses, 2015 Nov 19; 7(11). PMID: 26580645    Free PMC article.
[Molecular diagnosis of melanocytic tumors].
J Bauer.
Hautarzt, 2015 Nov 22; 67(1). PMID: 26589514
Designing a broad-spectrum integrative approach for cancer prevention and treatment.
Keith I Block, Charlotte Gyllenhaal, +177 authors, Massimo Zollo.
Semin Cancer Biol, 2015 Nov 23; 35 Suppl. PMID: 26590477    Free PMC article.
Highly Cited. Review.
Engineering opportunities in cancer immunotherapy.
Laura Jeanbart, Melody A Swartz.
Proc Natl Acad Sci U S A, 2015 Nov 26; 112(47). PMID: 26598681    Free PMC article.
Combination cancer immunotherapies tailored to the tumour microenvironment.
Mark J Smyth, Shin Foong Ngiow, Antoni Ribas, Michele W L Teng.
Nat Rev Clin Oncol, 2015 Nov 26; 13(3). PMID: 26598942
Highly Cited. Review.
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging.
Roy L Maute, Sydney R Gordon, +10 authors, Aaron M Ring.
Proc Natl Acad Sci U S A, 2015 Nov 26; 112(47). PMID: 26604307    Free PMC article.
Highly Cited.
Immune checkpoint inhibitors: therapeutic advances in melanoma.
Ivan Márquez-Rodas, Pablo Cerezuela, +4 authors, Salvador Martín-Algarra.
Ann Transl Med, 2015 Nov 26; 3(18). PMID: 26605313    Free PMC article.
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Olivier Demaria, Aude De Gassart, +11 authors, Michel Gilliet.
Proc Natl Acad Sci U S A, 2015 Nov 27; 112(50). PMID: 26607445    Free PMC article.
Highly Cited.
Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells.
David A Quigley, Vessela Kristensen.
Mol Oncol, 2015 Nov 27; 9(10). PMID: 26607741    Free PMC article.
Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma.
Melody J Xu, Jay F Dorsey, +7 authors, Gary D Kao.
Oncologist, 2015 Nov 29; 21(1). PMID: 26614709    Free PMC article.
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Paolo A Ascierto, Michael Atkins, +34 authors, Magdalena Thurin.
J Transl Med, 2015 Dec 02; 13. PMID: 26619946    Free PMC article.
Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery.
Agnieszka Kolacinska, Barbara Cebula-Obrzut, +7 authors, Piotr Smolewski.
Oncol Lett, 2015 Dec 02; 10(2). PMID: 26622629    Free PMC article.
New strategies in immunotherapy for non-small cell lung cancer.
Daniel R Carrizosa, Kathryn A Gold.
Transl Lung Cancer Res, 2015 Dec 03; 4(5). PMID: 26629424    Free PMC article.
Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.
Jeryl Villadolid, Asim Amin.
Transl Lung Cancer Res, 2015 Dec 03; 4(5). PMID: 26629425    Free PMC article.
Highly Cited. Review.
Identification of a Novel Pathogenic Germline KDR Variant in Melanoma.
Ines P Silva, Amel Salhi, +11 authors, Iman Osman.
Clin Cancer Res, 2015 Dec 04; 22(10). PMID: 26631613    Free PMC article.
Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
Samantha Turnbull, Emma J West, +3 authors, Christy Ralph.
Viruses, 2015 Dec 04; 7(12). PMID: 26633468    Free PMC article.
T Lymphocyte-Endothelial Interactions: Emerging Understanding of Trafficking and Antigen-Specific Immunity.
Christopher V Carman, Roberta Martinelli.
Front Immunol, 2015 Dec 05; 6. PMID: 26635815    Free PMC article.
Advances in the treatment of newly diagnosed glioblastoma.
Brett J Theeler, Mark R Gilbert.
BMC Med, 2015 Dec 10; 13. PMID: 26646075    Free PMC article.
The Role of Chemokines in Shaping the Balance Between CD4(+) T Cell Subsets and Its Therapeutic Implications in Autoimmune and Cancer Diseases.
Nathan Karin, Gizi Wildbaum.
Front Immunol, 2015 Dec 10; 6. PMID: 26648938    Free PMC article.
MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.
Jun Wei, Edjah K Nduom, +13 authors, Amy B Heimberger.
Neuro Oncol, 2015 Dec 15; 18(5). PMID: 26658052    Free PMC article.
Highly Cited.
RNA-Based Vaccines in Cancer Immunotherapy.
Megan A McNamara, Smita K Nair, Eda K Holl.
J Immunol Res, 2015 Dec 15; 2015. PMID: 26665011    Free PMC article.
Clinical relevance of host immunity in breast cancer: from TILs to the clinic.
Peter Savas, Roberto Salgado, +4 authors, Sherene Loi.
Nat Rev Clin Oncol, 2015 Dec 17; 13(4). PMID: 26667975
Highly Cited. Review.
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
Clemens Krepler, Min Xiao, +19 authors, Meenhard Herlyn.
Clin Cancer Res, 2015 Dec 18; 22(7). PMID: 26673799    Free PMC article.
Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications.
Kenneth F Grossmann, Kim Margolin.
Ther Adv Med Oncol, 2015 Dec 18; 7(3). PMID: 26673806    Free PMC article.
Targeting the indoleamine 2,3-dioxygenase pathway in cancer.
Yong Wha Moon, Joud Hajjar, Patrick Hwu, Aung Naing.
J Immunother Cancer, 2015 Dec 18; 3. PMID: 26674411    Free PMC article.
Highly Cited. Review.
Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies.
Noura Choudhury, Yusuke Nakamura.
Cancer Sci, 2015 Dec 19; 107(2). PMID: 26678880    Free PMC article.
Immunosuppressive cells in tumor immune escape and metastasis.
Yang Liu, Xuetao Cao.
J Mol Med (Berl), 2015 Dec 23; 94(5). PMID: 26689709
Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms' Tumor 1 in Patients with Advanced Colorectal Cancer.
Shigetaka Shimodaira, Kenji Sano, +8 authors, Tomonobu Koizumi.
Vaccines (Basel), 2015 Dec 23; 3(4). PMID: 26690485    Free PMC article.
Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy.
Shari Pilon-Thomas, Krithika N Kodumudi, +8 authors, Robert J Gillies.
Cancer Res, 2016 Jan 01; 76(6). PMID: 26719539    Free PMC article.
Highly Cited.
Current progress in immunotherapy for pancreatic cancer.
Kelly Foley, Victoria Kim, Elizabeth Jaffee, Lei Zheng.
Cancer Lett, 2016 Jan 03; 381(1). PMID: 26723878    Free PMC article.
Highly Cited. Review.
Immune Checkpoint Blockade in Hepatocellular Carcinoma.
M Kudo.
Liver Cancer, 2016 Jan 07; 4(4). PMID: 26732472    Free PMC article.
Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma.
Adarsh Vennepureddy, Nishitha Thumallapally, +2 authors, Terenig Terjanian.
J Clin Med Res, 2016 Jan 15; 8(2). PMID: 26767073    Free PMC article.
2015 Guidance on cancer immunotherapy development in early-phase clinical studies.
Guidance Development Review Committee, Working Group for Clinical Studies of Cancer Immunotherapy, +4 authors, Biostatistics Subcommittee.
Cancer Sci, 2016 Jan 16; 106(12). PMID: 26767933    Free PMC article.
Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.
Jing Zeng, Xin-Ke Zhang, +3 authors, Su-Xia Lin.
Oncotarget, 2016 Jan 16; 7(8). PMID: 26771840    Free PMC article.
Ligand-targeted theranostic nanomedicines against cancer.
Virginia J Yao, Sara D'Angelo, +10 authors, Renata Pasqualini.
J Control Release, 2016 Jan 17; 240. PMID: 26772878    Free PMC article.
Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
Zhong-Yi Dong, Si-Pei Wu, +2 authors, Yi-Long Wu.
Tumour Biol, 2016 Jan 19; 37(4). PMID: 26779629
Updates in Therapy for Advanced Melanoma.
Bhavana P Singh, April K S Salama.
Cancers (Basel), 2016 Jan 20; 8(1). PMID: 26784231    Free PMC article.
TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.
Elien M Doorduijn, Marjolein Sluijter, +5 authors, Thorbald van Hall.
J Clin Invest, 2016 Jan 20; 126(2). PMID: 26784543    Free PMC article.
Synthetic RORγt Agonists Enhance Protective Immunity.
Mi Ra Chang, Venkatasubramanian Dharmarajan, +5 authors, Patrick R Griffin.
ACS Chem Biol, 2016 Jan 20; 11(4). PMID: 26785144    Free PMC article.
Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
Jianda Yuan, Priti S Hegde, +16 authors, Bernard A Fox.
J Immunother Cancer, 2016 Jan 21; 4. PMID: 26788324    Free PMC article.
Highly Cited. Review.
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
S Diem, B Kasenda, +4 authors, J Larkin.
Br J Cancer, 2016 Jan 23; 114(3). PMID: 26794281    Free PMC article.
Highly Cited.
Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer.
Santiago Viteri, María González-Cao, +2 authors, Rafael Rosell.
Transl Lung Cancer Res, 2016 Jan 23; 4(6). PMID: 26798585    Free PMC article.
Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.
Camille Guillerey, Kyohei Nakamura, +2 authors, Mark J Smyth.
Cell Mol Life Sci, 2016 Jan 24; 73(8). PMID: 26801219
Targeted therapies in gastric cancer and future perspectives.
Ozan Yazici, M Ali Nahit Sendur, Nuriye Ozdemir, Sercan Aksoy.
World J Gastroenterol, 2016 Jan 27; 22(2). PMID: 26811601    Free PMC article.
Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer.
Katsuhiko Nosho, Yasutaka Sukawa, +11 authors, Yasuhisa Shinomura.
World J Gastroenterol, 2016 Jan 27; 22(2). PMID: 26811607    Free PMC article.
Highly Cited. Review.
Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
Andrea Marie Ibrahim, Yao-He Wang.
World J Gastroenterol, 2016 Jan 27; 22(2). PMID: 26811622    Free PMC article.
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.
Douglas B Johnson, Monica V Estrada, +18 authors, Justin M Balko.
Nat Commun, 2016 Jan 30; 7. PMID: 26822383    Free PMC article.
Highly Cited.
Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent.
Pan Pantziarka, Vidula Sukhatme, +2 authors, Vikas P Sukhatme.
Ecancermedicalscience, 2016 Jan 30; 10. PMID: 26823679    Free PMC article.
Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.
Zheng Hu, Jinxing Xia, +2 authors, Yong-Guang Yang.
Oncotarget, 2016 Jan 30; 7(6). PMID: 26824989    Free PMC article.
Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic.
Kinga Majchrzak, Michelle H Nelson, +5 authors, Chrystal M Paulos.
Cancer Immunol Immunother, 2016 Jan 31; 65(3). PMID: 26825102    Free PMC article.
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.
Silvia Carvalho, Francesca Levi-Schaffer, Michael Sela, Yosef Yarden.
Br J Pharmacol, 2016 Feb 03; 173(9). PMID: 26833433    Free PMC article.
How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances.
Jonathan L Messerschmidt, George C Prendergast, Gerald L Messerschmidt.
Oncologist, 2016 Feb 03; 21(2). PMID: 26834161    Free PMC article.
Advances in immunotherapy for melanoma.
Jason M Redman, Geoffrey T Gibney, Michael B Atkins.
BMC Med, 2016 Feb 07; 14. PMID: 26850630    Free PMC article.
Highly Cited. Review.
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?
Joseph M Ryan, Jeffrey S Wasser, Adam J Adler, Anthony T Vella.
Expert Opin Biol Ther, 2016 Feb 09; 16(5). PMID: 26855028    Free PMC article.
Dendritic cell-based vaccine for pancreatic cancer in Japan.
Masato Okamoto, Masanori Kobayashi, +2 authors, Sadamu Homma.
World J Gastrointest Pharmacol Ther, 2016 Feb 09; 7(1). PMID: 26855819    Free PMC article.
Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report.
Andrew J Dooley, Avinash Gupta, Mark R Middleton.
Target Oncol, 2016 Feb 10; 11(4). PMID: 26857260    Free PMC article.
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Scott Antonia, Sarah B Goldberg, +8 authors, Naiyer A Rizvi.
Lancet Oncol, 2016 Feb 10; 17(3). PMID: 26858122    Free PMC article.
Highly Cited.
Basics of PD-1 in self-tolerance, infection, and cancer immunity.
Shunsuke Chikuma.
Int J Clin Oncol, 2016 Feb 13; 21(3). PMID: 26864303
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.
Christina Pfirschke, Camilla Engblom, +18 authors, Mikael J Pittet.
Immunity, 2016 Feb 14; 44(2). PMID: 26872698    Free PMC article.
Highly Cited.
Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.
Jeffrey Weber, Geoffrey Gibney, +11 authors, Yian Ann Chen.
Cancer Immunol Res, 2016 Feb 14; 4(4). PMID: 26873574    Free PMC article.
Highly Cited.
Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints.
Maria Alsina, Markus Moehler, +2 authors, Josep Tabernero.
Target Oncol, 2016 Feb 18; 11(4). PMID: 26880697
Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium.
Eileen S Kim, Jennifer E Kim, +3 authors, Michael Lim.
J Immunol Res, 2016 Feb 18; 2016. PMID: 26881264    Free PMC article.
Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses.
Alison Taylor, James A Harker, +3 authors, Christopher E Rudd.
Immunity, 2016 Feb 18; 44(2). PMID: 26885856    Free PMC article.
Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.
Paola Savoia, Chiara Astrua, Paolo Fava.
Hum Vaccin Immunother, 2016 Feb 19; 12(5). PMID: 26889818    Free PMC article.
Evaluation of Costimulatory Molecules in Peripheral Blood Lymphocytes of Canine Patients with Histiocytic Sarcoma.
Michihito Tagawa, Naoya Maekawa, Satoru Konnai, Satoshi Takagi.
PLoS One, 2016 Feb 24; 11(2). PMID: 26901565    Free PMC article.
[Immunomodulation as innovative therapy for head and neck tumors : Current developments].
P J Schuler, J C Doescher, S Laban, T K Hoffmann.
HNO, 2016 Feb 26; 64(7). PMID: 26912050
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.
Claire F Friedman, Michael A Postow.
Curr Oncol Rep, 2016 Feb 29; 18(4). PMID: 26922327    Free PMC article.
DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR.
Goran Micevic, Viswanathan Muthusamy, +6 authors, Marcus Bosenberg.
Cell Rep, 2016 Mar 01; 14(9). PMID: 26923591    Free PMC article.
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.
Angela K B Alme, Beerinder S Karir, Bishoy M Faltas, Charles G Drake.
Urol Oncol, 2016 Mar 01; 34(4). PMID: 26923782    Free PMC article.
Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities.
K M Morrissey, T M Yuraszeck, +2 authors, S Kasichayanula.
Clin Transl Sci, 2016 Mar 01; 9(2). PMID: 26924066    Free PMC article.
Highly Cited. Review.
Novel targets in the treatment of advanced gastric cancer: a perspective review.
Elisa Fontana, Elizabeth C Smyth.
Ther Adv Med Oncol, 2016 Mar 02; 8(2). PMID: 26929787    Free PMC article.
Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma.
Jennifer Nguyen, Richard Bernert, +4 authors, K Taraszka Hastings.
Melanoma Res, 2016 Mar 02; 26(2). PMID: 26930048    Free PMC article.
CD40-activated B cells induce anti-tumor immunity in vivo.
Kerstin Wennhold, Tanja M Weber, +9 authors, Michael von Bergwelt-Baildon.
Oncotarget, 2016 Mar 05; 8(17). PMID: 26934557    Free PMC article.
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.
Weiping Zou, Jedd D Wolchok, Lieping Chen.
Sci Transl Med, 2016 Mar 05; 8(328). PMID: 26936508    Free PMC article.
Highly Cited. Review.
PD-1 expression conditions T cell avidity within an antigen-specific repertoire.
Sylvain Simon, Virginie Vignard, +4 authors, N Labarriere.
Oncoimmunology, 2016 Mar 05; 5(1). PMID: 26942093    Free PMC article.
Doubling the blockade for melanoma immunotherapy.
Lorenzo Galluzzi, Alexander Eggermont, Guido Kroemer.
Oncoimmunology, 2016 Mar 05; 5(1). PMID: 26942094    Free PMC article.
Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer.
Kosuke Kawaguchi, Eiji Suzuki, +3 authors, Masakazu Toi.
Breast Cancer, 2016 Mar 05; 24(1). PMID: 26942414    Free PMC article.
Imaging Biomarkers in Immunotherapy.
Rosalyn A Juergens, Katherine A Zukotynski, +3 authors, Karen Y Gulenchyn.
Biomark Cancer, 2016 Mar 08; 8(Suppl 2). PMID: 26949344    Free PMC article.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Jonathan E Rosenberg, Jean Hoffman-Censits, +28 authors, Robert Dreicer.
Lancet, 2016 Mar 10; 387(10031). PMID: 26952546    Free PMC article.
Highly Cited.
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations.
Axel Hoos.
Nat Rev Drug Discov, 2016 Mar 12; 15(4). PMID: 26965203
Highly Cited.
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.
Haidong Tang, Yang Wang, +6 authors, Yang-Xin Fu.
Cancer Cell, 2016 Mar 16; 29(3). PMID: 26977880    Free PMC article.
Highly Cited.
Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies.
Arta M Monjazeb, Michael S Kent, +13 authors, William J Murphy.
Clin Cancer Res, 2016 Mar 17; 22(17). PMID: 26979392    Free PMC article.
CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment.
Yonghao Cao, Alyssa Nylander, +7 authors, David Pitt.
Neurology, 2016 Mar 18; 86(16). PMID: 26984943    Free PMC article.
The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines.
Xiuwen Guan, Haijuan Wang, +3 authors, Binghe Xu.
Medicine (Baltimore), 2016 Mar 18; 95(11). PMID: 26986169    Free PMC article.
Fractionated radiotherapy combined with PD-1 pathway blockade promotes CD8 T cell-mediated tumor clearance for the treatment of advanced malignancies.
Tijana Martinov, Brian T Fife.
Ann Transl Med, 2016 Mar 24; 4(4). PMID: 27004229    Free PMC article.
Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Amanda Contreras, Siddhartha Sen, +5 authors, Clifford S Cho.
Cancer Immunol Immunother, 2016 Mar 25; 65(5). PMID: 27011014    Free PMC article.
Clinical utility of nivolumab in the treatment of advanced melanoma.
Ramsey Asmar, Jessica Yang, Richard D Carvajal.
Ther Clin Risk Manag, 2016 Mar 26; 12. PMID: 27013881    Free PMC article.
From kinetics and cellular cooperations to cancer immunotherapies.
Alain Trautmann.
Oncotarget, 2016 Mar 26; 7(28). PMID: 27014912    Free PMC article.
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.
Dmitriy Zamarin, Amir A Jazaeri.
Gynecol Oncol, 2016 Mar 27; 141(1). PMID: 27016233    Free PMC article.
Enhanced Anti-Tumor Efficacy through a Combination of Integrin αvβ6-Targeted Photodynamic Therapy and Immune Checkpoint Inhibition.
Liquan Gao, Chenran Zhang, +6 authors, Zhaofei Liu.
Theranostics, 2016 Mar 30; 6(5). PMID: 27022411    Free PMC article.
Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions.
Cassandra C Skinner, Elizabeth L McMichael, +3 authors, William E Carson.
Melanoma Res, 2016 Apr 02; 26(4). PMID: 27035691    Free PMC article.
Novel Therapies in Development for Metastatic Colorectal Cancer.
Michael S Lee, Scott Kopetz.
Gastrointest Cancer Res, 2014 Sep 01; 7(4 Suppl 1). PMID: 27053975    Free PMC article.
Flagellin is a strong vaginal adjuvant of a therapeutic vaccine for genital cancer.
Shee Eun Lee, Seol Hee Hong, +9 authors, Joon Haeng Rhee.
Oncoimmunology, 2016 Apr 09; 5(2). PMID: 27057462    Free PMC article.
Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction.
Paul C McDonald, Shawn C Chafe, Shoukat Dedhar.
Front Cell Dev Biol, 2016 Apr 12; 4. PMID: 27066484    Free PMC article.
PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer.
Shijie Yang, Qiuyang Zhang, +2 authors, Zongbing You.
Am J Clin Exp Urol, 2016 Apr 14; 4(1). PMID: 27069956    Free PMC article.
Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition.
Jurjen Tel, Rutger Koornstra, +9 authors, Stanleyson V Hato.
J Transl Med, 2016 Apr 15; 14. PMID: 27075584    Free PMC article.
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.
Suzanne L Topalian, Janis M Taube, Robert A Anders, Drew M Pardoll.
Nat Rev Cancer, 2016 Apr 16; 16(5). PMID: 27079802    Free PMC article.
Highly Cited. Review.
Emerging Opportunities and Challenges in Cancer Immunotherapy.
Theresa L Whiteside, Sandra Demaria, +2 authors, Ignacio Melero.
Clin Cancer Res, 2016 Apr 17; 22(8). PMID: 27084738    Free PMC article.
Highly Cited. Review.
A rare case of thyroid storm.
Brock McMillen, Manvinder Shelley Dhillon, Sabrina Yong-Yow.
BMJ Case Rep, 2016 Apr 20; 2016. PMID: 27090545    Free PMC article.
Advances in targeted and immunobased therapies for colorectal cancer in the genomic era.
Heng Fong Seow, Wai Kien Yip, Theodora Fifis.
Onco Targets Ther, 2016 Apr 22; 9. PMID: 27099521    Free PMC article.
The challenge of developmental therapeutics for adrenocortical carcinoma.
Ricardo Costa, Benedito A Carneiro, +6 authors, Francis J Giles.
Oncotarget, 2016 Apr 23; 7(29). PMID: 27102148    Free PMC article.
PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC.
Malaka Ameratunga, Khashayar Asadi, +6 authors, Thomas John.
PLoS One, 2016 Apr 23; 11(4). PMID: 27104612    Free PMC article.
Adapting Cancer Immunotherapy Models for the Real World.
Lauryn E Klevorn, Ryan M Teague.
Trends Immunol, 2016 Apr 24; 37(6). PMID: 27105824    Free PMC article.
Immune Checkpoint Therapy and the Search for Predictive Biomarkers.
Padmanee Sharma.
Cancer J, 2016 Apr 26; 22(2). PMID: 27111900    Free PMC article.
Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer.
Dmitriy Zamarin, Jedd D Wolchok.
Mol Ther Oncolytics, 2014 Jan 01; 1. PMID: 27119094    Free PMC article.
Antimelanoma CTL recognizes peptides derived from an ORF transcribed from the antisense strand of the 3' untranslated region of TRIT1.
Rolf K Swoboda, Rajasekharan Somasundaram, +4 authors, Dorothee Herlyn.
Mol Ther Oncolytics, 2015 Jan 01; 1. PMID: 27119099    Free PMC article.
Immune based therapy for melanoma.
Robert Ancuceanu, Monica Neagu.
Indian J Med Res, 2016 Apr 29; 143(2). PMID: 27121512    Free PMC article.
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
S Bowyer, P Prithviraj, +17 authors, O Klein.
Br J Cancer, 2016 Apr 29; 114(10). PMID: 27124339    Free PMC article.
Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories.
Ping Qiu, Ling Pang, +4 authors, Diane Levitan.
Int J Mol Sci, 2016 May 03; 17(5). PMID: 27136543    Free PMC article.
Planes, Trains, and Automobiles: Perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies.
Saar Gill.
Curr Hematol Malig Rep, 2016 May 04; 11(4). PMID: 27136938    Free PMC article.
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.
Kristina Iribarren, Norma Bloy, +9 authors, Lorenzo Galluzzi.
Oncoimmunology, 2016 May 04; 5(3). PMID: 27141345    Free PMC article.
Highly Cited. Review.
Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model.
De-Kuan Chang, Eric Peterson, +6 authors, Wayne A Marasco.
Oncoimmunology, 2016 May 04; 5(3). PMID: 27141347    Free PMC article.
FAK goes nuclear to control antitumor immunity-a new target in cancer immuno-therapy.
Alan Serrels, Margaret C Frame.
Oncoimmunology, 2016 May 04; 5(4). PMID: 27141405    Free PMC article.
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
Celine Boutros, Ahmad Tarhini, +14 authors, Caroline Robert.
Nat Rev Clin Oncol, 2016 May 05; 13(8). PMID: 27141885
Highly Cited. Review.
Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
Eloah Rabello Suarez, De Kuan Chang, +5 authors, Wayne A Marasco.
Oncotarget, 2016 May 05; 7(23). PMID: 27145284    Free PMC article.
Highly Cited.
Cancer immunotherapy: the beginning of the end of cancer?
Sofia Farkona, Eleftherios P Diamandis, Ivan M Blasutig.
BMC Med, 2016 May 07; 14. PMID: 27151159    Free PMC article.
Highly Cited. Review.
Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.
Paula Kroon, Jules Gadiot, +7 authors, Inge Verbrugge.
Cancer Immunol Immunother, 2016 May 11; 65(6). PMID: 27160390    Free PMC article.
Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials.
Seongseok Yun, Nicole D Vincelette, +2 authors, Ivo Abraham.
Cancer Med, 2016 May 12; 5(7). PMID: 27167347    Free PMC article.
Systematic Review.
T cell Bim levels reflect responses to anti-PD-1 cancer therapy.
Roxana S Dronca, Xin Liu, +11 authors, Haidong Dong.
JCI Insight, 2016 May 18; 1(6). PMID: 27182556    Free PMC article.
Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.
Hong Zheng, Xin Liu, +7 authors, Chandra P Belani.
Oncotarget, 2016 May 19; 7(35). PMID: 27191652    Free PMC article.
Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.
John Attanasio, E John Wherry.
Immunity, 2016 May 19; 44(5). PMID: 27192569    Free PMC article.
Highly Cited. Review.
PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion.
Roberto Tinoco, Florent Carrette, +5 authors, Linda M Bradley.
Immunity, 2016 May 19; 44(5). PMID: 27192578    Free PMC article.
Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.
Rikke B Holmgaard, Dmitriy Zamarin, +2 authors, Jedd D Wolchok.
EBioMedicine, 2016 May 24; 6. PMID: 27211548    Free PMC article.
Highly Cited.
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.
A M Udager, T-Y Liu, +16 authors, R Mehra.
Ann Oncol, 2016 May 25; 27(9). PMID: 27217541    Free PMC article.
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Lucia Festino, Gerardo Botti, +5 authors, Paolo A Ascierto.
Drugs, 2016 May 28; 76(9). PMID: 27229745
Highly Cited. Review.
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Jeffrey S Weber, Geoff Gibney, +14 authors, F Stephen Hodi.
Lancet Oncol, 2016 Jun 09; 17(7). PMID: 27269740    Free PMC article.
Highly Cited.
T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.
Aude G Chapuis, Ilana M Roberts, +12 authors, Cassian Yee.
J Clin Oncol, 2016 Jun 09; 34(31). PMID: 27269940    Free PMC article.
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Alexander M Lesokhin, Stephen M Ansell, +20 authors, John Timmerman.
J Clin Oncol, 2016 Jun 09; 34(23). PMID: 27269947    Free PMC article.
Highly Cited.
What does the future hold for immunotherapy in cancer?
Jarushka Naidoo, Bob T Li, Katja Schindler, David B Page.
Ann Transl Med, 2016 Jun 09; 4(9). PMID: 27275490    Free PMC article.
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Pei-Ling Chen, Whijae Roh, +41 authors, Jennifer A Wargo.
Cancer Discov, 2016 Jun 16; 6(8). PMID: 27301722    Free PMC article.
Highly Cited.
Molecular and genetic inflammation networks in major human diseases.
Yongzhong Zhao, Christian V Forst, +3 authors, Bin Zhang.
Mol Biosyst, 2016 Jun 16; 12(8). PMID: 27303926    Free PMC article.
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.
Elisa González-Rodríguez, Delvys Rodríguez-Abreu, Spanish Group for Cancer Immuno-Biotherapy (GETICA).
Oncologist, 2016 Jun 17; 21(7). PMID: 27306911    Free PMC article.
Highly Cited. Review.
Acid-induced aggregation propensity of nivolumab is dependent on the Fc.
Boning Liu, Huaizu Guo, +11 authors, Hao Wang.
MAbs, 2016 Jun 17; 8(6). PMID: 27310175    Free PMC article.
Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
Dionisia Quiroga, H Kim Lyerly, Michael A Morse.
Curr Treat Options Oncol, 2016 Jun 18; 17(8). PMID: 27315067
Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.
Shivshankari Rajkumar, Ian R Watson.
Br J Cancer, 2016 Jun 24; 115(2). PMID: 27336610    Free PMC article.
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
Chrisann Kyi, Michael A Postow.
Immunotherapy, 2016 Jun 29; 8(7). PMID: 27349981    Free PMC article.
Highly Cited. Review.
CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
Zhenhua Ren, Jingya Guo, +7 authors, Yang-Xin Fu.
Clin Cancer Res, 2016 Jun 30; 23(1). PMID: 27354469    Free PMC article.
The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
Leora Horn, Martin Reck, David R Spigel.
Oncologist, 2016 Jun 30; 21(8). PMID: 27354668    Free PMC article.
Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model.
Katherine A Waugh, Sonia M Leach, +3 authors, Jill E Slansky.
J Immunol, 2016 Jul 03; 197(4). PMID: 27371726    Free PMC article.
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.
Seth P Lerner, Dean F Bajorin, +33 authors, Diane Zipursky Quale.
Bladder Cancer, 2016 Jul 05; 2(2). PMID: 27376138    Free PMC article.
Differential Expression of Immune Checkpoint Modulators on In Vitro Primed CD4(+) and CD8(+) T Cells.
Nina C Sabins, Benjamin C Harman, +2 authors, Sandra Santulli-Marotto.
Front Immunol, 2016 Jul 06; 7. PMID: 27379090    Free PMC article.
Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.
Natalie Vandeven, Paul Nghiem.
Immunotherapy, 2016 Jul 07; 8(8). PMID: 27381685    Free PMC article.
Updates in the management of brain metastases.
Nils D Arvold, Eudocia Q Lee, +9 authors, Patrick Y Wen.
Neuro Oncol, 2016 Jul 07; 18(8). PMID: 27382120    Free PMC article.
Highly Cited. Review.
Pembrolizumab (Keytruda).
Gerry Kwok, Thomas C C Yau, +2 authors, Yok-Lam Kwong.
Hum Vaccin Immunother, 2016 Jul 12; 12(11). PMID: 27398650    Free PMC article.
Recent advances and future of immunotherapy for glioblastoma.
Neha Kamran, Alexandra Calinescu, +7 authors, Maria G Castro.
Expert Opin Biol Ther, 2016 Jul 14; 16(10). PMID: 27411023    Free PMC article.
Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity.
Stefano Di Biase, Changhan Lee, +9 authors, Valter D Longo.
Cancer Cell, 2016 Jul 15; 30(1). PMID: 27411588    Free PMC article.
Highly Cited.
Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.
Angel Qin, David G Coffey, Edus H Warren, Nithya Ramnath.
Cancer Med, 2016 Jul 16; 5(9). PMID: 27416962    Free PMC article.
Malignant Melanoma.
Eshini Perera, Neiraja Gnaneswaran, Ross Jennens, Rodney Sinclair.
Healthcare (Basel), 2013 Jan 01; 2(1). PMID: 27429256    Free PMC article.
Purity of transferred CD8(+) T cells is crucial for safety and efficacy of combinatorial tumor immunotherapy in the absence of SHP-1.
H Angharad Watson, Garry Dolton, +10 authors, Ann Ager.
Immunol Cell Biol, 2016 Jul 20; 94(8). PMID: 27430370    Free PMC article.
Metastatic melanoma and immunotherapy.
Benjamin Herzberg, David E Fisher.
Clin Immunol, 2016 Jul 20; 172. PMID: 27430520    Free PMC article.
PD-L1 expression is associated with advanced non-small cell lung cancer.
Zhiquan Chen, Jiandong Mei, +6 authors, Liu Zhang.
Oncol Lett, 2016 Jul 23; 12(2). PMID: 27446371    Free PMC article.
Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer.
Zhongfu Mo, Jing Liu, +7 authors, Zongbing You.
Oncol Lett, 2016 Jul 23; 12(2). PMID: 27446374    Free PMC article.
Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response.
Maria Gonzalez-Cao, Aram Boada, +11 authors, Rafael Rosell.
Oncotarget, 2016 Jul 23; 7(35). PMID: 27447748    Free PMC article.
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
Leonid Cherkassky, Aurore Morello, +5 authors, Prasad S Adusumilli.
J Clin Invest, 2016 Jul 28; 126(8). PMID: 27454297    Free PMC article.
Highly Cited.
Advances in immunotherapy for melanoma management.
Mohammed Dany, Rose Nganga, +3 authors, Dirk Elston.
Hum Vaccin Immunother, 2016 Jul 28; 12(10). PMID: 27454404    Free PMC article.
Immuno-oncology combinations: raising the tail of the survival curve.
Samuel J Harris, Jessica Brown, Juanita Lopez, Timothy A Yap.
Cancer Biol Med, 2016 Jul 28; 13(2). PMID: 27458526    Free PMC article.
The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma.
Kim Margolin.
Curr Treat Options Oncol, 2016 Jul 28; 17(9). PMID: 27461037
An update on clinical oncology for the non-oncologist.
Rafael Aliosha Kaliks.
Einstein (Sao Paulo), 2016 Jul 28; 14(2). PMID: 27462901    Free PMC article.
Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer.
Jin S Im, Amanda C Herrmann, +4 authors, Roman Perez-Soler.
PLoS One, 2016 Jul 29; 11(7). PMID: 27467256    Free PMC article.
Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma.
Ioannis Karydis, Pui Ying Chan, +3 authors, Christian H Ottensmeier.
Oncoimmunology, 2016 Jul 29; 5(5). PMID: 27467964    Free PMC article.
PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Adrian M Seifert, Shan Zeng, +11 authors, Ronald P DeMatteo.
Clin Cancer Res, 2016 Jul 30; 23(2). PMID: 27470968    Free PMC article.
Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis.
Katharina Lankes, Gheorghe Hundorfean, +9 authors, Lucie Heinzerling.
Oncoimmunology, 2016 Jul 30; 5(6). PMID: 27471608    Free PMC article.
A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice.
Zhida Liu, Hang Zhou, +2 authors, Mingzhao Zhu.
Oncoimmunology, 2016 Jul 30; 5(6). PMID: 27471615    Free PMC article.
T cell immunoglobulin domain and mucin domain-3 as an emerging target for immunotherapy in cancer management.
Akihiro Yoneda, Masahisa Jinushi.
Immunotargets Ther, 2013 Jan 01; 2. PMID: 27471694    Free PMC article.
Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design.
Susan F Slovin.
Immunotargets Ther, 2014 Jan 01; 3. PMID: 27471695    Free PMC article.
Therapeutic cancer vaccines and combination immunotherapies involving vaccination.
Trang Nguyen, Julie Urban, Pawel Kalinski.
Immunotargets Ther, 2014 Jan 01; 3. PMID: 27471705    Free PMC article.
Update on use of aldesleukin for treatment of high-risk metastatic melanoma.
Rodabe N Amaria, Alexandre Reuben, Zachary A Cooper, Jennifer A Wargo.
Immunotargets Ther, 2015 Jan 01; 4. PMID: 27471714    Free PMC article.
CD28 co-stimulation in T-cell homeostasis: a recent perspective.
Niklas Beyersdorf, Thomas Kerkau, Thomas Hünig.
Immunotargets Ther, 2015 Jan 01; 4. PMID: 27471717    Free PMC article.
Immunotherapy as a Potential Treatment for Chordoma: a Review.
Shalin S Patel, Joseph H Schwab.
Curr Oncol Rep, 2016 Aug 01; 18(9). PMID: 27475804
Evolving Immunotherapy Approaches for Renal Cell Carcinoma.
Susanna A Curtis, Justine V Cohen, Harriet M Kluger.
Curr Oncol Rep, 2016 Aug 01; 18(9). PMID: 27475806
MicroRNA-491 regulates the proliferation and apoptosis of CD8(+) T cells.
Ting Yu, Qian-Fei Zuo, +3 authors, Bin Xiao.
Sci Rep, 2016 Aug 04; 6. PMID: 27484289    Free PMC article.
An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.
Jessica L F Teh, Timothy J Purwin, +4 authors, Andrew E Aplin.
Cancer Res, 2016 Aug 05; 76(18). PMID: 27488531    Free PMC article.
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy.
Lewis Zhichang Shi, Tihui Fu, +7 authors, Padmanee Sharma.
Nat Commun, 2016 Aug 09; 7. PMID: 27498556    Free PMC article.
The Role of Molecular Diagnostics in the Management of Patients with Gliomas.
Hans-Georg Wirsching, Michael Weller.
Curr Treat Options Oncol, 2016 Aug 10; 17(10). PMID: 27501915
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting.
Belal Chaudhary, Eyad Elkord.
Vaccines (Basel), 2016 Aug 12; 4(3). PMID: 27509527    Free PMC article.
Highly Cited. Review.
Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy.
Boris Simovic, Scott R Walsh, Yonghong Wan.
Oncolytic Virother, 2015 Jan 01; 4. PMID: 27512679    Free PMC article.
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.
Aung Naing, Kyriakos P Papadopoulos, +17 authors, Jeffrey R Infante.
J Clin Oncol, 2016 Aug 17; 34(29). PMID: 27528724    Free PMC article.
The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
Alexander N Shoushtari, Rodrigo R Munhoz, +17 authors, Michael A Postow.
Cancer, 2016 Oct 21; 122(21). PMID: 27533633    Free PMC article.
Highly Cited.
PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course.
Mizuki Nishino, Nikhil H Ramaiya, +7 authors, F Stephen Hodi.
Clin Cancer Res, 2016 Aug 19; 22(24). PMID: 27535979    Free PMC article.
Highly Cited.
Harnessing the immune system to improve cancer therapy.
Nikos E Papaioannou, Ourania V Beniata, +2 authors, Pinelopi Samara.
Ann Transl Med, 2016 Aug 27; 4(14). PMID: 27563648    Free PMC article.
Highly Cited. Review.
Melanoma immunotherapy dominates the field.
Panagiotis Diamantopoulos, Helen Gogas.
Ann Transl Med, 2016 Aug 27; 4(14). PMID: 27563656    Free PMC article.
Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
Kazuhiko Shien, Vassiliki A Papadimitrakopoulou, Ignacio I Wistuba.
Lung Cancer, 2016 Aug 28; 99. PMID: 27565919    Free PMC article.
PD-L1 expression in human cancers and its association with clinical outcomes.
Xin Wang, Feifei Teng, Li Kong, Jinming Yu.
Onco Targets Ther, 2016 Aug 31; 9. PMID: 27574444    Free PMC article.
Highly Cited. Review.
Monitoring of the Immune Dysfunction in Cancer Patients.
Saskia J A M Santegoets, Marij J P Welters, Sjoerd H van der Burg.
Vaccines (Basel), 2016 Sep 07; 4(3). PMID: 27598210    Free PMC article.
Current treatment options of brain metastases and outcomes in patients with malignant melanoma.
Jadwiga Nowak-Sadzikowska, Tomasz Walasek, +2 authors, Marian Reinfuss.
Rep Pract Oncol Radiother, 2016 Sep 08; 21(3). PMID: 27601961    Free PMC article.
[Immunotherapeutic studies of head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].
C-J Busch, S Laban, R Knecht, T K Hoffmann.
HNO, 2016 Sep 09; 64(10). PMID: 27604282
Combination therapeutics in complex diseases.
Bing He, Cheng Lu, +5 authors, Aiping Lu.
J Cell Mol Med, 2016 Sep 09; 20(12). PMID: 27605177    Free PMC article.
Immunological battlefield in gastric cancer and role of immunotherapies.
Minyu Wang, Rita A Busuttil, +2 authors, Alex Boussioutas.
World J Gastroenterol, 2016 Sep 09; 22(28). PMID: 27605873    Free PMC article.
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
Mark J Selby, John J Engelhardt, +11 authors, Alan J Korman.
PLoS One, 2016 Sep 10; 11(9). PMID: 27610613    Free PMC article.
Highly Cited.
Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy.
Rikke B Holmgaard, Alexandra Brachfeld, +7 authors, Taha Merghoub.
Oncoimmunology, 2016 Sep 14; 5(7). PMID: 27622016    Free PMC article.
PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.
Chang-Long Chen, Qiu-Zhong Pan, +12 authors, Jian-Chuan Xia.
Oncoimmunology, 2016 Sep 14; 5(7). PMID: 27622026    Free PMC article.
Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design.
Martin G Klatt, Daniel J Kowalewski, +5 authors, Stefan Stevanović.
Oncoimmunology, 2016 Sep 14; 5(8). PMID: 27622074    Free PMC article.
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
F Stephen Hodi, Jason Chesney, +18 authors, Michael A Postow.
Lancet Oncol, 2016 Sep 14; 17(11). PMID: 27622997    Free PMC article.
Highly Cited.
Reevaluating stereotactic radiosurgery for glioblastoma: new potential for targeted dose-escalation.
Ted K Yanagihara, Heva J Saadatmand, Tony J C Wang.
J Neurooncol, 2016 Sep 16; 130(3). PMID: 27632018
Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma.
Nicholas D Klemen, Paul L Feingold, +6 authors, Richard M Sherry.
Ann Surg Oncol, 2016 Sep 18; 24(1). PMID: 27638681    Free PMC article.
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.
Klaus Okkenhaug, Mariona Graupera, Bart Vanhaesebroeck.
Cancer Discov, 2016 Sep 23; 6(10). PMID: 27655435    Free PMC article.
Highly Cited. Review.
The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma.
Joo Kyung Park, Yejin Kim, +6 authors, Jae Seung Kang.
Oncotarget, 2016 Sep 23; 7(46). PMID: 27655706    Free PMC article.
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
Archana Anantharaman, Terence Friedlander, +14 authors, Pamela L Paris.
BMC Cancer, 2016 Sep 24; 16(1). PMID: 27658492    Free PMC article.
The emerging role of immunotherapy in colorectal cancer.
David Lynch, Adrian Murphy.
Ann Transl Med, 2016 Sep 27; 4(16). PMID: 27668225    Free PMC article.
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.
Peter E Clark, Philippe E Spiess, +33 authors, Courtney Smith.
J Natl Compr Canc Netw, 2016 Oct 05; 14(10). PMID: 27697976    Free PMC article.
TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies.
Tristan Courau, Djamel Nehar-Belaid, +5 authors, David Klatzmann.
JCI Insight, 2016 Oct 05; 1(9). PMID: 27699271    Free PMC article.
PD-1 expression on the surface of peripheral blood CD4+ T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma.
Wei Zhang, Jie-Fei Bai, +6 authors, Dao-Bin Zhou.
Cancer Med, 2016 Oct 07; 5(11). PMID: 27709793    Free PMC article.
Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis.
Xi Zhang, Yuge Ran, +2 authors, Jinghua Li.
Drug Des Devel Ther, 2016 Oct 13; 10. PMID: 27729774    Free PMC article.
A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.
Nageatte Ibrahim, Elizabeth I Buchbinder, +7 authors, F Stephen Hodi.
Cancer Med, 2016 Oct 18; 5(11). PMID: 27748045    Free PMC article.
Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer.
Yi Zheng, Yicheng Yang, +3 authors, Xiaopeng Liu.
Bioengineered, 2016 Oct 19; 8(4). PMID: 27754760    Free PMC article.
Oral mucosal melanoma treated with carbon ion radiotherapy: a case report.
Atsushi Musha, Jun-Ichi Saitoh, +3 authors, Takashi Nakano.
J Med Case Rep, 2016 Oct 21; 10(1). PMID: 27756356    Free PMC article.
Antitumor adaptive immunity remains intact following inhibition of autophagy and antimalarial treatment.
Hanna Starobinets, Jordan Ye, +6 authors, Jayanta Debnath.
J Clin Invest, 2016 Oct 25; 126(12). PMID: 27775547    Free PMC article.
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy.
Ju Yeon Lee, Hyun Tae Lee, +11 authors, Yong-Seok Heo.
Nat Commun, 2016 Nov 01; 7. PMID: 27796306    Free PMC article.
Highly Cited.
Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition.
Charissa Kim, Jianjun Gao, Vickie R Shannon, Arlene Siefker-Radtke.
BMJ Case Rep, 2016 Nov 01; 2016. PMID: 27797838    Free PMC article.
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Aaron Goodman, Sandip P Patel, Razelle Kurzrock.
Nat Rev Clin Oncol, 2016 Nov 03; 14(4). PMID: 27805626
Highly Cited. Review.
The Kynurenine/Tryptophan Ratio and Glioblastoma Patients Treated with Hsppc-96 Vaccine.
Alicia Lenzen, Lijie Zhai, +6 authors, Derek A Wainwright.
Immunotherapy (Los Angel), 2016 Nov 08; 2(3). PMID: 27819068    Free PMC article.
DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis.
Marian C Okondo, Darren C Johnson, +12 authors, Daniel A Bachovchin.
Nat Chem Biol, 2016 Nov 08; 13(1). PMID: 27820798    Free PMC article.
Highly Cited.
Gene-expression profiling to predict responsiveness to immunotherapy.
N B Jamieson, A V Maker.
Cancer Gene Ther, 2016 Nov 12; 24(3). PMID: 27834354    Free PMC article.
The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis.
BaSang CiRen, Xinhua Wang, Ziwen Long.
Oncotarget, 2016 Nov 16; 7(49). PMID: 27845904    Free PMC article.
Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk.
Jing Li, Gulidanna Shayan, +6 authors, Robert L Ferris.
Oncoimmunology, 2016 Nov 18; 5(10). PMID: 27853635    Free PMC article.
Nivolumab-associated acute glomerulonephritis: a case report and literature review.
Kyungsuk Jung, Xu Zeng, Marijo Bilusic.
BMC Nephrol, 2016 Nov 24; 17(1). PMID: 27876011    Free PMC article.
Ipilimumab: from preclinical development to future clinical perspectives in melanoma.
Paul Letendre, Varun Monga, Mohammed Milhem, Yousef Zakharia.
Future Oncol, 2016 Nov 25; 13(7). PMID: 27882779    Free PMC article.
Evasion of host immune defenses by human papillomavirus.
Joseph A Westrich, Cody J Warren, Dohun Pyeon.
Virus Res, 2016 Nov 29; 231. PMID: 27890631    Free PMC article.
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Giuseppe V Masucci, Alessandra Cesano, +10 authors, Magdalena Thurin.
J Immunother Cancer, 2016 Nov 30; 4. PMID: 27895917    Free PMC article.
Highly Cited. Review.
Recent Advances in Immunotherapy in Metastatic NSCLC.
Pranshu Bansal, Diaa Osman, +2 authors, Yanis Boumber.
Front Oncol, 2016 Nov 30; 6. PMID: 27896216    Free PMC article.
What does PD-L1 positive or negative mean?
Antoni Ribas, Siwen Hu-Lieskovan.
J Exp Med, 2016 Dec 03; 213(13). PMID: 27903604    Free PMC article.
Highly Cited. Review.
Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing.
Benjamin E Paluch, Sean T Glenn, +14 authors, Carl D Morrison.
Oncotarget, 2016 Dec 03; 8(2). PMID: 27911273    Free PMC article.
CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.
Alexander Semaan, Dimo Dietrich, +7 authors, Diane Goltz.
Virchows Arch, 2016 Dec 04; 470(2). PMID: 27913861
Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.
Corinne A Levingston, M Rita I Young.
Int J Cancer, 2016 Dec 04; 140(7). PMID: 27914100    Free PMC article.
Pharmacological and immunological targeting of tumor mesenchymalization.
Justin M David, Charli Dominguez, Claudia Palena.
Pharmacol Ther, 2016 Dec 06; 170. PMID: 27916651    Free PMC article.
Hijacker of the Antitumor Immune Response: Autophagy Is Showing Its Worst Facet.
Elodie Viry, Muhammad Zaeem Noman, +6 authors, Bassam Janji.
Front Oncol, 2016 Dec 06; 6. PMID: 27917371    Free PMC article.
Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities.
Sadanori Furudate, Taku Fujimura, +3 authors, Setsuya Aiba.
Case Rep Oncol, 2016 Dec 07; 9(3). PMID: 27920696    Free PMC article.
Ipilimumab-Induced Enteritis without Colitis: A New Challenge.
Marcus Messmer, Sunita Upreti, +4 authors, Matthias Holdhoff.
Case Rep Oncol, 2016 Dec 07; 9(3). PMID: 27920706    Free PMC article.
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.
Gerald Goh, Ramona Schmid, +16 authors, Charles Swanton.
PLoS Med, 2016 Dec 07; 13(12). PMID: 27923043    Free PMC article.
Developmental therapeutics for inflammatory breast cancer: Biology and translational directions.
Ricardo Costa, Cesar A Santa-Maria, +5 authors, Massimo Cristofanilli.
Oncotarget, 2016 Dec 08; 8(7). PMID: 27926493    Free PMC article.
Role of immune cells in pancreatic cancer from bench to clinical application: An updated review.
Jae Hyuck Chang, Yongjian Jiang, Venu G Pillarisetty.
Medicine (Baltimore), 2016 Dec 09; 95(49). PMID: 27930550    Free PMC article.
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Matthew D Hellmann, Naiyer A Rizvi, +14 authors, Scott J Antonia.
Lancet Oncol, 2016 Dec 10; 18(1). PMID: 27932067    Free PMC article.
Highly Cited.
Molecular Pathways: The Necrosome-A Target for Cancer Therapy.
Lena Seifert, George Miller.
Clin Cancer Res, 2016 Dec 10; 23(5). PMID: 27932417    Free PMC article.
Cancer and inflammation.
Lance L Munn.
Wiley Interdiscip Rev Syst Biol Med, 2016 Dec 13; 9(2). PMID: 27943646    Free PMC article.
Highly Cited. Review.
Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition.
Nina Deppisch, Peter Ruf, +2 authors, Ralph Mocikat.
Oncotarget, 2016 Dec 15; 8(3). PMID: 27966460    Free PMC article.
PD-1 and its ligands are important immune checkpoints in cancer.
Yinan Dong, Qian Sun, Xinwei Zhang.
Oncotarget, 2016 Dec 16; 8(2). PMID: 27974689    Free PMC article.
Highly Cited. Review.
Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
Aaron T Mayer, Arutselvan Natarajan, +5 authors, Sanjiv S Gambhir.
J Nucl Med, 2016 Dec 17; 58(4). PMID: 27980047    Free PMC article.
Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update.
M Kudo.
Liver Cancer, 2016 Dec 21; 6(1). PMID: 27995082    Free PMC article.
Immuno-Oncology: The Third Paradigm in Early Drug Development.
Juan Martin-Liberal, Cinta Hierro, Maria Ochoa de Olza, Jordi Rodon.
Target Oncol, 2016 Dec 21; 12(2). PMID: 27995439
LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma.
Wei-Wei Deng, Liang Mao, +7 authors, Zhi-Jun Sun.
Oncoimmunology, 2016 Dec 22; 5(11). PMID: 27999760    Free PMC article.
Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.
Adam J Adler, Payal Mittal, +3 authors, Anthony T Vella.
Immunotherapy, 2016 Dec 22; 9(1). PMID: 28000531    Free PMC article.
The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.
Souvik Karmakar, Karlyne M Reilly.
CNS Oncol, 2016 Dec 22; 6(1). PMID: 28001089    Free PMC article.
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
Xinqi Wu, Anita Giobbie-Hurder, +15 authors, F Stephen Hodi.
Cancer Immunol Res, 2016 Dec 23; 5(1). PMID: 28003187    Free PMC article.
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.
Kankana Bardhan, Theodora Anagnostou, Vassiliki A Boussiotis.
Front Immunol, 2016 Dec 27; 7. PMID: 28018338    Free PMC article.
Highly Cited. Review.
PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment.
Andrew S Flies, A Bruce Lyons, +5 authors, John D Hayball.
Front Immunol, 2016 Dec 27; 7. PMID: 28018348    Free PMC article.
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors.
G Bajaj, X Wang, +3 authors, Y Feng.
CPT Pharmacometrics Syst Pharmacol, 2016 Dec 27; 6(1). PMID: 28019091    Free PMC article.
Highly Cited.
Update on immune checkpoint inhibitors in gynecological cancers.
Valerie Heong, Natalie Ngoi, David Shao Peng Tan.
J Gynecol Oncol, 2016 Dec 29; 28(2). PMID: 28028993    Free PMC article.
Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer.
Yu Wang, Jiacheng Lin, +4 authors, Liwei Wang.
Oncotarget, 2016 Dec 29; 8(6). PMID: 28030840    Free PMC article.
PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.
Elise A Chong, J Joseph Melenhorst, +5 authors, Stephen J Schuster.
Blood, 2016 Dec 30; 129(8). PMID: 28031179    Free PMC article.
Highly Cited.
Advances in the molecular genetics of gliomas - implications for classification and therapy.
Guido Reifenberger, Hans-Georg Wirsching, Christiane B Knobbe-Thomsen, Michael Weller.
Nat Rev Clin Oncol, 2016 Dec 30; 14(7). PMID: 28031556
Highly Cited. Review.
A New VISTA on combination therapy for negative checkpoint regulator blockade.
Jie Deng, Isabelle Le Mercier, Anna Kuta, Randolph J Noelle.
J Immunother Cancer, 2016 Dec 30; 4. PMID: 28031817    Free PMC article.
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy.
Jared R Lowe, Daniel J Perry, +3 authors, Brent A Hanks.
J Immunother Cancer, 2016 Dec 30; 4. PMID: 28031819    Free PMC article.
Canine cancer immunotherapy studies: linking mouse and human.
Jiwon S Park, Sita S Withers, +9 authors, Robert J Canter.
J Immunother Cancer, 2016 Dec 30; 4. PMID: 28031824    Free PMC article.
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab.
Claire F Friedman, Varina Clark, +8 authors, Michael A Postow.
J Natl Cancer Inst, 2017 Jan 04; 109(4). PMID: 28040701    Free PMC article.
Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.
M González-Cao, A Arance, +22 authors, Spanish Melanoma Group.
Clin Transl Oncol, 2017 Jan 06; 19(6). PMID: 28054320
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
Sandra P D'Angelo, James Larkin, +19 authors, Jedd D Wolchok.
J Clin Oncol, 2017 Jan 06; 35(2). PMID: 28056206    Free PMC article.
Highly Cited.
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.
W Joost Lesterhuis, Anthony Bosco, +3 authors, Richard A Lake.
Nat Rev Drug Discov, 2017 Jan 07; 16(4). PMID: 28057932
Highly Cited. Review.
Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects.
Kenneth G Liu, Sorab Gupta, Sanjay Goel.
Oncotarget, 2017 Jan 07; 8(10). PMID: 28061473    Free PMC article.
Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.
Lei Qin, Xiang Li, +4 authors, Geoffrey S Young.
Neuroradiology, 2017 Jan 11; 59(2). PMID: 28070598    Free PMC article.
Strategies to overcome therapeutic resistance in renal cell carcinoma.
Peter J Siska, Kathryn E Beckermann, W Kimryn Rathmell, Scott M Haake.
Urol Oncol, 2017 Jan 17; 35(3). PMID: 28089416    Free PMC article.
Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies.
Andrew Kwong, Martina Sanlorenzo, Klemens Rappersberger, Igor Vujic.
Wien Med Wochenschr, 2017 Jan 17; 169(13-14). PMID: 28091975
Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R Weichselbaum, Hua Liang, Liufu Deng, Yang-Xin Fu.
Nat Rev Clin Oncol, 2017 Jan 18; 14(6). PMID: 28094262
Highly Cited. Review.
Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.
Paola Falletta, Luis Sanchez-Del-Campo, +17 authors, Colin R Goding.
Genes Dev, 2017 Jan 18; 31(1). PMID: 28096186    Free PMC article.
Highly Cited.
Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.
Marta Braschi-Amirfarzan, Sree Harsha Tirumani, Frank Stephen Hodi, Mizuki Nishino.
Korean J Radiol, 2017 Jan 18; 18(1). PMID: 28096717    Free PMC article.
Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.
David J Byun, Jedd D Wolchok, Lynne M Rosenberg, Monica Girotra.
Nat Rev Endocrinol, 2017 Jan 21; 13(4). PMID: 28106152    Free PMC article.
Highly Cited. Review.
New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.
Siwen Hu-Lieskovan, Antoni Ribas.
Cancer J, 2017 Jan 24; 23(1). PMID: 28114250    Free PMC article.
The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches.
Pankita H Pandya, Mary E Murray, Karen E Pollok, Jamie L Renbarger.
J Immunol Res, 2017 Jan 25; 2016. PMID: 28116316    Free PMC article.
Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic.
Kenneth Oguejiofor, Henry Galletta-Williams, +3 authors, Catharine M L West.
Oncotarget, 2017 Jan 26; 8(9). PMID: 28122336    Free PMC article.
Redirecting the focus of cancer immunotherapy to premalignant conditions.
M Rita I Young.
Cancer Lett, 2017 Jan 29; 391. PMID: 28130162    Free PMC article.
PD-L1 Expression in Pancreatic Cancer.
Lei Zheng.
J Natl Cancer Inst, 2017 Jan 31; 109(6). PMID: 28131993    Free PMC article.
Medication-associated gastrointestinal tract injury.
Michael Vieth, Elizabeth Montgomery.
Virchows Arch, 2017 Jan 31; 470(3). PMID: 28133700
Overcoming therapeutic resistance in glioblastoma: the way forward.
Satoru Osuka, Erwin G Van Meir.
J Clin Invest, 2017 Feb 02; 127(2). PMID: 28145904    Free PMC article.
Highly Cited. Review.
Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy.
Paul M Tyler, Mariah M Servos, +6 authors, Stephanie K Dougan.
Mol Cancer Ther, 2017 Feb 06; 16(3). PMID: 28148714    Free PMC article.
Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.
M Higgins, G Curigliano, +14 authors, P Goss.
Breast Cancer Res Treat, 2017 Feb 09; 162(3). PMID: 28176175    Free PMC article.
Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
A K S Salama, S J Moschos.
Ann Oncol, 2017 Feb 09; 28(1). PMID: 28177433    Free PMC article.
Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.
Lijie Zhai, Erik Ladomersky, +8 authors, Derek A Wainwright.
Brain Behav Immun, 2017 Feb 10; 62. PMID: 28179106    Free PMC article.
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, Antoni Ribas.
Cell, 2017 Feb 12; 168(4). PMID: 28187290    Free PMC article.
Highly Cited. Review.
Interferon-α-inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity.
Terutsugu Koya, Ryu Yanagisawa, +2 authors, Shigetaka Shimodaira.
Sci Rep, 2017 Feb 14; 7. PMID: 28191816    Free PMC article.
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer.
Ruea-Yea Huang, Ariel Francois, +2 authors, Kunle Odunsi.
Oncoimmunology, 2017 Feb 16; 6(1). PMID: 28197366    Free PMC article.
Highly Cited.
Transient Cannabinoid Receptor 2 Blockade during Immunization Heightens Intensity and Breadth of Antigen-specific Antibody Responses in Young and Aged mice.
Emmanuel Dotsey, Irina Ushach, +9 authors, Philip L Felgner.
Sci Rep, 2017 Feb 18; 7. PMID: 28209996    Free PMC article.
Targeting PD-1/PD-L1 in lung cancer: current perspectives.
María González-Cao, Niki Karachaliou, +6 authors, Rafael Rosell.
Lung Cancer (Auckl), 2015 Jul 31; 6. PMID: 28210151    Free PMC article.
Bidirectional Crosstalk between Lymphatic Endothelial Cell and T Cell and Its Implications in Tumor Immunity.
Kim Pin Yeo, Veronique Angeli.
Front Immunol, 2017 Feb 22; 8. PMID: 28220121    Free PMC article.
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Harriet M Kluger, Christopher R Zito, +9 authors, Lucia B Jilaveanu.
Clin Cancer Res, 2017 Feb 23; 23(15). PMID: 28223273    Free PMC article.
Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma.
Alan T Yeo, Alain Charest.
J Cell Biochem, 2017 Feb 24; 118(9). PMID: 28230277    Free PMC article.
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
Gerardo Botti, Federica Fratangelo, +15 authors, Giosuè Scognamiglio.
J Transl Med, 2017 Feb 25; 15(1). PMID: 28231855    Free PMC article.
A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity.
Jewell N Walters, Bernadette Ferraro, +8 authors, David B Weiner.
Mol Ther, 2017 Feb 27; 25(4). PMID: 28237837    Free PMC article.
Combination immunotherapy: a road map.
Patrick A Ott, F Stephen Hodi, +2 authors, Jedd D Wolchok.
J Immunother Cancer, 2017 Feb 28; 5. PMID: 28239469    Free PMC article.
Highly Cited. Review.
FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer.
Stefan N Symeonides, Stephen M Anderton, Alan Serrels.
J Immunother Cancer, 2017 Feb 28; 5. PMID: 28239470    Free PMC article.
First-line treatment of metastatic melanoma: role of nivolumab.
Jeremy Force, April Ks Salama.
Immunotargets Ther, 2017 Mar 01; 6. PMID: 28243579    Free PMC article.
Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.
Arutselvan Natarajan, Aaron T Mayer, +2 authors, Sanjiv Sam Gambhir.
Mol Imaging Biol, 2017 Mar 02; 19(6). PMID: 28247187    Free PMC article.
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.
Whijae Roh, Pei-Ling Chen, +37 authors, P Andrew Futreal.
Sci Transl Med, 2017 Mar 03; 9(379). PMID: 28251903    Free PMC article.
Highly Cited.
Renal cell carcinoma: molecular characterization and evolving treatment paradigms.
Mark W Ball, Eric A Singer, Ramaprasad Srinivasan.
Curr Opin Oncol, 2017 Mar 03; 29(3). PMID: 28252459    Free PMC article.
The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors.
Andrew S Luksik, Russell Maxwell, Tomas Garzon-Muvdi, Michael Lim.
Neurotherapeutics, 2017 Mar 05; 14(4). PMID: 28258545    Free PMC article.
Introduction to checkpoint inhibitors and cancer immunotherapy.
Arlene H Sharpe.
Immunol Rev, 2017 Mar 05; 276(1). PMID: 28258698    Free PMC article.
Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.
Liliana E Lucca, David A Hafler.
Immunol Rev, 2017 Mar 05; 276(1). PMID: 28258696    Free PMC article.
Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.
Liting Guo, Haijun Zhang, Baoan Chen.
J Cancer, 2017 Mar 07; 8(3). PMID: 28261342    Free PMC article.
Precision medicine driven by cancer systems biology.
Fabian V Filipp.
Cancer Metastasis Rev, 2017 Mar 08; 36(1). PMID: 28265786    Free PMC article.
Advancing Immune and Cell-Based Therapies Through Imaging.
Vladimir Ponomarev.
Mol Imaging Biol, 2017 Mar 09; 19(3). PMID: 28271366    Free PMC article.
Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway.
Junghwa Lee, Eunseon Ahn, Haydn T Kissick, Rafi Ahmed.
For Immunopathol Dis Therap, 2015 Jan 01; 6(1-2). PMID: 28286692    Free PMC article.
Single vs. combination immunotherapeutic strategies for glioma.
Mayuri Chandran, Marianela Candolfi, +6 authors, Maria G Castro.
Expert Opin Biol Ther, 2017 Mar 14; 17(5). PMID: 28286975    Free PMC article.
The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists.
Sunil Thomas, Jacques Izard, +12 authors, George C Prendergast.
Cancer Res, 2017 Mar 16; 77(8). PMID: 28292977    Free PMC article.
Highly Cited. Review.
Multiscale Modeling of Complex Formation and CD80 Depletion during Immune Synapse Development.
István P Sugár, Jayajit Das, Ciriyam Jayaprakash, Stuart C Sealfon.
Biophys J, 2017 Mar 16; 112(5). PMID: 28297658    Free PMC article.
Advances in Immunotherapy for Glioblastoma Multiforme.
Boyuan Huang, Hongbo Zhang, +4 authors, Xiaoxing Xiong.
J Immunol Res, 2017 Mar 17; 2017. PMID: 28299344    Free PMC article.
TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action.
Wenwen Du, Min Yang, +5 authors, Binfeng Lu.
Int J Mol Sci, 2017 Mar 17; 18(3). PMID: 28300768    Free PMC article.
[Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma].
A Neubauer.
Internist (Berl), 2017 Mar 18; 58(4). PMID: 28303311
Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy.
Mee Y Bartee, Katherine M Dunlap, Eric Bartee.
Cancer Res, 2017 Mar 21; 77(11). PMID: 28314785    Free PMC article.
Highly Cited.
Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.
Jennifer D Moy, Jessica M Moskovitz, Robert L Ferris.
Eur J Cancer, 2017 Mar 23; 76. PMID: 28324750    Free PMC article.
A quantitative method for screening and identifying molecular targets for nanomedicine.
Peng Guo, Jiang Yang, +4 authors, Debra T Auguste.
J Control Release, 2017 Mar 28; 263. PMID: 28341549    Free PMC article.
Development of CAR T cells designed to improve antitumor efficacy and safety.
Janneke E Jaspers, Renier J Brentjens.
Pharmacol Ther, 2017 Mar 28; 178. PMID: 28342824    Free PMC article.
An Anti-Programmed Death-1 Antibody (αPD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional αPD-1 Nanoparticle.
Peng Zhao, Djordje Atanackovic, +3 authors, Mingnan Chen.
Mol Pharm, 2017 Mar 28; 14(5). PMID: 28343398    Free PMC article.
Function and Clinical Implications of Long Non-Coding RNAs in Melanoma.
Georg Richtig, Barbara Ehall, +3 authors, Martin Pichler.
Int J Mol Sci, 2017 Mar 30; 18(4). PMID: 28350340    Free PMC article.
Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.
Michael R Cassidy, Rachel E Wolchok, +5 authors, Charlotte Ariyan.
EBioMedicine, 2017 Mar 31; 18. PMID: 28356222    Free PMC article.
Role of TIM-3 in ovarian cancer.
Y Xu, H Zhang, +2 authors, F Zheng.
Clin Transl Oncol, 2017 Mar 31; 19(9). PMID: 28357631
Immunotherapy for Esophageal Squamous Cell Carcinoma.
Takashi Kojima, Toshihiko Doi.
Curr Oncol Rep, 2017 Apr 01; 19(5). PMID: 28361224    Free PMC article.
Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer.
Angel Qin, Lindsay Street, +4 authors, Nithya Ramnath.
Clin Lung Cancer, 2017 Apr 04; 18(5). PMID: 28366756    Free PMC article.
Targeted Therapies for Melanoma Brain Metastases.
Anna S Berghoff, Matthias Preusser.
Curr Treat Options Neurol, 2017 Apr 05; 19(4). PMID: 28374234    Free PMC article.
Targeted agents and immunotherapies: optimizing outcomes in melanoma.
Jason J Luke, Keith T Flaherty, Antoni Ribas, Georgina V Long.
Nat Rev Clin Oncol, 2017 Apr 05; 14(8). PMID: 28374786
Highly Cited. Review.
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment.
James L Gulley, Ravi A Madan, +4 authors, Charles G Drake.
J Natl Cancer Inst, 2017 Apr 05; 109(4). PMID: 28376158    Free PMC article.
Highly Cited. Review.
Cancer immunotherapies targeting the PD-1 signaling pathway.
Yoshiko Iwai, Junzo Hamanishi, Kenji Chamoto, Tasuku Honjo.
J Biomed Sci, 2017 Apr 06; 24(1). PMID: 28376884    Free PMC article.
Highly Cited. Review.
UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model.
Jake Wang, Curtis J Perry, +6 authors, Marcus Bosenberg.
Pigment Cell Melanoma Res, 2017 Apr 06; 30(4). PMID: 28379630    Free PMC article.
Highly Cited.
Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.
Azharuddin Sajid Syed Khaja, Salman M Toor, +4 authors, Eyad Elkord.
Oncotarget, 2017 Apr 08; 8(20). PMID: 28388539    Free PMC article.
Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.
Daniel O Villarreal, Diana Chin, +2 authors, Linda A Snyder.
Oncotarget, 2017 Apr 08; 8(24). PMID: 28388572    Free PMC article.
Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
Yubo Jiang, Anthony W I Lo, +4 authors, Jianming Xu.
Oncotarget, 2017 Apr 14; 8(18). PMID: 28404915    Free PMC article.
A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer.
Zu-Jun Sun, Yi Wu, +4 authors, Min Yu.
Oncotarget, 2017 Apr 14; 8(17). PMID: 28404966    Free PMC article.
HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy.
Annika Nelde, Juliane Sarah Walz, +14 authors, Alexander N R Weber.
Oncoimmunology, 2017 Apr 14; 6(3). PMID: 28405493    Free PMC article.
Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma.
Ester Simeone, Antonio Maria Grimaldi, +8 authors, Paolo Antonio Ascierto.
Oncoimmunology, 2017 Apr 14; 6(3). PMID: 28405510    Free PMC article.
Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.
Katrijn Broos, Marleen Keyaerts, +7 authors, Nick Devoogdt.
Oncotarget, 2017 Apr 15; 8(26). PMID: 28410210    Free PMC article.
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.
Paul C Tumeh, Matthew D Hellmann, +31 authors, Adil Daud.
Cancer Immunol Res, 2017 Apr 16; 5(5). PMID: 28411193    Free PMC article.
Highly Cited.
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
Wei Ding, Betsy R LaPlant, +32 authors, Stephen M Ansell.
Blood, 2017 Apr 21; 129(26). PMID: 28424162    Free PMC article.
Highly Cited.
Dendritic cell based vaccination strategy: an evolving paradigm.
Anna C Filley, Mahua Dey.
J Neurooncol, 2017 Apr 24; 133(2). PMID: 28434112    Free PMC article.
The use of immunotherapy in the treatment of melanoma.
Tala Achkar, Ahmad A Tarhini.
J Hematol Oncol, 2017 Apr 25; 10(1). PMID: 28434398    Free PMC article.
Signaling by Antibodies: Recent Progress.
Stylianos Bournazos, Taia T Wang, +2 authors, Jeffrey V Ravetch.
Annu Rev Immunol, 2017 Apr 28; 35. PMID: 28446061    Free PMC article.
Highly Cited. Review.
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.
Alice O Kamphorst, Rathi N Pillai, +16 authors, Suresh S Ramalingam.
Proc Natl Acad Sci U S A, 2017 Apr 28; 114(19). PMID: 28446615    Free PMC article.
Highly Cited.
Harnessing antitumor immunity: Employment of tumor recall antigens to optimize the inflammatory response to cancer.
Kimberly A Silverio, Shyam A Patel.
Oncol Lett, 2017 Apr 30; 13(4). PMID: 28454356    Free PMC article.
Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy.
David M Francis, Susan N Thomas.
Adv Drug Deliv Rev, 2017 Apr 30; 114. PMID: 28455187    Free PMC article.
Concordance measure and discriminatory accuracy in transformation cure models.
Yilong Zhang, Yongzhao Shao.
Biostatistics, 2017 May 10; 19(1). PMID: 28481968    Free PMC article.
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
Udupi A Ramagopal, Weifeng Liu, +10 authors, Steven C Almo.
Proc Natl Acad Sci U S A, 2017 May 10; 114(21). PMID: 28484017    Free PMC article.
Transcriptional response profiles of paired tumor-normal samples offer novel perspectives in pan-cancer analysis.
Shuofeng Hu, Hanyu Yuan, +7 authors, Xiaomin Ying.
Oncotarget, 2017 May 11; 8(25). PMID: 28489584    Free PMC article.
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
James Larkin, Bartosz Chmielowski, +9 authors, David A Reardon.
Oncologist, 2017 May 13; 22(6). PMID: 28495807    Free PMC article.
Highly Cited.
Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies.
Upendra P Hegde, Bijay Mukherji.
Cancer Immunol Immunother, 2017 May 13; 66(9). PMID: 28497159    Free PMC article.
Post-chemotherapy PD-L1 expression correlates with clinical outcomes in Japanese bladder cancer patients treated with total cystectomy.
Daisuke Noro, Shingo Hatakeyama, +4 authors, Chikara Ohyama.
Med Oncol, 2017 May 14; 34(6). PMID: 28500617
Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.
Jessica M Moskovitz, Jennifer Moy, Tanguy Y Seiwert, Robert L Ferris.
Oncologist, 2017 May 17; 22(6). PMID: 28507203    Free PMC article.
Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.
Andrew S Flies, Nicholas B Blackburn, +2 authors, Gregory M Woods.
Front Immunol, 2017 May 19; 8. PMID: 28515726    Free PMC article.
Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma.
Jessie R Nedrow, Anders Josefsson, +3 authors, George Sgouros.
J Nucl Med, 2017 May 20; 58(10). PMID: 28522738    Free PMC article.
Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.
Anna Oh, Dang M Tran, +4 authors, Leslie Wilson.
J Manag Care Spec Pharm, 2017 May 23; 23(6). PMID: 28530525    Free PMC article.
Combinatorial drug delivery approaches for immunomodulation.
Joshua M Stewart, Benjamin G Keselowsky.
Adv Drug Deliv Rev, 2017 May 24; 114. PMID: 28532690    Free PMC article.
Immune Checkpoint in Glioblastoma: Promising and Challenging.
Jing Huang, Fangkun Liu, +4 authors, Jindong Chen.
Front Pharmacol, 2017 May 26; 8. PMID: 28536525    Free PMC article.
Highly Cited. Review.
Delivering safer immunotherapies for cancer.
Lauren Milling, Yuan Zhang, Darrell J Irvine.
Adv Drug Deliv Rev, 2017 May 27; 114. PMID: 28545888    Free PMC article.
Highly Cited. Review.
Challenges in the delivery of therapies to melanoma brain metastases.
Gautham Gampa, Shruthi Vaidhyanathan, +4 authors, William F Elmquist.
Curr Pharmacol Rep, 2017 May 27; 2(6). PMID: 28546917    Free PMC article.
Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma.
Xiaomeng Dai, Jun Xue, +8 authors, Tao Zhang.
Transl Oncol, 2017 May 31; 10(4). PMID: 28558264    Free PMC article.
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.
Jingyu Zhang, Dai Liu, +4 authors, Jennifer D Wu.
Sci Adv, 2017 Jun 01; 3(5). PMID: 28560327    Free PMC article.
Targeting Melanoma with Cancer-Killing Viruses.
Tiantian Zhang, Yogesh R Suryawanshi, Helene M Woyczesczyk, Karim Essani.
Open Virol J, 2017 Jun 02; 11. PMID: 28567163    Free PMC article.
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.
Roberta Mazzone, Clemens Zwergel, Antonello Mai, Sergio Valente.
Clin Epigenetics, 2017 Jun 03; 9. PMID: 28572863    Free PMC article.
Highly Cited. Review.
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Glen J Weiss, Jordan Waypa, +7 authors, Vivek Khemka.
Br J Cancer, 2017 Jun 08; 117(1). PMID: 28588322    Free PMC article.
PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells.
Carmen Stecher, Claire Battin, +5 authors, Peter Steinberger.
Front Immunol, 2017 Jun 08; 8. PMID: 28588576    Free PMC article.
Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG.
Justin M Roberts, Rebeca San Martin, +7 authors, Nancy L Weigel.
Oncotarget, 2017 Jun 08; 8(27). PMID: 28591703    Free PMC article.
Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.
Mizuki Nishino, Anita Giobbie-Hurder, +5 authors, F Stephen Hodi.
Clin Cancer Res, 2017 Jun 09; 23(16). PMID: 28592629    Free PMC article.
Intratumoral FoxP3+Helios+ Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer.
Azharuddin Sajid Syed Khaja, Salman M Toor, +2 authors, Eyad Elkord.
Front Immunol, 2017 Jun 13; 8. PMID: 28603527    Free PMC article.
Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
Danae A Delivanis, Michael P Gustafson, +5 authors, Mabel Ryder.
J Clin Endocrinol Metab, 2017 Jun 15; 102(8). PMID: 28609832    Free PMC article.
Highly Cited.
Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
Elena Czink, Matthias Kloor, +10 authors, Christoph Springfeld.
Cold Spring Harb Mol Case Stud, 2017 Jun 18; 3(5). PMID: 28619747    Free PMC article.
Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study.
José Mordoh, María Betina Pampena, +11 authors, María Marcela Barrio.
Front Immunol, 2017 Jun 18; 8. PMID: 28620382    Free PMC article.
Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.
Jeong A Park, Nai-Kong V Cheung.
Cancer Treat Rev, 2017 Jun 18; 58. PMID: 28622628    Free PMC article.
Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy.
Daniel E Meyers, Amanda A Wang, Chandini M Thirukkumaran, Don G Morris.
Front Oncol, 2017 Jun 22; 7. PMID: 28634571    Free PMC article.
Cellular immunotherapies for cancer.
Pedro Berraondo, Sara Labiano, +5 authors, Ignacio Melero.
Oncoimmunology, 2017 Jun 24; 6(5). PMID: 28638729    Free PMC article.
Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy.
Jose D Sandoval-Sus, Francis Mogollon-Duffo, +4 authors, Michael V Jagal.
J Immunother Cancer, 2017 Jun 24; 5. PMID: 28642818    Free PMC article.
PD-1 and cancer: molecular mechanisms and polymorphisms.
Arash Salmaninejad, Vahid Khoramshahi, +6 authors, Sayed Mostafa Hosseini.
Immunogenetics, 2017 Jun 24; 70(2). PMID: 28642997
Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity.
Maher G Nawaf, Maria H Ulvmar, +7 authors, Peter J L Lane.
J Immunol, 2017 Jun 25; 199(3). PMID: 28646041    Free PMC article.
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016.
Prasad S Adusumilli, Edward Cha, +18 authors, Daniel S Chen.
J Immunother Cancer, 2017 Jun 27; 5. PMID: 28649381    Free PMC article.
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.
Yuanzeng Min, Kyle C Roche, +12 authors, Andrew Z Wang.
Nat Nanotechnol, 2017 Jun 27; 12(9). PMID: 28650437    Free PMC article.
Highly Cited.
Health-related quality of life results from the phase III CheckMate 067 study.
Dirk Schadendorf, James Larkin, +20 authors, Georgina V Long.
Eur J Cancer, 2017 Jun 27; 82. PMID: 28651159    Free PMC article.
Monitoring immune-checkpoint blockade: response evaluation and biomarker development.
Mizuki Nishino, Nikhil H Ramaiya, Hiroto Hatabu, F Stephen Hodi.
Nat Rev Clin Oncol, 2017 Jun 28; 14(11). PMID: 28653677    Free PMC article.
Highly Cited. Review.
Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.
Xinxin Zhu, Jinghe Lang.
J Gynecol Oncol, 2017 Jun 29; 28(5). PMID: 28657225    Free PMC article.
Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma.
Kerem M Senses, Mehdi Ghasemi, +7 authors, Ali O Gure.
Medchemcomm, 2017 Jul 04; 8(1). PMID: 28670440    Free PMC article.
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
James Larkin, David Minor, +20 authors, Jeffrey Weber.
J Clin Oncol, 2017 Jul 04; 36(4). PMID: 28671856    Free PMC article.
Highly Cited.
Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Casey R Ager, Matthew J Reilley, +3 authors, Michael A Curran.
Cancer Immunol Res, 2017 Jul 05; 5(8). PMID: 28674082    Free PMC article.
Highly Cited.
Primary malignant melanoma of the lung: A case report.
Yoko Yamamoto, Ken Kodama, +4 authors, Taiki Isei.
Mol Clin Oncol, 2017 Jul 08; 7(1). PMID: 28685072    Free PMC article.
Immune profiles and clinical outcomes between sepsis patients with or without active cancer requiring admission to intensive care units.
Wen-Feng Fang, Yu-Mu Chen, +8 authors, Meng-Chih Lin.
PLoS One, 2017 Jul 12; 12(7). PMID: 28692671    Free PMC article.
Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
Alex B Blair, Lei Zheng.
Chin Clin Oncol, 2017 Jul 15; 6(3). PMID: 28705008    Free PMC article.
Supportive care for patients undergoing immunotherapy.
Bernardo Leon Rapoport, Ronwyn van Eeden, +4 authors, Devan Moodley.
Support Care Cancer, 2017 Jul 15; 25(10). PMID: 28707167
Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas.
Wanlu Du, Ivan Seah, +6 authors, Khalid Shah.
Proc Natl Acad Sci U S A, 2017 Jul 16; 114(30). PMID: 28710334    Free PMC article.
Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Lea Bottlaender, Anne-Laure Breton, +3 authors, Stephane Dalle.
J Immunother Cancer, 2017 Jul 19; 5(1). PMID: 28716106    Free PMC article.
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.
Hyun Tae Lee, Ju Yeon Lee, +6 authors, Yong-Seok Heo.
Sci Rep, 2017 Jul 19; 7(1). PMID: 28717238    Free PMC article.
NKT cell-dependent glycolipid-peptide vaccines with potent anti-tumour activity.
Regan J Anderson, Benjamin J Compton, +11 authors, Gavin F Painter.
Chem Sci, 2015 Sep 01; 6(9). PMID: 28717498    Free PMC article.
NLRC5/CITA: A Key Player in Cancer Immune Surveillance.
Sayuri Yoshihama, Saptha Vijayan, Tabasum Sidiq, Koichi S Kobayashi.
Trends Cancer, 2017 Jul 19; 3(1). PMID: 28718425    Free PMC article.
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
Benjamin Izar, William Sharfman, +14 authors, Michael B Atkins.
Cancer Med, 2017 Jul 19; 6(8). PMID: 28719152    Free PMC article.
Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.
Pedro R Lowenstein, Maria G Castro.
Clin Immunol, 2017 Jul 20; 189. PMID: 28720549    Free PMC article.
PDL1: The Illusion of an Ideal Biomarker.
Andrea B Apolo.
Eur Urol Focus, 2016 Feb 01; 1(3). PMID: 28723398    Free PMC article.
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.
Robert T Manguso, Hans W Pope, +16 authors, W Nicholas Haining.
Nature, 2017 Jul 21; 547(7664). PMID: 28723893    Free PMC article.
Highly Cited.
Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy.
Kimberly Loo, Katy K Tsai, +14 authors, Adil I Daud.
JCI Insight, 2017 Jul 21; 2(14). PMID: 28724802    Free PMC article.
Fatty Acid Uptake in T Cell Subsets Using a Quantum Dot Fatty Acid Conjugate.
Megan E Muroski, Jason Miska, +6 authors, Maciej S Lesniak.
Sci Rep, 2017 Jul 21; 7(1). PMID: 28724939    Free PMC article.
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.
Alexandre Reuben, Rachel Gittelman, +37 authors, Jianjun Zhang.
Cancer Discov, 2017 Jul 25; 7(10). PMID: 28733428    Free PMC article.
Biological agents in gastrointestinal cancers: adverse effects and their management.
Nivedita Arora, Arjun Gupta, Preet Paul Singh.
J Gastrointest Oncol, 2017 Jul 25; 8(3). PMID: 28736636    Free PMC article.
Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis.
Courtney P Rudick, David L Cornell, Devendra K Agrawal.
Expert Rev Clin Immunol, 2017 Jul 26; 13(9). PMID: 28742984    Free PMC article.
Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy.
Yosuke Ohno, Yujiro Toyoshima, +12 authors, Hidemitsu Kitamura.
Cancer Sci, 2017 Jul 27; 108(10). PMID: 28746799    Free PMC article.
Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.
Hidemitsu Kitamura, Yosuke Ohno, +5 authors, Akinobu Taketomi.
Cancer Sci, 2017 Jul 28; 108(10). PMID: 28749573    Free PMC article.
Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors.
Nathan O Siemers, James L Holloway, +4 authors, Joseph D Szustakowski.
PLoS One, 2017 Jul 28; 12(7). PMID: 28749946    Free PMC article.
Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers.
Claire Vanpouille-Box, Silvia C Formenti, Sandra Demaria.
Clin Cancer Res, 2017 Jul 29; 24(2). PMID: 28751442    Free PMC article.
Highly Cited. Review.
Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival.
Lijie Zhai, Erik Ladomersky, +12 authors, Derek A Wainwright.
Clin Cancer Res, 2017 Jul 29; 23(21). PMID: 28751450    Free PMC article.
Highly Cited.
Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
Yuan Gao, Su Li, +9 authors, Minghuang Hong.
Chin J Cancer, 2017 Jul 30; 36(1). PMID: 28754154    Free PMC article.
An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection.
Casey W Shuptrine, Reham Ajina, +4 authors, Louis M Weiner.
Cancer Immunol Immunother, 2017 Aug 05; 66(12). PMID: 28770278    Free PMC article.
Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12-13 May 2017.
Peter L Stern.
Ther Adv Vaccines, 2017 Aug 11; 5(3). PMID: 28794878    Free PMC article.
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.
François Bertucci, Anthony Gonçalves.
Curr Oncol Rep, 2017 Aug 12; 19(10). PMID: 28799073
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
Spencer C Wei, Jacob H Levine, +8 authors, James P Allison.
Cell, 2017 Aug 15; 170(6). PMID: 28803728    Free PMC article.
Highly Cited.
Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.
Masahiro Kikuchi, David A Clump, +6 authors, Robert L Ferris.
Oncoimmunology, 2017 Aug 16; 6(7). PMID: 28811971    Free PMC article.
Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.
Sabrina Rossi, Luca Toschi, +3 authors, Egesta Lopci.
Eur J Nucl Med Mol Imaging, 2017 Aug 18; 44(13). PMID: 28815334
Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.
Alexander N Shoushtari, Claire F Friedman, +6 authors, Paul B Chapman.
JAMA Oncol, 2017 Aug 18; 4(1). PMID: 28817755    Free PMC article.
Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer.
Kazuhiko Takaya, Miwa Sonoda, Ayako Fuchigami, Toru Hiyoshi.
Intern Med, 2017 Aug 22; 56(18). PMID: 28824067    Free PMC article.
The colorectal cancer immune microenvironment and approach to immunotherapies.
Minoru Koi, John M Carethers.
Future Oncol, 2017 Aug 23; 13(18). PMID: 28829193    Free PMC article.
Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma.
Akira Shimizu, Kyoichi Kaira, +6 authors, Osamu Ishikawa.
J Glob Oncol, 2017 Aug 24; 3(4). PMID: 28831444    Free PMC article.
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M Goodman, Shumei Kato, +6 authors, Razelle Kurzrock.
Mol Cancer Ther, 2017 Aug 25; 16(11). PMID: 28835386    Free PMC article.
Highly Cited.
c-Jun N-terminal kinase in pancreatic tumor stroma augments tumor development in mice.
Takeshi Sato, Wataru Shibata, +14 authors, Shin Maeda.
Cancer Sci, 2017 Aug 25; 108(11). PMID: 28837246    Free PMC article.
The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches.
Panagiota Economopoulou, Ioannis Kotsantis, Amanda Psyrri.
ESMO Open, 2017 Aug 30; 1(6). PMID: 28848660    Free PMC article.
Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future.
Ece Esin.
Biomed Res Int, 2017 Aug 30; 2017. PMID: 28848761    Free PMC article.
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
David J Messenheimer, Shawn M Jensen, +6 authors, Bernard A Fox.
Clin Cancer Res, 2017 Sep 01; 23(20). PMID: 28855348    Free PMC article.
Highly Cited.
Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment.
Frank Xiaoqing Liu, Edward A Witt, +4 authors, Richard W Joseph.
Patient Prefer Adherence, 2017 Sep 02; 11. PMID: 28860722    Free PMC article.
From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.
Daphne Day, Arta M Monjazeb, +4 authors, Marcus O Butler.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864726    Free PMC article.
PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients.
Wei Wang, Ge Shen, +12 authors, Guangxian Liu.
Oncotarget, 2017 Sep 09; 8(31). PMID: 28881603    Free PMC article.
Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
Thomas B Huffaker, Soh-Hyun Lee, +11 authors, Ryan M O'Connell.
J Biol Chem, 2017 Sep 16; 292(45). PMID: 28912267    Free PMC article.
Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review.
Young Kwang Chae, Si Wang, +2 authors, Francis J Giles.
Oncotarget, 2017 Sep 17; 8(34). PMID: 28915720    Free PMC article.
Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study.
Salvinia Mletzko, David J Pinato, +4 authors, Mark Bower.
Oncoimmunology, 2017 Sep 19; 6(8). PMID: 28919987    Free PMC article.
Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients.
Arthur E Frankel, Laura A Coughlin, +4 authors, Andrew Y Koh.
Neoplasia, 2017 Sep 20; 19(10). PMID: 28923537    Free PMC article.
Highly Cited.
Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity.
Pearl Bakhru, Meng-Lei Zhu, +14 authors, Maureen A Su.
JCI Insight, 2017 Sep 22; 2(18). PMID: 28931755    Free PMC article.
The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma.
Jin Roh, Youkyoung Jeon, +10 authors, Chan-Sik Park.
Oncotarget, 2017 Sep 25; 8(35). PMID: 28938542    Free PMC article.
Endocrinopathies with use of cancer immunotherapies.
Natalie M Villa, Abtin Farahmand, +6 authors, Angela M Leung.
Clin Endocrinol (Oxf), 2017 Sep 25; 88(2). PMID: 28941311    Free PMC article.
Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
I H Sahin, G Askan, Z I Hu, E M O'Reilly.
Ann Oncol, 2017 Sep 26; 28(12). PMID: 28945842    Free PMC article.
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.
Ashley M Hopkins, Andrew Rowland, +5 authors, Michael J Sorich.
Br J Cancer, 2017 Sep 28; 117(7). PMID: 28950287    Free PMC article.
Highly Cited. Review.
In-vitro effect of pembrolizumab on different T regulatory cell subsets.
S M Toor, A S Syed Khaja, I Alkurd, E Elkord.
Clin Exp Immunol, 2017 Oct 01; 191(2). PMID: 28963773    Free PMC article.
Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma.
Sugabramya Kuru, Nazia Khan, Hamid Shaaban.
Int J Crit Illn Inj Sci, 2017 Oct 04; 7(3). PMID: 28971033    Free PMC article.
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Romualdo Barroso-Sousa, William T Barry, +4 authors, Sara M Tolaney.
JAMA Oncol, 2017 Oct 04; 4(2). PMID: 28973656    Free PMC article.
Highly Cited. Systematic Review.
Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth.
Gijung Kwak, Dongkyu Kim, +5 authors, Yoon Yeo.
ACS Nano, 2017 Oct 07; 11(10). PMID: 28985469    Free PMC article.
The diverse functions of the PD1 inhibitory pathway.
Arlene H Sharpe, Kristen E Pauken.
Nat Rev Immunol, 2017 Oct 11; 18(3). PMID: 28990585
Highly Cited. Review.
Challenging the standard of care in advanced melanoma: focus on pembrolizumab.
Raghad M Abdul-Karim, C Lance Cowey.
Cancer Manag Res, 2017 Oct 14; 9. PMID: 29026335    Free PMC article.
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer.
Isobel S Okoye, Michael Houghton, +2 authors, Shokrollah Elahi.
Front Immunol, 2017 Oct 17; 8. PMID: 29033936    Free PMC article.
Genomic insights into head and neck cancer.
Tim N Beck, Erica A Golemis.
Cancers Head Neck, 2016 Jan 01; 1. PMID: 29034103    Free PMC article.
Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer.
Nathan Singh, Junwei Shi, Carl H June, Marco Ruella.
Curr Hematol Malig Rep, 2017 Oct 19; 12(6). PMID: 29039115    Free PMC article.
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
Margaret K Callahan, Harriet Kluger, +9 authors, Mario Sznol.
J Clin Oncol, 2017 Oct 19; 36(4). PMID: 29040030    Free PMC article.
Highly Cited.
Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues.
Edwin R Parra, Naohiro Uraoka, +7 authors, Jaime Rodriguez-Canales.
Sci Rep, 2017 Oct 19; 7(1). PMID: 29042640    Free PMC article.
Highly Cited.
Clinical and molecular characterization of patients with cancer of unknown primary in the modern era.
A M Varghese, A Arora, +12 authors, L B Saltz.
Ann Oncol, 2017 Oct 19; 28(12). PMID: 29045506    Free PMC article.
Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma.
Taku Fujimura, Takanori Hidaka, +10 authors, Setsuya Aiba.
Oncotarget, 2017 Oct 21; 8(41). PMID: 29050354    Free PMC article.
Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.
Tamson Moore, Courtney Regan Wagner, +23 authors, Michael I Nishimura.
Cancer Immunol Immunother, 2017 Oct 21; 67(2). PMID: 29052782    Free PMC article.
Melanocortin-1 Receptor-Targeting Ultrasmall Silica Nanoparticles for Dual-Modality Human Melanoma Imaging.
Feng Chen, Xiuli Zhang, +14 authors, Thomas P Quinn.
ACS Appl Mater Interfaces, 2017 Oct 24; 10(5). PMID: 29058865    Free PMC article.
Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review.
Jennifer M Yoest.
Immunotargets Ther, 2017 Oct 27; 6. PMID: 29067284    Free PMC article.
An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma.
Felicity C Stark, Risini D Weeratna, +4 authors, Lakshmi Krishnan.
Vaccines (Basel), 2017 Oct 27; 5(4). PMID: 29072624    Free PMC article.
Immune checkpoint inhibitors in renal cell carcinoma.
Kirsty Ross, Rob J Jones.
Clin Sci (Lond), 2017 Oct 29; 131(21). PMID: 29079639    Free PMC article.
Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.
Hyunju Lee, F Stephen Hodi, +13 authors, Le Min.
Cancer Immunol Res, 2017 Oct 29; 5(12). PMID: 29079654    Free PMC article.
Regulation of human glioblastoma cell death by combined treatment of cannabidiol, γ-radiation and small molecule inhibitors of cell signaling pathways.
Vladimir N Ivanov, Jinhua Wu, Tom K Hei.
Oncotarget, 2017 Nov 02; 8(43). PMID: 29088769    Free PMC article.
Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma.
Hilary R Keller, Xin Zhang, +2 authors, James W Wells.
Oncotarget, 2017 Nov 02; 8(43). PMID: 29088901    Free PMC article.
The immunopeptidomic landscape of ovarian carcinomas.
Heiko Schuster, Janet K Peper, +21 authors, Philipp Wagner.
Proc Natl Acad Sci U S A, 2017 Nov 03; 114(46). PMID: 29093164    Free PMC article.
Highly Cited.
Dynamics of Heat Shock Protein 70 Serum Levels As a Predictor of Clinical Response in Non-Small-Cell Lung Cancer and Correlation with the Hypoxia-Related Marker Osteopontin.
Christian Ostheimer, Sophie Gunther, +2 authors, Gabriele Multhoff.
Front Immunol, 2017 Nov 03; 8. PMID: 29093708    Free PMC article.
Genomics and advances towards precision medicine for head and neck squamous cell carcinoma.
Carter Van Waes, Omar Musbahi.
Laryngoscope Investig Otolaryngol, 2017 Nov 03; 2(5). PMID: 29094075    Free PMC article.
BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma.
Qi Liu, Hongda Zhu, +2 authors, Leaf Huang.
Cancer Immunol Immunother, 2017 Nov 03; 67(2). PMID: 29094184    Free PMC article.
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.
Lidia M Yshii, Reinhard Hohlfeld, Roland S Liblau.
Nat Rev Neurol, 2017 Nov 07; 13(12). PMID: 29104289
Cardiotoxicity of immune checkpoint inhibitors.
Gilda Varricchi, Maria Rosaria Galdiero, +5 authors, Carlo Gabriele Tocchetti.
ESMO Open, 2017 Nov 07; 2(4). PMID: 29104763    Free PMC article.
Highly Cited. Review.
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.
Antonio Omuro, Gordana Vlahovic, +13 authors, John H Sampson.
Neuro Oncol, 2017 Nov 07; 20(5). PMID: 29106665    Free PMC article.
Highly Cited.
CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy.
Anna Wasiuk, James Testa, +9 authors, Li-Zhen He.
J Immunol, 2017 Nov 08; 199(12). PMID: 29109120    Free PMC article.
The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts.
Xiaolei Shi, Alpaslan Tasdogan, +3 authors, Ralph J DeBerardinis.
Sci Adv, 2017 Nov 08; 3(11). PMID: 29109980    Free PMC article.
Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management.
Stefania Stucci, Raffaele Palmirotta, +6 authors, Franco Silvestris.
Oncol Lett, 2017 Nov 09; 14(5). PMID: 29113194    Free PMC article.
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.
Glen J Weiss, Lisa Blaydorn, +4 authors, Vivek Khemka.
Invest New Drugs, 2017 Nov 10; 36(1). PMID: 29119276
Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis.
Daniel Y Wang, Fei Ye, Shilin Zhao, Douglas B Johnson.
Oncoimmunology, 2017 Nov 11; 6(10). PMID: 29123955    Free PMC article.
A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.
Sandra P D'Angelo, Omid A Hamid, +10 authors, Richard D Carvajal.
Invest New Drugs, 2017 Nov 12; 36(1). PMID: 29127533
A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry.
Jinkai Teo, Anja Mirenska, +9 authors, David Ag Skibinski.
Future Sci OA, 2017 Nov 15; 3(4). PMID: 29134128    Free PMC article.
Immune checkpoint inhibitors: new strategies to checkmate cancer.
R A M Wilson, T R J Evans, A R Fraser, R J B Nibbs.
Clin Exp Immunol, 2017 Nov 16; 191(2). PMID: 29139554    Free PMC article.
Primary malignant melanoma of the lung: A case report and literature review.
Juan Peng, Fengfeng Han, +3 authors, Xuejun Guo.
Medicine (Baltimore), 2017 Nov 18; 96(46). PMID: 29145332    Free PMC article.
Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.
Paolo A Ascierto, Sanjiv S Agarwala, +20 authors, Magdalena Thurin.
J Transl Med, 2017 Nov 18; 15(1). PMID: 29145885    Free PMC article.
Immune-related tumour response assessment criteria: a comprehensive review.
Bhanusupriya Somarouthu, Susanna I Lee, +3 authors, Avinash Kambadakone.
Br J Radiol, 2017 Nov 28; 91(1084). PMID: 29172675    Free PMC article.
Management of intracranial melanomas in the era of precision medicine.
Grace J Young, Wenya Linda Bi, +3 authors, Ian F Dunn.
Oncotarget, 2017 Nov 29; 8(51). PMID: 29179523    Free PMC article.
Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells.
Rand Arafeh, Karen Flores, +5 authors, Yardena Samuels.
Sci Rep, 2017 Nov 29; 7(1). PMID: 29180761    Free PMC article.
Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Boning Liu, Huaizu Guo, +9 authors, Yajun Guo.
MAbs, 2017 Nov 29; 10(2). PMID: 29182441    Free PMC article.
Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model.
Yang Du, Ting Sun, +5 authors, Jie Tian.
Int J Nanomedicine, 2017 Dec 05; 12. PMID: 29200846    Free PMC article.
Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition.
Arlene Siefker-Radtke, Brendan Curti.
Nat Rev Urol, 2017 Dec 06; 15(2). PMID: 29205200
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet.
Anna C Filley, Mario Henriquez, Mahua Dey.
Oncotarget, 2017 Dec 07; 8(53). PMID: 29207684    Free PMC article.
Highly Cited. Review.
Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma.
Daniel E Meyers, Satbir Thakur, Chandini M Thirukkumaran, Don G Morris.
Blood Cancer J, 2017 Dec 07; 7(12). PMID: 29208938    Free PMC article.
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.
Mariona Cabo, Rienk Offringa, +3 authors, Lorenzo Galluzzi.
Oncoimmunology, 2017 Dec 07; 6(12). PMID: 29209572    Free PMC article.
Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors.
Denis L Jardim, Débora de Melo Gagliato, Francis J Giles, Razelle Kurzrock.
Clin Cancer Res, 2017 Dec 08; 24(8). PMID: 29212781    Free PMC article.
The role of STAT3 in leading the crosstalk between human cancers and the immune system.
Yu Wang, Yicheng Shen, +2 authors, Xuan Zhou.
Cancer Lett, 2017 Dec 10; 415. PMID: 29222039    Free PMC article.
Highly Cited. Review.
Nanoscale Tuning of VCAM-1 Determines VLA-4-Dependent Melanoma Cell Plasticity on RGD Motifs.
Katharina Amschler, Eugen Kossmann, +6 authors, Michael P Schön.
Mol Cancer Res, 2017 Dec 10; 16(3). PMID: 29222169    Free PMC article.
Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer.
Ying Guan, Rui Zhang, +3 authors, Yansong Wang.
J Bone Oncol, 2017 Dec 12; 9. PMID: 29226090    Free PMC article.
Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling.
Isobel Okoye, Afshin Namdar, +2 authors, Shokrollah Elahi.
Oncotarget, 2017 Dec 13; 8(58). PMID: 29228684    Free PMC article.
Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.
Andres Chang, Danielle Schlafer, Christopher R Flowers, Pamela B Allen.
Expert Opin Investig Drugs, 2017 Dec 13; 27(1). PMID: 29228840    Free PMC article.
The Role of Checkpoint Inhibition in Non-Small Cell Lung Cancer.
Jonathan Lu, Robert A Ramirez.
Ochsner J, 2017 Dec 13; 17(4). PMID: 29230122    Free PMC article.
The Future of Immunotherapy: A 20-Year Perspective.
David C Wraith.
Front Immunol, 2017 Dec 14; 8. PMID: 29234325    Free PMC article.
Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.
Young Kwang Chae, Michael S Oh, Francis J Giles.
Oncologist, 2017 Dec 16; 23(4). PMID: 29242279    Free PMC article.
Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer.
Xiaoli Ju, Rong Shen, +4 authors, Miao Chen.
Oncotarget, 2017 Dec 17; 8(59). PMID: 29245908    Free PMC article.
Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?
Young Kwang Chae, Ayush Arya, +9 authors, Francis Giles.
Oncotarget, 2017 Dec 17; 8(59). PMID: 29246028    Free PMC article.
Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy.
Anne-Sophie Gautron, Alexandre Juillerat, +5 authors, Laurent Poirot.
Mol Ther Nucleic Acids, 2017 Dec 17; 9. PMID: 29246309    Free PMC article.
Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT.
Elizabeth K Duperret, Megan C Wise, +8 authors, David B Weiner.
Mol Ther, 2017 Dec 19; 26(2). PMID: 29249395    Free PMC article.
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.
Brendan Curti, Gregory A Daniels, +10 authors, Janice P Dutcher.
J Immunother Cancer, 2017 Dec 20; 5(1). PMID: 29254506    Free PMC article.
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Zijun Y Xu-Monette, Mingzhi Zhang, Jianyong Li, Ken H Young.
Front Immunol, 2017 Dec 20; 8. PMID: 29255458    Free PMC article.
Highly Cited. Review.
Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.
Claire Lhuillier, Claire Vanpouille-Box, +2 authors, Sandra Demaria.
Semin Cancer Biol, 2017 Dec 21; 52(Pt 2). PMID: 29258856    Free PMC article.
Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma.
Zhiying Shao, Andrew Z Wang, Daniel J George, Tian Zhang.
Asian J Urol, 2016 Oct 01; 3(4). PMID: 29264195    Free PMC article.
How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know.
Marianne Davies.
J Adv Pract Oncol, 2016 Jul 01; 7(5). PMID: 29282426    Free PMC article.
High macrophage PD-L1 expression not responsible for T cell suppression.
Naomi Goldman, Yelizavet D Lomakova, +4 authors, James E Riggs.
Cell Immunol, 2018 Jan 07; 324. PMID: 29305065    Free PMC article.
PD-1 related transcriptome profile and clinical outcome in diffuse gliomas.
Shuai Liu, Zheng Wang, +5 authors, Tao Jiang.
Oncoimmunology, 2018 Jan 09; 7(2). PMID: 29308304    Free PMC article.
Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy.
Emily Z Keung, Jen-Wei Tsai, +10 authors, Christina L Roland.
Oncoimmunology, 2018 Jan 09; 7(2). PMID: 29308306    Free PMC article.
Early B cell changes predict autoimmunity following combination immune checkpoint blockade.
Rituparna Das, Noffar Bar, +10 authors, Kavita M Dhodapkar.
J Clin Invest, 2018 Jan 09; 128(2). PMID: 29309048    Free PMC article.
Highly Cited.
Glycogen Synthase Kinase 3 Inactivation Compensates for the Lack of CD28 in the Priming of CD8+ Cytotoxic T-Cells: Implications for anti-PD-1 Immunotherapy.
Alison Taylor, Christopher E Rudd.
Front Immunol, 2018 Jan 10; 8. PMID: 29312284    Free PMC article.
New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.
Isabel Corraliza-Gorjón, Beatriz Somovilla-Crespo, +2 authors, Leonor Kremer.
Front Immunol, 2018 Jan 10; 8. PMID: 29312320    Free PMC article.
Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?
Thomas C Wirth, Florian Kühnel.
Front Immunol, 2018 Jan 10; 8. PMID: 29312332    Free PMC article.
Highly Cited. Review.
[Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma].
S Troyanova-Slavkova, L Eickenscheidt, K Dumann, L Kowalzick.
Hautarzt, 2018 Jan 14; 69(8). PMID: 29330579
A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma.
Lukas Krähenbühl, Simone M Goldinger, +7 authors, Phil F Cheng.
Neoplasia, 2018 Jan 15; 20(2). PMID: 29331888    Free PMC article.
Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer.
Tamara Muliaditan, James W Opzoomer, +14 authors, James N Arnold.
Clin Cancer Res, 2018 Jan 18; 24(7). PMID: 29339440    Free PMC article.
Liquid biomarkers in melanoma: detection and discovery.
Su Yin Lim, Jenny H Lee, +2 authors, Helen Rizos.
Mol Cancer, 2018 Jan 19; 17(1). PMID: 29343260    Free PMC article.
Acute Angle Closure Precipitated by Hemorrhage and Necrosis of a Large Uveal Melanoma in the Setting of Systemic Immunomodulatory Therapy.
Chau M Pham, Krishna Kalyam, +2 authors, John B Holds.
Ocul Oncol Pathol, 2018 Jan 19; 3(4). PMID: 29344476    Free PMC article.
Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy.
Akihiro Hosoi, Kazuyoshi Takeda, +10 authors, Kazuhiro Kakimi.
Sci Rep, 2018 Jan 20; 8(1). PMID: 29348598    Free PMC article.
Checkpoint Inhibitors, Palliative Care, or Hospice.
Mellar P Davis, Rajiv Panikkar.
Curr Oncol Rep, 2018 Jan 20; 20(1). PMID: 29349518
Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy.
Wen Cheng, Dian Fu, Feng Xu, Zhengyu Zhang.
Oncogenesis, 2018 Jan 24; 7(1). PMID: 29358573    Free PMC article.
Clinical Development of PD-1 in Advanced Melanoma.
Rodrigo Ramella Munhoz, Michael Andrew Postow.
Cancer J, 2018 Jan 24; 24(1). PMID: 29360722    Free PMC article.
Ex Vivo Imaging of Resident CD8 T Lymphocytes in Human Lung Tumor Slices Using Confocal Microscopy.
Elisa Peranzoni, Houcine Bougherara, +4 authors, Emmanuel Donnadieu.
J Vis Exp, 2018 Jan 25; (130). PMID: 29364247    Free PMC article.
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
Sandra P D'Angelo, Michelle R Mahoney, +8 authors, Howard Streicher.
Lancet Oncol, 2018 Jan 27; 19(3). PMID: 29370992    Free PMC article.
Highly Cited.
Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors.
Adam Diehl, Mark Yarchoan, +2 authors, Stuart A Grossman.
Oncotarget, 2018 Jan 27; 8(69). PMID: 29371985    Free PMC article.
Highly Cited.
Current challenges for cancer vaccine adjuvant development.
William S Bowen, Abhishek K Svrivastava, +2 authors, Haval Shirwan.
Expert Rev Vaccines, 2018 Jan 27; 17(3). PMID: 29372660    Free PMC article.
The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation.
Wenwen Xu, TạMinh Hiếu, Subramaniam Malarkannan, Li Wang.
Cell Mol Immunol, 2018 Jan 30; 15(5). PMID: 29375120    Free PMC article.
IDO1 in cancer: a Gemini of immune checkpoints.
Lijie Zhai, Erik Ladomersky, +5 authors, Derek A Wainwright.
Cell Mol Immunol, 2018 Jan 30; 15(5). PMID: 29375124    Free PMC article.
Highly Cited. Review.
PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
Priya Srinivasan, Xiaofang Wu, +2 authors, Anthony D Sandler.
PLoS Med, 2018 Jan 30; 15(1). PMID: 29377881    Free PMC article.
Cloning and expansion of antigen-specific T cells using iPS cell technology: development of "off-the-shelf" T cells for the use in allogeneic transfusion settings.